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Atrial fibrillation (AF) is the most common clinical arrhythmia, posing a major 
risk for occurrence of ischemic stroke. Oral anticoagulation and antiplatelet agents are 
used to prevent stroke. One major complication related to these therapies is the 
development of a hemorrhage. Providers are faced with treating older adults with AF who 
have concomitant geriatric syndromes that potentially alter treatment outcomes. This 
study involved examining records of subjects age ≥ 65 diagnosed with AF and 
concomitant geriatric syndromes (dementia, frailty, and/or falls) to describe differences in 
incidence of strokes and hemorrhages, depending upon the type of prevention therapy, 
and differences in incidences of stroke in patients with and without geriatric syndromes. 
Older adult patients with geriatric syndromes were divided into three groups 
based on the type of antithrombotic therapy prescribed at diagnosis of AF: oral 
anticoagulation, antiplatelet agents, or no oral anticoagulants or antiplatelet agents, with 
primary outcomes of a stroke or hemorrhage. In a separate analysis, older adults with and 
without geriatric syndromes across the three therapy groups were compared with primary 
outcome for stroke. Multivariable Cox hazard, logistic regression, and Kaplan Meier 
survival curves were utilized to determine association of treatment with risk-adjusted 
stroke and hemorrhage incidence.  
Compared to patients prescribed no antithrombotic therapy, the reduced stroke 
occurrence was 75% to 82% oral anticoagulants and 70% to 74% in those prescribed 
 iv 
 
antiplatelet agents (both p < .001), after controlling for risk. Patients prescribed 
antiplatelet agents and oral anticoagulants were 3.28 and 3.19 times more likely, 
respectively, than patients not prescribed antithrombotics to develop noncranial 
hemorrhage (p < .05). Patients with geriatric syndromes experienced higher incidence of 
stroke when prescribed oral anticoagulants (p = 0.00) and antiplatelet agents (p < 0.001), 
compared to patients without geriatric syndromes. 
Subjects with geriatric syndromes had benefit and risk profiles when prescribed 
oral anticoagulant and antiplatelet therapies to prevent thromboembolism similar to other 
populations recorded, although overall stroke incidence was greater. This suggests that 
populations with geriatric syndromes should be specifically incorporated into the 
guidelines clinicians use to tailor antithrombotic therapies to individual patient risk. 
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Statement of the Problem 
Atrial fibrillation (AF), the most common form of irregular heart rhythm, has 
increased prevalence in older adults (Olesen, Lip, & Lane, 2011). Baseline frequency in 
patients age 65 and older has been estimated at 7.2% (Lip, Tse, & Lane, 2012). This 
arrhythmia is projected to affect 15.9 million older adults in the United States by the year 
2050 (Lip et al., 2012). According to the National Institutes of Health (2010), it has been 
estimated that the cost of this disease is $6.4 billion annually in the United States alone. 
AF is associated with 15% to 25% of ischemic strokes (Hendriks, de Wit, 
Vrijhoef, Tieleman, & Crijns, 2010). Treatment with oral anticoagulants (OAC) to 
prevent the formation of blood clots due to blood stasis in a fibrillating atria decreases the 
risk of stroke by 68% (Jacobs, Billett, Freeman, Dinglas, & Jumaquio, 2009). Treatment 
of this same condition with antiplatelet therapy decreases the risk of stroke by 40% (Hart, 
Pearce, & Aguilar, 2007). 
Studies show that OAC causes an increase in the likelihood of intracranial and 
other types of hemorrhages, as well as death in older populations (Pieracci, Eachempati, 





older adults is beneficial, providers are often reluctant to prescribe this therapy for 
patients with geriatric syndromes such as falls and/or dementia and/or frailty (Morley, 
2008). The use of OAC also correlates with the highest number of preventable 
hospitalizations of older adults, with warfarin contributing to 33.3% of these adverse drug 
events (Budnitz, Lovegrove, Shehab, & Richards, 2011).  
The older patient with AF exists on a continuum of risks. At one extreme is a 
stroke risk if inadequately treated, and at the other is a bleeding risk. Somewhere in the 
middle is the optimal balance, but the dilemma is that the optimal point differs based on 
individual patient characteristics; this is why it is necessary to examine other aspects of 
thromboembolism-prevention therapy. Simply applying existing methods and 
recommendations has proven to lead only to more debate on the subject, both nationally 
and internationally, resulting in more questions as opposed to more answers (Gladstone et 
al., 2011). Providers are expected to follow guidelines for prevention of a stroke, but 
following the guidelines puts patients at risk for a life-threatening bleed, which prevents 
many providers from prescribing oral anticoagulants (Garwood & Corbett, 2008).  
Personalized medicine, the concept of providing medical care based on phenotype 
and patient preferences, is the future of healthcare (Kravitz, 2014). For example, patients 
may decide to forgo OAC therapy after having examined their risk factors and life quality 
issues with their provider. Clinicians practicing personalized medicine are poised to 
participate in balancing both extremes of the spectrum of therapy with OAC. 
Within the clinical arena the two most widely used predictive schemas to 
determine the appropriate therapy for prevention of cerebrovascular accident (CVA) in 





mellitus, vascular disease (coronary artery disease, peripheral artery disease or aortic 
plaque), age 65 to 74 years old, and sex (female gender). This schema includes risk 
factors for the initiation of OAC in clinical settings for the prevention of a stroke. In this 
schema, the risk of a stroke is calculated as a percentage-per-year value. Guidelines for 
stroke-prevention therapy include consideration of scores of these schemas. This schema 
does not include consideration of falls, dementia, and frailty, but providers do consider 
these factors when assessing for the initiation of OAC therapy. According to guidelines, 
these conditions do not contraindicate the use of OAC therapy; however, in practice, 
many providers are reluctant to initiate this therapy in patients with falls, dementia, and 
frailty, contributing to the underutilization of OAC in older adults (Garwood & Corbett, 
2008; Tulner et al., 2010). A patient with dementia who is administering his or her own 
medications may mix up their OACs and take too much or not enough, which may lead to 
a stroke or a bleed. Fall-prone patients on OACs may sustain trauma with resultant bleed 
that can be life threatening. Frail patients are not only prone to falls, but may also have 
impaired organ function, increasing the risk of medication toxicity.  
 
Significance of the Problem 
Within the overall population, the number of people age 65 and older will 
increase from 40.4 million in 2010 to 55 million in 2020 (U.S. Department of Health and 
Human Services, 2011). The prevalence of AF increases with age, from 5% in individuals 
over age 65 to 10% in people age 80 and older (Marinigh, Lip, Fiotti, Giansante, & Lane, 
2010). AF also has a high mortality rate: up to 15% within the first 30 days of diagnosis 





(Bajorek, Krass, Ogle, Duguid, & Shenfield, 2005). The need for development and 
testing of a risk stratification tool for AF and its thromboembolic complications was 
specifically identified in a recent National Institutes of Health (NIH) report (NIH, 2010). 
The Patient-Centered Outcomes Research Institute (PCORI) is committed to 
providing beneficial research outcomes to patients and providers (Wallis, 2014). In the 
spirit of PCORI, this proposed study contributes to an understanding of antithrombotic 
therapy as a basis for future intervention protocols that may lead to patient-centered 
outcomes for older adults on OACs. 
This study will begin the research trajectory toward that end, and provides 
information about achieving more effective OAC management in older adults. This 
retrospective descriptive study was designed to inform clinicians and patients with AF 
about the outcomes of suboptimal preventive therapy, including stroke and hemorrhage in 
older adults with AF, by assessing the association of these outcomes with OAC use, and 
to examine the implications of the falls, dementia, and frailty on this therapy. 
 
Innovation 
The disciplines of cardiology and internal medicine provide a body of research 
concerning OAC in stroke prevention, while pharmacology and geriatrics provide 
cautious information concerning adverse drug effects and poor outcomes of OAC therapy 
associated with aging. Geriatric providers are concerned with quality-of-life issues of 
older individuals, tailoring therapy to the needs of each patient across multiple chronic 
conditions; however, these patients most likely are treated by several providers, which 





use of OACs. There is no consensus among providers or among disciplines when it 
comes to the use of OACs. This transdisciplinary study brought together the disciplines 
of nursing, cardiology, internal medicine, and pharmacology to determine the risk-versus-
benefit ratio of using OACs. The study provides answers to clinicians and patients to aid 
in decisions regarding the use of OACs.  
There is a vital need to re-evaluate this complex issue from the standpoint of 
patient-centered outcomes. Examining this problem by exploring patient comorbidity 
outcomes will provide additional considerations that are missing from the use of this 
therapy. This study will better equip providers and patients for future decisions they will 
make in prescribing OACs in older adults with AF. The study will also lead to future 
studies seeking interventions that deliver maximum benefit to older patients with AF. 
Such studies may ultimately lead to the reexamination of existing guidelines and the 
incorporation of additional risk considerations, allowing individual patients a more 
suitably tailored therapy. 
 
Purpose of the Study 
Complications resulting from AF increase both the burden of healthcare cost and 
what is ultimately the most feared outcome, the potential for stroke. Current research 
confirms that the optimal use of OACs in this population would reduce thromboembolic 
events, in turn decreasing debility, hospitalization, and healthcare expenditures without 
incurring debility, hospitalizations, and undue burden resulting from treatment (Gorin et 
al., 2011). Fewer than 50% of high-stroke-risk patients are treated with anticoagulants, 






The potential for misuse of OACs demands answers regarding their optimal use. 
Recorded within the literature is the fact that the presence of one or more specific 
geriatric syndromes (falls, dementia, frailty) directly influences decision making on the 
part of providers. Although these factors have been mentioned in the literature 
individually, they have not been studied in combination with one another, nor have they 
been explored thoroughly enough to explain the issues related to their occurrence as it 
pertains to the opposing ends of the continuum for prescribing antithrombotic therapy.  
 
Specific Aims 
The following were the specific aims of the study: Among older adults with atrial 
fibrillation, 
1. Identify differences in risk-adjusted stroke rates depending on CHA2DS2-
VASc among older adults with a geriatric syndrome (falls, dementia, and/or 
frailty) prescribed an OAC, antiplatelet agents, or no antithrombotic therapy.  
Hypothesis: Contingent on CHA2DS2-VASc scores, patients with a geriatric 
syndrome who are prescribed an OAC or antiplatelet agent will have a higher 
rate of strokes and TIAs than patients who are prescribed an OAC or 
antiplatelet agent. 
2. Describe the difference in risk-adjusted hemorrhage rates contingent  on HAS-
BLED scores in older adults with a geriatric syndrome (falls, dementia, and/or 






Hypothesis: Contingent on HAS-BLED scores, patients with a geriatric 
syndrome who are not prescribed an OAC or antiplatelet agent will report a 
lower rate of hemorrhages than patients who are prescribed an OAC or 
antiplatelet agent. 
3. Using a factorial design, determine the main and interaction effects of 
thromboembolic therapy for older adults with chronic atrial fibrillation and the 
presence of a geriatric syndrome (falls, dementia, and/or frailty), contingent 
on CHA2DS2-VASc scores.  
Hypothesis 3A: Contingent on CHA2DS2-VASc scores, there is a main effect 
of thromboembolism prevention therapy for older adult patients with AF on 
incidence of stroke and TIA, with the order from lowest to highest being 
OACs, antiplatelet agents, and no antithrombotic therapy groups.  
Hypothesis 3B: Contingent on CHA2DS2-VASc scores, there is a main effect 
of geriatric syndromes (falls, dementia, and/or frailty) on incidences of strokes 
and TIAs in older adults having atrial fibrillation diagnosis, with those without 
a geriatric syndrome having a lower incidence. 
Hypothesis 3C: Contingent on the CHA2DS2-VASc score is an interaction of 
thromboembolism prevention therapy and the presence of a geriatric 








Organization of the Dissertation 
This dissertation is organized into seven chapters. Chapter 2 is a review of the 
literature on cerebrovascular accident (CVA)/transient ischemic attack (TIA), atrial 
fibrillation, therapy, management of heart rhythm, thromboembolism, stroke prevention, 
risk stratification schema for the assessment of stroke risk, adverse effects: hemorrhages, 
risk stratification schema for the assessment of a bleeding risk, existing guidelines, falls, 
dementia, and frailty. The methods used in the entire study compose Chapter 3. Chapter 4 
describes differences in incidence of stroke in AF patients with geriatric syndromes over 
3-year follow up depending on the type of stroke-prevention therapy: oral anticoagulants 
(OAC), antiplatelet agents (ATPL), or none of these (No OAC/ATPL). Chapter 5 
discusses the surveying of medical records of AF patients age 65 years and older also 
diagnosed with geriatric syndromes to contrast hemorrhage incidence differences during 
the 3-year follow up, while considering the following stroke prevention therapies: OAC, 
ATPLs, or no OAC/ATPL. Chapter 6 contains a discussion of observed electronic 
medical records of participants age 65 years and over with AF and geriatric syndromes 
and another group with AF and no geriatric syndromes, to ascertain variations in stroke 
occurrence over a 3-year follow up, while considering the type of stroke-prevention 
therapy used (OAC), ATPL, or no OAC/ATPL). Discussion and the conclusions of the 
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REVIEW OF THE LITERATURE 
 
Cerebrovascular Accident and Transient Ischemic Attack 
Definition 
It is estimated that in the United States there are 795,000 strokes, or 
cerebrovascular accidents, every year, with 137, 000 of those resulting in death (Fonarow 
et al., 2010). Age is the most important risk factor for all strokes, including ischemic 
stroke, related to atrial fibrillation (AF), with a doubling of the risk for a stroke for every 
10 years, starting at the age of 55 years (Fonarow et al., 2010). In the 34 years of follow-
ups in the Framingham Study, records show that among people ages 50 to 89 there were 
572 strokes (122 ischemic CVAs, 256 thrombotic brain infarcts, 114 embolisms, 27 
intracerebral hemorrhages, 39 subarachnoid hemorrhages, 14 miscellaneous causes), with 
AF diagnosed in 311 of these subjects (Wolf, Abbott, & Kannel, 1991). The researchers 
concluded that warfarin, a drug used for oral anticoagulation, prevents up to 80% of 








In a study of age-related difference among patients who experienced a stroke, 
older patients had more comorbid conditions, were more likely to be female, and were 
less likely to receive oral anticoagulants indicated to prevent stroke (Saposnik et al., 
2009). The researchers found that morbidity at 7 days, 30 days, and 1 year were the 
highest among patients 80 years and older. Providers are faced with complex issues 
related to the care of older patients and are expected to make the “right” treatment 
decisions, which may be substantially complicated due to the variety of contributing 
factors. Under certain conditions, patients experiencing a stroke and treated in a hospital 
within a critical window of time can be given tissue plasminogen activator (tPA), which 
is used to dissolve blood clots; however, older patients are less likely to receive this 
therapy, primarily due to the concern about a subsequent hemorrhage (Fonarow et al., 
2010).  
 
Types and Contributing Factors 
A transient ischemic attack (TIA) is a brief interruption of blood flow to the brain 
that generally results in no sequela, or very minor symptomology, compared to a stroke. 
Acute ischemic stroke is an interruption of blood flow to the brain that results in cellular 
death and permanent damage. Aggressive rehabilitation after a stroke may result in better 
outcomes for patients; however, older patients may not completely recover. Acute 
ischemic stroke results in death one third of the time, and physicians must decide what 
kind of poststroke care should be developed for surviving patients (O'Donnell et al., 





require institutional care for 3 months or longer (Holloway et al., 2010). Each year in the 
United Sates between 1999 and 2009, 795,000 people experienced a stroke (ischemic or 
hemorrhagic); this represents 6.8 million stroke victims in the United States during this 
period. AF increases ischemic stroke risk 5-fold in individuals of all ages (Go et al., 
2013). Ischemic strokes are estimated to comprise 87% of all strokes occurring in the 
United States. Of post-ischemic-stroke patient discharges, only 45% returned directly to 
their home, while 24% were admitted to inpatient rehabilitation facilities and the 
remaining 31% were admitted to skilled nursing facilities. People age 85 years and older 
comprise 17% of all strokes. In 2009 the estimated healthcare cost of all strokes in the 
United States was $22.8 billion (Go et al., 2013). 
In summary, older patients with AF are more likely to have a stroke, and these 
same patients are less likely to be treated with OAC therapy, as recommended in the 
guidelines. Older patients are more likely to have comorbid conditions, complicating 
their course of therapy following a stroke, and many may require institutionalization 
following an ischemic stroke. When institutionalized following a stroke, many older 




In a normally functioning heart, electrical impulses are generated in the sinoatrial 
node, which is located at the top of the right atria and acts as the natural pacemaker of the 
heart. The electrical signal generated spreads first through the right atria and then through 





contraction of the atria, blood is pushed into the ventricles, which are the main pumping 
chambers of the heart. The electrical impulse then travels to the atrioventricular node and 
then down both ventricles, causing them to contract as well (Waktare, 2002). The term 
normal sinus rhythm is used to describe a normal heart rhythm, which is between 60 and 
100 beats per minute (BPM). 
AF is an irregular heart rhythm that occurs with the abnormal introduction of 
disorganized electrical impulses generated in various foci within the atria. These are most 
commonly found around pulmonary veins, and cause the atria to experience a rate of 300 
to 600 BPM; however, during AF the atrioventricular node does not allow all of the 300 
to 600 impulses to be conducted from the atria to the ventricles. It acts something like a 
toll gate in that it typically allows conduction of only between 110 and 180 BPM, which 
is the common range associated with the presence of AF (Waktare, 2002). During AF 
there is stagnation of the blood in the atria, which is what contributes to the formation of 
a blood clot, or thromboembolism. These blood clots, or thrombi, may travel to the brain, 
causing a stroke or cerebrovascular accident by occluding the blood vessel and causing 
severe restriction of blood flow; thus the name ischemic stroke (Padanilam & 
Prystowsky, 2009). AF is the most commonly encountered tachyarrhythmia, which in 
itself is not causative of death; however, complications of this tachyarrhythmia may lead 
to a stroke, congestive heart failure, and/or death. AF is prevalent in older adults, with an 
incidence of 6% in those 65 to 74 years of age, 12% in those 75 to 84 years, and 16% in 







Incidence and Risk Factors 
One effect of the Baby Boom generation is a dramatic increase in the number of 
older adults in the United States. Between 2004 and 2014 the U.S. population ≥ age 65 
experienced a 28% increase, growing from 36.2 to 46.2 million, and it is expected to 
reach 98 million by 2060. Older adults in the United Sates represent the largest segment 
of the population and account for 36% of healthcare expenditures and 42% of 
prescription drug costs (Herrera et al., 2010).  
Currently, AF affects 2.3 million people in the United States and 6 million people 
in Europe (Chinitz, Castellano, Kovacic, & Fuster, 2012). The incidence of AF is known 
to increase with age and is conservatively projected to double, at the very least, within the 
next 50 years (Chinitz et al., 2012). Age increases the potential for stroke by as much as 3 
to 5 times (Benjamin et al., 1998; Tsang et al., 2003), and although women in the United 
States typically live longer than men, advanced age predicts greater prevalence of AF 
regardless of gender. In 2010 in the United States, women outnumbered men, 
representing 57% of the population age 65 and older and 67% of the population age 85 
and older. These statistics clearly demonstrate that in the near future clinicians will be 
treating many more patients with AF, and will encounter more comorbidity issues 
associated with AF than they do currently. This dilemma is faced not only by the United 
Sates but most European countries as well, and is contributing directly to the ongoing 
research efforts on this subject that are taking place in Europe, Canada, and elsewhere.  
AF is strongly associated with significant comorbidities that are common in older 
adults, such as congestive heart failure, coronary artery disease, hypertension, and 





ventricle to enlarge over time, causing stretching of the tissue and making it more 
irritable around pulmonary veins, thereby causing AF (Padanilam & Prystowsky, 2009).  
 
Sequelae 
Studies have shown that AF is responsible for 36% of the ischemic strokes 
occurring in adults age 80 and older (Padanilam & Prystowsky, 2009). In the 
Framingham Study, AF was associated with increased mortality in adults of 65 years and 
older. Mortality was high within 30 days of the diagnosis of AF, at 15%. After the 30-day 
period, AF was associated with a doubling of the mortality rate (Benjamin et al., 1998). 
Something else being studied is the comorbid conditions contributing to or associated 
with AF and their impact on the associated increase in mortality. The research 
surrounding this question so far has determined that AF independently adds a risk of 
stroke, myocardial infarction (MI), and death in addition to the other risk factors 
(Crandall et al., 2009). Despite the fact that scientists and clinicians are utilizing clinical 
trials to discover new management strategies for AF, mortality remains high. The 
Institute of Medicine declared that AF treatment strategies are a national priority for 
comparative effectiveness research (Piccini et al., 2012) 
 
Therapy 
Treatment of AF is complex because it involves both prevention of 
thromboembolism and management of the heart rhythm. Oral anticoagulants are used for 
the prevention of thromboembolism, and have a demonstrated 64% overall reduction in 





Management of Heart Rhythm 
In a clinical setting, some patients are left in persistent atrial fibrillation, with 
heart-rate control accomplished through the use of beta blockers or calcium channel 
blockers. Rate control may also be enhanced by the addition of digoxin; however, this 
medication has been associated with an increase in all-cause mortality (Whitbeck et al., 
2012). Most frequently, patients having persistent AF are older and are not symptomatic 
with AF. If rate control becomes a problem, these patients may undergo atrioventricular 
node ablation with permanent pacemaker implantation. This allows the patient to 
continue having AF in the atria while the pacemaker controls the heart rate in the 
ventricles, decreasing symptoms of palpitation and preventing ventricles from beating 
fast when AF beats are conducted rapidly to the ventricles. Rhythm control may be 
achieved through the administration of antiarrhythmic drugs; direct current cardioversion, 
which involves shocking the patient to convert to normal sinus rhythm; and 
radiofrequency catheter ablation.  
In the Pharmacological Intervention in Atrial Fibrillation (PIAF) trial of rate 
versus rhythm control in symptomatic patients, it was shown that there was no superiority 
of one or the other strategy in improvement of the AF symptoms (Hohnloser, Kuck, & 
Lilienthal, 2000). The Strategies of Treatment of Atrial Fibrillation (STAF) study 
compared rhythm versus rate control in a randomized controlled trial, with the final result 
showing no superiority of rate versus rhythm-control treatment strategy (Carlsson et al., 
2003). In the Atrial Fibrillation Follow-Up Investigation of Rhythm Management 
(AFFIRM) study, rhythm and rate control were compared and neither one showed 





and Mortality on Dofetilide (DIAMOND) study showed that patients who had normal 
sinus rhythm with or without antiarrhythmic medications had a better prognosis than 
patients in AF (Corley et al., 2004).  
The AFFIRM investigators followed with an assessment of the survival rate of 
their subjects; that analysis showed that the presence of a normal sinus rhythm was 
associated with a significant reduction in the risk of mortality, displaying consistency 
with the DIAMOND study (Corley et al., 2004). In a placebo-controlled, double-blind, 
parallel-arm trial to assess the efficacy of dronedarone 400mg twice a day for the 
prevention of cardiovascular hospitalization or death from any cause in patients with 
atrial fibrillation/atrial flutter (ATHENA) trial, it was shown that patients who took 
dronedarone, an antiarrhythmic medication, had a lower risk of stroke (Connolly, Crijns, 
et al., 2009). These studies aided us in the development of our understanding that patients 
on antiarrhythmic medications who maintain a normal sinus rhythm have a lower risk of 
stroke. In a recent study from Intermountain Medical Center in Salt Lake City, Utah, it 
was shown that patients who undergo radiofrequency catheter ablation (RFCA) exhibit 
lower rates of death, stroke, and dementia when compared to their counterparts who did 
not undergo RFCA  (Bunch et al., 2013). These results are encouraging and reinforce the 
assertion that management of rhythm is superior to other therapies. Furthermore, patients 
who undergo an AF radiofrequency catheter ablation and maintain a normal sinus rhythm 
are likely to have the same mortality outcomes as patients who never experience AF 
(Bunch et al., 2013). The Catheter Ablation versus Antiarrhythmic Drug Therapy for 
Atrial Fibrillation (CABANA) trial is presently ongoing and will answer questions 





antiarrhythmic medications in maintaining a normal sinus rhythm (Bunch et al., 2013); 
the researchers are also examining mortality rates associated with AF.  
 
Thromboembolism and Stroke Prevention 
Rates of thromboembolism vary depending on coexisting conditions that patients 
may have. In this section the criteria used to assess the risks of stroke and need for 
preventative treatment, as well as adverse effects of treatment with anticoagulants, are 
discussed, followed by a presentation of oral anticoagulants used to prevent stroke. 
 
Risk Stratification Schemas for the Assessment of Stroke Risk 
CHADS2 is a scoring system used for assessment of the risk factors for stroke in 
patients with AF. CHADS2 assigns one point for each of the following: congestive heart 
failure, hypertension, age ≥75 years, and diabetes mellitus; additionally, it assigns 2 
points for each previous stroke or TIA.  
Subsequent to the development and use of the CHADS2 schema was the 
development and implementation of another stroke risk assessment tool, the CHA2DS2-
VASc schema, which was used in this study. The CHA2DS2-VASc schema assigns one 
point for each of the following: congestive heart failure, hypertension, diabetes mellitus, 
vascular disease (coronary artery disease, peripheral artery disease, or aortic plaque), age 
65 to 74 years, and sex (female gender); in addition, 2 points are assigned for previous 
stroke or TIA and age ≥ 75 years.  
An aggregate score of 0 to 9 is derived and used to predict annual stroke risk, 





9. When utilizing this scoring system, patients are divided into the following categories: 
(a) low risk, which is associated with a CHA2DS2-VASc score of 0, which may or may 
not require aspirin; (b) intermediate risk, which is associated with a CHA2DS2-VASc 
score of 1, which indicates antiplatelet (aspirin or aspirin and clopidogrel) or OAC; and 
(c) high risk, which is associated with a CHA2DS2-VASc score of 2 or higher, which 
recommends OAC (Pamukcu, Lip, & Lane, 2010). 
CHA2DS2-VASc was compared to the CHADS2 schema in 2009. In a cohort of 
1,084 patients diagnosed with AF it was found to be as predictive as the CHADS2 
schema. The average age of patients included in the analyses was 66 years; 40.8% of 
them were women. Hypertension was the most prevalent stroke risk in this sample. This 
schema validation demonstrated a C-statistic value of 0.66, and possessed a superior 
predictive ability compared to that of other schemas (Gage et al., 2001). C-statistics (c 
stands for concordance) is an accepted method used to assess predictive and observed 
outcomes (Harrell, Lee, & Mark, 1996). C-statistic 0.5 indicates no predictive ability and 
1.00 indicates perfect predictive ability. Validity of an instrument is determined by 
assessing the correlation between variables and predictive abilities of the instrument 
(DeVellis, 2011).  
The CHA2DS2-VASc schema was incorporated into the European Society of 
Cardiology guidelines in 2010. It was proposed as an alternative to CHADS2 and was 
found to be more specific in predicting stroke risk in low-risk-group patients (Piccini & 
Singer, 2012). Sandhu, Bakal, Ezekowitz, and McAlister (2011) demonstrated that the 
CHA2DS2-VASc schema predicted the risk of thromboembolism better than did the 





Adverse Effects: Hemorrhages 
The major adverse event associated with OACs is hemorrhage. Ogilvie, Welner, 
Cowell, and Lip (2011), in a meta-analysis, reported that patients treated with OACs did 
have higher rates of hemorrhages when compared to patients treated with antiplatelet 
therapy. They also found that patients who began taking OACs were more likely to 
develop a major bleed during the first 90 days of the OAC therapy, especially if they 
were age 80 or older. The risk of hemorrhage is highest during the first 30 days of OAC 
therapy, with resulting hemorrhages at 1% and an increased risk of bleeding in patients 
with a CHADS2 score of 4 or higher. Additionally, clinical trials have revealed lower 
rates of hemorrhages resulting from careful selection of subjects, strict adherence to the 
protocol, and aggressive patient monitoring—circumstances that are not always present 
in real-life settings. Consequently, hemorrhage rates are higher in clinical settings outside 
of clinical trials (Gomes et al., 2013).  
In a prospective study of 783 older AF patients age 80 and older who were using 
warfarin, the rate of a major bleeding was low, at 2.5/100 patient years (Poli et al., 2009). 
Participants were followed closely throughout the study, and any bleeding event that 
occurred was immediately treated aggressively. This type of close scrutiny during a study 
better positions the study population for early detection of any bleeding events. Another 
advantage among this population was that they had few comorbidities that predisposed 
them to increased risk of a major bleed (Poli et al., 2009). The cohort also lacked frail 
patients who were less likely to be referred to an outpatient service (Poli et al., 2009).  
It has been shown previously that patients age 65 years and older are predisposed 





warfarin increases the risk of major bleeding 2.3 to 2.5 times (Lane, Kamphuisen, Minini, 
Büller, & Lip, 2011). It is also noted in the literature that the definition of major bleeding 
has not been consistent among various trials, which makes it tremendously difficult to 
compare bleeding risk based on these trials (Lane et al., 2011). The association of 
increased bleeding risk with concomitant OAC and antiplatelet therapy is related to the 
treatment of older patients with more comorbid conditions, such as coronary artery 
disease, diabetes mellitus, or previous stroke; they therefore require the addition of 
antiplatelet therapy, such as aspirin, which predisposes to a higher risk of bleeding.  
Another Canadian study of 266,460 patients age 66 years and older explored the 
rate of hemorrhages associated with OAC therapy and found the rates of bleeding at 3.8% 
per person year, compared to the 6.8% to 7.2% per person year reported in the literature 
(Gomes et al., 2012). Healthcare costs are increased for patients who are hospitalized for 
a major bleed. For example, in their study, Ghate, Biskupiak, Ye, Kwong, and Brixner 
(2011) found that the cost for patients with a minor gastrointestinal (GI) bleed was 
$22,507, for patients with an intracranial bleed was $42, 574, and for patients with a 
major GI bleed was $36,571.  
Providers are less likely to prescribe OACs to patients age 80 years and older due 
to the increased fear of bleeding. Moreover, physicians are more likely to stop OAC 
therapy and prescribe antiplatelet therapy for older patients, although it is less efficacious 
(Riva, Smith, & Lane, 2011). In particular, this situation occurs when older adults are 
suffering from frailty, falls, or dementia. These cognitive and physical declines 
predispose older patients to complications due to comorbid conditions coupled with OAC 





increase in bleeding risk in older individuals with the above-mentioned conditions. 
 
Risk Stratification Schema for the Assessment of a Bleeding Risk 
The development of the HAS-BLED schema arose from the database of the 
SPORTIF trial, in which the sample consisted of 5,272 patients age 18 years and older 
(mean age = 79.3 years; Hankey et al., 2012). The acronym HAS-BLED represents the 
risk factors of hypertension, abnormal renal or liver function, stroke, bleeding history or 
predisposition, labile international normalized ratio (INR), elderly (age 65 and older), 
drug or alcohol use. The researchers in the SPORTIF trial (Hankey et al., 2012) used 
univariate analysis for the potential risk factors for a bleed (p < 0.01); these factors were 
subsequently included in the multivariate logistic regression in addition to the clinically 
known risk factors. In the final model, variables with a p value of <0.05 were considered 
to be significant. The resulting model was the basis for the HAS-BLED schema, which is 
the most commonly used clinical bleeding risk schema. The presence of any of the risk 
factors contained in the schema indicates an increased risk for the development of a 
bleed.  
Each HAS-BLED risk factor is assigned a 1-point value, for a maximum of 9 
points. The annual bleeding risk varies from 1.13% for a HAS-BLED score of 0, up to 
19.6% for a HAS-BLED score of 9. When interpreting these results for a bleed risk, 0 
and 1 are low risk, 2 is moderate risk, and scores of 3 and above are high risk. The HAS-
BLED schema validation demonstrated a C-statistic value of 0.72 and possessed a 
superior predictive ability compared to that of other schemas (Pisters et al., 2010).  





that must be followed. When contemplating the use of an OAC, clinicians use the HAS-
BLED schema to assist them in determining whether or not to withhold OACs (Piccini & 




Warfarin is a vitamin K antagonist that has been known to be an effective 
anticoagulant for about 60 years. It reduces the synthesis of vitamin K and in turn 
prevents the formation of coagulation factors II, VII, IX, and X (Davie, 1995; Nutescu, 
Shapiro, Ibrahim, & West, 2006). Metabolism and plasma concentrations of warfarin are 
affected by liver function, genetics, alcohol, and food consumption. Warfarin therapy has 
a very narrow therapeutic range, and is measured by the international normalized ratio 
(INR), with 2.5 (range 2.0 to 3.0) being the usual therapeutic target for the INR during 
warfarin therapy for AF (Davie, 1995; Ghate, Biskupiak, Ye, Hagan, et al., 2011). The 
antidote for warfarin is vitamin K, which may be administered through intravenous or 
oral routes.  
Warfarin dosing requires close monitoring due to multiple patient variables that 
may affect drug-level fluctuations, such as food, medication, and alcohol intake. Because 
many of the foods that patients normally consume contain vitamin K, diet significantly 
affects coagulant properties, as well as the target levels of warfarin within the blood 
(Custodio das Dores et al., 2007). Moderation in the consumption of green leafy 
vegetables and vegetable oils, which affect vitamin K levels the most, may be required 






In 1991, the Canadian Atrial Fibrillation Anticoagulation (CAFA) study 
(Connolly et al., 1991) randomized patients into two groups: one was receiving warfarin 
with therapeutic INR between 2 and 3,and another group was receiving a placebo. This 
study was discontinued prematurely when the ethics oversight committee determined that 
the warfarin group was receiving stroke-prevention benefits, whereas the control group 
was not; it was deemed unethical to withhold warfarin from the control group (Connolly 
et al., 1991). A similar study conducted in the United Sates, the Stroke Prevention in 
Atrial Fibrillation (SPAF) study, and the Copenhagen Atrial Fibrillation, Aspirin, and 
Anticoagulation (AFASAK) study, found similar results of thromboembolism prevention 
with the use of warfarin (Connolly et al., 1991; Mant et al., 2007; Petersen, Boysen, 
Godtfredsen, Andersen, & Andersen, 1989; Stroke Prevention in Atrial Fibrillation 
Investigators, 1991). The Boston Area Anticoagulation Trial for Atrial Fibrillation 
(BAATAF) study also showed high efficacy of warfarin in preventing strokes, but was 
terminated early by the ethics committee for the same reason as the CAFA study (Boston 
Area Anticoagulation Trial for Atrial Fibrillation Investigators, 1990). These studies 
helped providers recognize that therapeutic levels of warfarin are highly effective in the 
prevention of strokes.  
Additionally, it was demonstrated that warfarin at lower therapeutic levels of 
INR—between 1.3 and 1.6—is still protective against strokes (Kistler et al., 1993). The 
AFFIRM trail showed not only that warfarin reduced strokes, but that it also reduced the 
risk of death (Corley et al., 2004). Patients who are on warfarin therapy and have already 





patients without previous events (1.66%; Hankey et al., 2012). Another consideration of 
warfarin therapy is suboptimal therapeutic INR range in high-risk patients, indicating 
deficiencies of care and the need for improvement (Hankey et al., 2012). Although it has 
been shown in numerous studies that warfarin is superior to aspirin in the prevention of 
strokes, providers are still reluctant to prescribe OACs to older adults. As the CHADS2 
scores increase, warfarin prescriptions decrease, when in fact warfarin prescriptions 
should be increasing with rising CHADS2 scores (Kalus, 2010).  
 
Safety 
Warfarin is broken down by the cytochrome P450 (CYP) in the liver. The 
variability in age, weight, albumin levels, and other medications correlates with changes 
in the warfarin dose to achieve effective anticoagulation (Nutescu et al., 2006). Warfarin 
metabolism is decreased by medications that inhibit cytochrome P450 enzymes, resulting 
in increased warfarin concentrations and effects. As older adults age, the composition of 
their body changes, requiring continual adjustment to their individual warfarin dose. This 
is an ongoing trial-and-error process of adjusting the dose until the therapeutic range is 
reached. Additionally, changes in other medications, chronic diseases, and changes in 
body weight will contribute to changes in warfarin dosing (Singla & Morrill, 2005). As 
the geriatric population ages and their body mass index decreases, the warfarin dose 
required to reach a therapeutic level also decreases (Singla & Morrill, 2005). Despite the 
fact that some models were published to predict warfarin maintenance dosing, 
octogenarians were not adequately represented, and therefore we still do not have a good 





Hughes, & Hylek, 2005).  
The most common food sources of vitamin K are dark green vegetables and oils 
(Nutescu et al., 2006). The challenges of maintaining warfarin levels within the 
therapeutic range in older individuals are associated with their diet, other medications, 
comorbid conditions, and the problem of transportation to and from clinics for necessary 
and sometimes frequent INR checks. This may contribute to missed appointments and 
has the potential to lead to a spontaneous hemorrhage or stroke due to the lack of a 
properly adjusted therapeutic dose. This particular dilemma encountered by providers 
contributes to underutilization of warfarin due to a fear of noncompliance with follow-up 
and maintenance doses (Garcia et al., 2005).  
Individual responses to warfarin therapy depend on the genetic composition of the 
vitamin K receptors and warfarin metabolism. Determination of genetic coding for the 
CYP2C9 (metabolizing enzyme) and VKORC1 (receptor) enzymes has proven clinically 
useful in managing warfarin therapy (Custodio das Dores et al., 2007). The CYP2C9 and 
VKORC1 genotypic variants have been examined and do influence warfarin dosing; 
however, it has been shown that outcomes of pharmacogenomics-guided dosing and 
regular warfarin INR-tested dosing are similar (Hynicka, Cahoon, & Bukaveckas, 2008). 
Presently, health insurance companies do not cover any warfarin-related genetic testing, 
as it has not been shown to be beneficial in maintaining warfarin therapy (Gandara & 
Wells, 2010). Age bias is also an issue; often, a patient’s age rather than the patient’s 
well-being is what affects decision making on the part of providers when assessing for 
the use of OACs (Herrera et al., 2010).  





results in to the office. This would allow for dose adjustments to be made via telephone 
for virtually all patients. Unfortunately, home monitors for INRs maybe cost-prohibitive 
for some older adults.  
Of the 99,628 general emergency hospitalizations in the United States from 2007 
to 2009, a full one third were attributed to the implications of warfarin therapy, and the 
majority of this one third were due to unintentional overdoses causing bleeding (Budnitz, 
Lovegrove, Shehab, & Richards, 2011). Therefore, the capacity to take the drug may 
influence the decision to prescribe warfarin. If a particular patient has a major bleed, he 
or she is not likely to be prescribed warfarin again, and as an alternative, aspirin or 
aspirin plus clopidogrel would be considered for the prevention of thromboembolism. 
Patients’ preferences should also be taken into consideration.  
We do not have a wealth of information concerning the degree to which patients 
actually understand the broader picture regarding warfarin therapy. In a study that 
surveyed patients prescribed warfarin, it was discovered that patients with the highest 
CHADS2 score and subsequently the highest risk of thromboembolism demonstrated 
average and below-average knowledge of OAC drugs (Smith et al., 2010). These patients 
were not aware of the vitamin K content in various foods, and 68% of them were 
unaware of the fact that their food choices were directly related to their warfarin therapy, 
or that various drugs and herbal products can also affect warfarin levels (Smith et al., 
2010). This study illuminates various aspects of the lack of education, ineffective 
education, and/or reinforcement of education, in patients on warfarin therapy. 
European studies have demonstrated that older adults are less aggressively 





age (Fonarow et al., 2010). The reasons for less evidence-based adherence on the part of 
providers may be related to various factors, such as underrepresentation of older 
individuals in the studies, comorbid conditions, polypharmacy, lack of an available 
caregiver, and end-of-life issues (Fonarow et al., 2010). Rates of thromboembolism vary, 
depending on coexisting conditions that patients may have. OACs are used for the 
prevention of thromboembolism, and have provided a demonstrated 64% reduction in 
stroke and 26% reduction in overall mortality in older adults (Lip et al., 2012). 
 
Aspirin and Aspirin Plus Clopidogrel 
Pharmacology 
Aspirin, or acetylsalicylic acid, inhibits cyclooxygenase 1 and 2, resulting in the 
inhibition of prostaglandins and thromboxane A2 and subsequently inhibiting platelet 
aggregation. It has anti-inflammatory, antipyretic, and analgesic properties (Roth & 
Majerus, 1975). This drug has been in use since the 1950s in the United States. In the 
1970s, the first trials showed that aspirin was effective in preventing the frequency of 
strokes and TIAs (Caplan, 2006). 
 
Efficacy and Safety 
Aspirin has been compared to warfarin or placebo in randomized controlled trial 
and has been found to be less effective than warfarin in the prevention of 
thromboembolic events (Healey et al., 2008). The therapeutic dose of aspirin is still 
controversial. In the ACTIVE W trial, which included 6,706 patients who were randomly 





(75mg) or to warfarin (INR 2 to 3), warfarin was shown to be superior to the combination 
of clopidogrel and aspirin (3.9% versus 5.6%), relative risk 0.69 (confidence interval [CI] 
0.57 to 0.85), in the prevention of strokes (Healey et al., 2008). Another discovery of the 
BAATAF study (Kistler et al., 1993) was that aspirin was also effective in preventing 
strokes, but the SPAF (Stroke Prevention in Atrial Fibrillation Study Investigators, 1991) 
and AFASAK   (Petersen, Boysen, Godtfredsen, Andersen, & Andersen, 1989) studies 





Clopidogrel works by blocking the P2Y12 component of the adenosine 5'-
diphosphate pathway on the platelet surface, which blocks activation of GPIIb/IIIa 
receptors, subsequently decreasing platelet aggregation for the duration of their lifespan 
of 7 to 10 days (Caplan, 2006).  
 
Efficacy and Safety 
In a study of clopidogrel (75mg) versus aspirin (325mg) in patients at risk of 
ischemic events, a randomized double-blind trial of 19,185 patients, clopidogrel 
demonstrated an 8.7% decrease of relative risk when compared to aspirin (Caplan, 2006). 
The resultant stroke rate for the clopidogrel group was 405/17,636, or 2.3%, compared to 
the resultant stroke rate for the aspirin group, which was 430/17, 519, or 2.5%. In a recent 





concluded that there is not enough evidence to support this use (Ciccone, Motto, Abraha, 
Cozzolino, & Santilli, 2014). 
 
Combined Aspirin and Clopidogrel Therapy 
The ACTIVE W trial (Healey et al., 2008) demonstrated that patients with a 
CHADS2 score of 1 treated with clopidogrel plus aspirin had a very low stroke rate of 
1.2% per year, patients with a CHADS2 score of 2 had a stroke rate at 1.9% per year, and 
those with a CHADS2 score of 3 had a stroke rate of 2.8% per year, all of which were 
lower compared to patients treated with aspirin alone. Treatment with warfarin reduces 
the risk of stroke by 64%, whereas aspirin plus clopidogrel is associated with a smaller 
stroke risk of 22% (Duke Clinical Research Institute, 2010). In a meta-analysis of 
antiplatelet therapy with a placebo, or no treatment, it was shown that aspirin was 
associated with a 19% reduction of strokes, with absolute stroke risk reduction of 0.8% 
per year (Hart, Pearce, & Aguilar, 2007). In the ACTIVE W trial, OAC was superior in 
the prevention of strokes compared to aspirin plus clopidogrel (Healey et al., 2007). 
Aspirin reduces the risk of stroke by 36%, regardless of the aspirin dose; aspirin plus 







Direct Oral Anticoagulants 
Direct oral anticoagulants (DOACs), which began with the release of Pradaxa, 
became available in 2010. They do not require laboratory monitoring of blood level 
concentrations or any other tests. It is notable that there is no antidote for any of the 
DOAC medications.  
 
Dabigatran 
Dabigatran is a direct thrombin inhibitor with a half-life of 12 to 17 hours. The 
U.S. Food and Drug Administration (FDA) approved dabigatran for the prevention of 
thromboembolism related to nonvalvular AF in 2010 (Sanford & Plosker, 2008). The 
Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial (Eikelboom 
et al., 2011) included 18,113 patients who were randomly assigned to taking dabigatran at 
either 110mg twice a day or 150mg twice a day, with patients on warfarin at proper INR 
levels. The investigators concluded that dabigatran at 110mg twice a day was similar to 
warfarin in preventing stroke, but did exhibit a lower risk of bleeding than warfarin 
(relative risk 0.90, 95% CI 0.74 to 1.10). Dabigatran at 150mg twice a day was superior 
to warfarin in preventing stroke, but exhibited a risk of bleeding that is similar to that of 
warfarin (relative risk 0.65, 95% CI 0.52 to 0.81). Dabigatran was approved at doses of 
110mg twice a day and 150mg twice a day. Both doses were associated with lower risks 
of intracranial bleeding; however, higher doses of dabigatran correlated with higher 
incidences of gastrointestinal bleeding compared to that of warfarin (5.10% versus 4.37% 
per year; p = 0.07). There was significant correlation between patient age and the number 





compared to their counterparts who were age 75 and older. Patients exhibiting a 
creatinine clearance of less than 50 mL/min, when compared to patients at 80 mL/min or 
higher, experienced a 2-fold increase in risk of bleeding. This is because dabigatran is 
80% renally excreted, whereas warfarin is not renally excreted, and the fact that older 
patients suffer from deteriorated renal function explains the higher concentrations of the 
drug in the blood, which causes the increased risk of bleeding (Eikelboom et al., 2011).  
Comparing death rates in the RE-LY trial, warfarin deaths were at 4.13% per 
year, dabigatran 110mg twice a day at 3.75% per year, and dabigatran 150mg twice a day 
at 3.64% per year. The risk of myocardial infarction was 0.53% with warfarin, 0.72% 
with dabigatran at 110mg twice a day, and 0.74% with dabigatran 150mg twice a day. 
Major bleeding events with warfarin were at 3.36%, compared to 2.71% with dabigatran 
110mg twice a day, and 3.11% with dabigatran 150mg twice a day (Connolly, Ezekowitz, 
et al., 2009). An analysis of a subgroup of patients in the RE-LY trial who had previously 
suffered one or more strokes also revealed that dabigatran (150mg twice a day) was 
superior to warfarin in preventing further strokes (Diener et al., 2010). In the RE-LY trial 
(Eikelboom et al., 2011), 40% of the patients were taking aspirin in addition to dabigatran 
or warfarin, and adjuvant treatment with aspirin did not predispose either group to an 
increase in major bleeding events (Alberts, Bernstein, Naccarelli, & Garcia, 2012).  
There is no antidote for dabigatran, which presents a challenge for providers in 
the case of a major bleed. Although hemodialysis may be useful, it takes hours to 
accomplish. Activated prothrombin complex concentrate preparations may be effective; 
however, the dose for humans is unknown. Preclinical data show that the recombinant 





A May 2012 case report from the Neurosurgery Department of the University of 
Utah Hospital described the case of an 83-year-old male who was brought to the hospital 
after a fall and was diagnosed with an intracranial hemorrhage. He was taking dabigatran 
150mg twice a day for AF, and died several hours after his presentation, despite the 
efforts of the neurosurgery team to reverse the dabigatran effects (Garber, Sivakumar, & 
Schmidt, 2012).  
 
Rivaroxaban 
Rivaroxaban was approved by the FDA in 2011 for the prevention of 
thromboembolism in patients with nonvalvular AF; it is a direct factor Xa inhibitor. A 
full one third of each rivaroxaban dose is eliminated unchanged through the kidneys, 
while the remaining two thirds are metabolized by the liver (Duke Clinical Research 
Institute, 2010). In the ROCKET AF trial (Patel et al., 2011), it was found that 
rivaroxaban was not inferior to warfarin, with no significant differences in rates of major 
bleedings, and that fatal bleedings occurred less frequently in the rivaroxaban group. The 
researchers concluded that a stroke or systemic embolism occurred at the rate of 1.7% in 
the rivaroxaban group and 2.2% in the warfarin group. In the same trial, major bleeding 
outcomes in the rivaroxaban group were at 3.6% and 3.4% in the warfarin group, with 
fewer fatal bleeds in the rivaroxaban group. In the rivaroxaban group, death occurred at 
1.9%, while in the warfarin group these occurrences were at 2.2% (Patel et al., 2011). 
The ROCKET AF trail also showed that patients treated with rivaroxaban who underwent 
rivaroxaban drug discontinuation had higher rates of stroke and systemic embolism 





overlapping treatment occurs with another OAC or aspirin when stopping this therapy 
(Patel et al., 2013). There is currently no reversal agent for rivaroxaban, although the 
search for a reversal agent continues.  
 
Apixaban 
Apixaban is a direct factor Xa inhibitor that was approved in the United States in 
2012 for thromboembolism prevention in nonvalvular AF; it is renally excreted at a rate 
of 25% of the dose. Granger et al. (2011), in their study, compared apixaban with 
warfarin, finding an event rate per year for strokes in the apixaban group at 1.19% and 
the warfarin group at 1.51%; the event rate per year for major bleeding was 2.13% in the 
apixaban group and 3.09% in the warfarin group. Death outcome event rates per year 
were 3.52% for the apixaban group and 3.94% for the warfarin group (Granger et al., 
2011).  
Granger et al. (2011) had similar findings regarding the reduced rate for stroke 
with apixaban compared to aspirin, without finding any difference in the rates of major 
bleeds. Lower rates of MI were also demonstrated in the apixaban group versus both the 
warfarin and aspirin groups. In the AVERROS trial, apixaban evidenced stroke rates of 
1.6% per year, while aspirin and clopidogrel produced stoke rates of 3.7% per year, 
leading to the early discontinuation of the trial due to the superiority of apixaban (Skanes 
et al., 2012).  
In the subgroup of the ARISTOTLE trial (Easton et al., 2010), the researchers 
found a 2-3 times higher risk of stroke or systemic embolism among patients with a 





experienced a previous stroke or TIA comprised 15% to 25% of the treated AF 
population, who were at high risk of subsequent thromboembolic events as well as 
increased risk of bleeding (Easton et al., 2012). Additionally, previous stroke was 
associated with an increased risk of death, which is consistent with previous studies. In 
patients with ischemic stroke, prescribing an OAC is a controversial issue. In the 
ARISTOTLE trial (Easton et al., 2010), patients who experienced a stroke or TIA within 
the previous 7 days were excluded; however, 234 patients who experienced a stroke or 
TIA within the previous 8 to 30 days were included. In the RE-LY trial (Connolly et al., 
2009), patients who experienced a stroke or TIA within the previous 14 days, and patients 
with severe stroke within the previous 6 months, were excluded. In the ROCKET AF trial 
(Patel et al., 2011), patients who experienced a severe stroke within the previous 3 
months or any stroke within 14 days were excluded. As a result of these variances, we 
have no confirmed answer as to whether it is safe to restart an OAC with novel agents 
after a stroke or a TIA (Easton et al., 2012).  
 
Antidote 
Scientists continue to search for a means to reverse the effects of DOACs, as well 
as for ways to develop blood-concentration tests for novel OACs. These strategies are of 
paramount importance in addressing the needs of patients who may suffer a major bleed, 








The overall cost burden of AF on the U.S. healthcare system is $26 billion 
annually, with hospitalizations generating 52% of these costs and medications generating 
23% of them (Limone, Baker, Kluger, & Coleman, 2013). The debate about the high cost 
of novel OACs continues, and one point made by the industry is that novel OACs do not 
require INR checks and therefore do not cost as much as is perceived by the public. 
When calculating related healthcare costs, dabigatran dosed at 150mg twice a day and at 
110mg twice a day was shown to be more cost effective compared to the cost of warfarin 
combined with the costs of the requisite INR check visits (Limone et al., 2013). It is 
presently quite difficult to assess the cost effectiveness of novel OACs, first because they 
have not been available for a sufficient length of time to allow for that assessment, and 
second because we are on the brink of discovering new agents, and reversal agents, 




Clinicians rely heavily on guidelines for the prevention of thromboembolism in 







Guidelines for the Management of Atrial Fibrillation: The Task Force for  
Management of Atrial Fibrillation of the  
European Society of Cardiology (ESC) 
According to the 2010 ESC guidelines for the management of AF, the focus is on 
prevention of thromboembolism, as well as elimination of symptoms and complications 
of AF. Patients who are diagnosed with paroxysmal AF should be treated similarly to 
patients with persistent AF with regard to their stroke risk (Camm et al., 2010). The 
CHADS2 schema should be used initially as a rapid screen for assessing stroke risk, and 
if it produces a score of 2 or higher, then warfarin should be recommended (INR 2–3). 
INR is an internationally established biologic test for the effects of warfarin on clotting 
activity. In these guidelines, the emphasis on the prevention of strokes was evident by the 
addition of the CHA2DS2-VASc schema to capture a wider number of patients who will 
benefit from an oral OAC (Camm et al., 2010). Researchers reported that annual stroke 
risk was decreased by 67% when using warfarin according to the guidelines for primary 
and secondary prevention; there was also a 26% reduction of all-cause mortality (Camm 
et al., 2010). The final consensus was to recommend warfarin treatment for patients with 
one or more risk factors.  
Aspirin was also discussed in light of stroke prevention, reporting that aspirin 
alone reduces stroke by 22% (Camm et al., 2010). The Birmingham Atrial Fibrillation 
Treatment of the Aged (BAFTA) study (Mant et al., 2007) showed that warfarin therapy, 
with target INR between 2 and 3, was superior to aspirin therapy by 52%, and revealed 
no difference in the occurrence of major hemorrhages between aspirin and warfarin 





both the combination of clopidogrel with aspirin and aspirin alone. The ACTIVE A study 
(Camm et al., 2010) demonstrated that the use of aspirin alone is inferior to that of aspirin 
plus clopidogrel therapy.  
The ESC guidelines currently rely on the CHADS2 schema for stroke prevention, 
with a score of 2 or more requiring chronic OAC with warfarin, with target INR between 
2 and 3. It is recommended that patients with a CHADS2 score of 0 to 1 use CHA2DS2-
VASc schema scores, as well as weighing the additional risk factors for bleeding (Camm 
et al., 2010).  
 
American College of Cardiology Foundation/American Heart  
Association/Heart Rhythm Society (ACCF/AHA/HRS)  
Task Force on Practice Guidelines With “Focused  
Update” in 2011 
The ACCF/AHA/HRS 2006 guidelines (Fuster et al., 2006) do not include 
recommendations based on the CHADS2 schema, although it is mentioned in the text of 
the guidelines. According to the guidelines, patients with no risk factors should be on 
aspirin 81mg to 325mg. Patients with one moderate risk factor should be on aspirin 81mg 
to 325mg, or warfarin with an INR between 2 and 3. Moderate risk factors include age 75 
years and older, hypertension, heart failure, impaired left ventricular systolic function 
with ejection fraction of 35% or less, and diabetes mellitus (Fuster et al., 2006). Patients 
with more than one moderate risk should also be anticoagulated with warfarin with INR 
between 2 and 3 (Fuster et al., 2006). The recommendations for warfarin are in place for 





These guidelines emphasize the existing controversy surrounding the treatment of 
patients with an intermediate stroke risk (3% to 5% per year), accentuating bleeding risks 
and patient preference (Fuster et al., 2006). 
The ACC/AHA/HRS 2006 guidelines were updated in 2011 due to the emergence 
of new evidence discovered in the RE-LY trial (Connolly et al., 2009), a significant trial 
that changed the practice of providers. It focused on dabigatran etexilate and its use for 
AF (Wann et al., 2011). Results of the study were published in 2009, showing the 
noninferiority of dabigatran when compared with warfarin in the prevention of strokes. In 
fact, 150mg of dabigatran twice a day showed superiority in the reduction of annual 
stroke risk  at 1.11%, when compared to warfarin, demonstrating a reduction of stroke 
risk annually to only 1.71%, (Wann et al., 2011). A dabigatran dose of 110mg twice a 
day was noninferior to warfarin, with dabigatran causing bleeds at the rate of 2.87% 
compared to warfarin at 3.57%, with INRs in the target range of 64.4% (Wann et al., 
2011). Dabigatran 150mg twice a day was approved and recommended in the United 
States for patients with creatinine clearance of 30 or higher (Wann et al., 2011).  
 
Canadian Cardiovascular Society (CCS) 2012 
The CCS guidelines recommend using CHADS2 for stroke risk and HAS-BLED 
for bleeding risk. They also recommend the use of dabigatran, rivaroxaban, or apixaban 
in preference to warfarin (Skanes et al., 2012). In further discussion of novel OACs 
compared to warfarin, the researchers observed that dabigatran and apixaban have greater 
efficacy than warfarin, and that rivaroxaban exhibits the same efficacy as warfarin in 





greater than 2 should be started on an OAC; intermediate-risk patients with a CHADS2 
score equal to 1 should receive an OAC, with aspirin being considered for some patients 
based on individual risk factors; and low-risk patients with a CHADS2 score of 0 should 
be evaluated for additional risk factors, such as age 64 to 74 years, female gender, and 
vascular disease. Within this category, an OAC is recommended for patients with high 
risks, such as age greater than 65 years or the combination of female gender and vascular 
disease. Aspirin 75mg to 325mg is recommended for patients with lower risks, such as 
female gender or vascular disease, and antithrombotic therapy is recommended for 
patients with the lowest risk (Skanes et al., 2012).  
 
National Institute of Health and Care Excellence  
(NICE) 2012 Update 
The 2012 update of the NICE guidelines occurred after the approval of dabigatran 
twice-per-day dosing at both 150mg and 110mg. The U.S. FDA did not approve 
dabigatran 110mg twice a day, instead approving 75mg twice a day for patients with 
renal insufficiency; however, this dose is not included in the NICE guidelines, as it has 
not yet been studied in randomized clinical trials (Ahmad & Lip, 2012). In the United 
Kingdom and European countries, dabigatran 110mg twice a day was approved and is 
presently in use. The NICE guidelines indicate that dabigatran should not be used in 
people in the following categories: patients with severe renal impairment, as this drug is 
renally excreted; patients with acute bleeding or who are at risk for bleeding; patients 
with impaired hemostasis; patients with liver impairment; and patients using certain 





& Lip, 2012). Another point made by these guidelines is that the CHADS2 schema is not 
very sensitive to patients with a score of 0, and that the CHA2DS2-VASc schema should 
be used for these patients (Ahmad & Lip, 2012). The use of the HAS-BLED schema is 
emphasized and recommended. It is also noted that patients with a high HAS-BLED 
score experience a greater clinical benefit from an OAC, as their risk of stroke is higher 
than their bleeding risk (Ahmad & Lip, 2012). These guidelines do not address the 
management of major bleeding situations on dabigatran, the replacement of dabigatran 
with other OAC, or perioperative situations.  
 
Antithrombotic Therapy and Prevention of Thrombosis, Ninth Edition:  
American College of Chest Physicians Evidence-Based  
Clinical Practice Guidelines 
These guidelines recommend no therapy for patients with a CHADS2 score of 0, 
or aspirin 75mg to 325mg a day, or a combination of aspirin and clopidogrel. For these 
patients it is recommended that other risk factors be assessed, such as bleeding risk, age 
65 to 74 years, and female gender, which would impact the decision regarding the use of 
an OAC. For patients with a CHADS2 score of 1, OAC is recommended, or an aspirin 
and clopidogrel combination for patients who choose not to take an OAC (Guyatt et al., 
2012). For patients with a CHADS2 score of 2, an OAC is recommended, or aspirin 
(75mg to 325mg/day), or a combination therapy of aspirin and clopidogrel. Dabigatran 
150mg twice a day instead of warfarin is also recommended for patients who are in need 







Clinicians in the United States rely on the various guidelines discussed above, and 
this presents a challenge, as there are differences among them. European and Canadian 
guidelines include CHA2DS2-VASc scores for further determination of a stroke risk. The 
U.S. guidelines do not use CHA2DS2-VASc scores and this is less advantageous for 
patients, as the CHA2DS2-VASc assesses more risk factors than CHADS2 does. For 
example, a 70-year-old female patient with AF who has a stroke risk of 0 according to the 
CHADS2 schema will have a stroke risk of 2 according to assessment by the CHA2DS2-
VASc schema (which scores for age and female gender), placing her in the category of a 
2.2% stroke risk per year and calling for the initiation of at least aspirin (Lip, Nieuwlaat, 
Pisters, Lane, & Crijns, 2010).  
As the guidelines evolve, the CHA2DS2-VASc schema scoring system will be 
implemented for use in the United States as it has been in Europe and Canada since 
2011–2012. Our understanding of this disease process affords us the insight to treat AF 
more aggressively to prevent devastating strokes. The controversy among clinicians with 
regard to treatment with an OAC is ongoing, because there is no present consensus 
among the guidelines or among clinicians. 
 
Frailty 
Frailty has been defined as the loss of reserves, to include physical, cognitive, and 
energetic. Another definition is the presence of three or more of the following symptoms: 
unintentional weight loss, feeling exhausted, weak grip strength, slow walking speed, and 





changes in pharmacokinetics, such as drug absorption; slowing of liver metabolism; and 
reduction in creatinine clearance; and these may be amplified in frailty. Morley et al. 
(2013) described frailty as physical and psychological declines, which are parts of the 
“medical syndrome.” There is currently no consensus regarding the definition of frailty 
within the medical community, which has led to various attempts to define this 
phenomenon; however, it is known that numerous body systems are involved in the 
condition. Frailty predicts disability, as well as both physical and cognitive declines 
(Fried, Ferrucci, Darer, Williamson, & Anderson, 2004).  
Frailty is a biologic syndrome characterized by the inability to withstand 
stressors; it also increases patient vulnerability to adverse outcomes. These characteristics 
arise from the aggregate deterioration of various biological systems of the patient. The 
declines manifest as decreases in strength, mobility, balance, body mass, and overall 
activity levels. The result is a disturbance of homeostasis, which renders affected 
individuals unable to react appropriately to stressors. In the presence of an OAC, these 
individuals are also more likely to develop hemorrhage that will typically be 
accompanied by further complications (Fried et al., 2001). The ICD-9 codes 
(International Classification of Diseases, 9th edition; Buck, 2012) used within this study 
include a variety of conditions related to these aging declines, and the presence of at least 
one of these declines is considered as the presence of frailty. 
Providers are faced with treating older frail patients—already at risk due to the 
decline in their health—with an OAC for AF. In a study of 228 adults age 76 years and 
older (mean age = 81 years) with AF and frailty, 30% of the participants died during the 





participants were treated with warfarin for AF, and they exhibited a 10% annual rate of  
major hemorrhage. In a study by Shivkumar, Jafri, and Gheorghiade (1996), a separate 
analysis of participants 75 years and older showed a hemorrhage rate of 4.2%.  Another 
study with participants age 75 years and older discovered that hemorrhage rates were 
9.8% with therapeutic INR (Johnson et al., 2005). These facts illustrate that older people, 
who are more likely to be frail, are at higher risk for hemorrhage from using OACs. GI 
bleeds occur in patients age 75 years and older at the rate of 30.2%; the stroke risk for 
those same patients is 8%. The hemorrhage risk is greater than 3.9% in frail individuals 
(Johnson et al., 2005).  
Our society views aging somewhat negatively, inspiring older individuals to strive 
to remain healthy, and age stigma may actually contribute to a more “fit” older 
population. These older adults are able to participate in clinical trials and take regular 
medications. Conversely, frail older adults are less likely to participate in clinical trials or 
take various medications and treatments (Herrera et al., 2010). Providers are faced with 
making decisions about recommending OACs to adults age 75 years and older. While this 
population is underrepresented in clinical trials, they must still be treated with OACs 
according to the guidelines; however, they are at risk for a hemorrhage as a result of 
increased frailty. Although the literature recommends treatment of adults age 75 years 
and older with an OAC because they are at the higher risk for stroke, in practice, OACs 
are underutilized. It has been clearly demonstrated that this causes embolic strokes, and 
in frail individuals this risk is up to 12.3% without an OAC (Tay, Lane, & Lip, 2009).  
Clinicians are aware that frailty is a state of vulnerability which in and of itself 





Moreover, frailty is the strongest predictor of underutilization of OAC or antithrombotic 
medications prescribed to older patients with AF upon discharge from the hospital. This 
was discerned from a prospective study of 220 patients admitted to an inpatient unit in 
one of the teaching hospitals in Australia (Perera, Bajorek, Matthews, & Hilmer, 2009). 
All of the patients were age 70 years or older and they were followed up for 6 months 
after their discharge. The resultant underutilization of warfarin was associated with a high 
risk of falls, history of bleeding, and impaired cognition. The picture of frail individuals 
is complex, and it is further compounded by increased mortality, functional limitations, 
and cognitive declines that may lead to the loss of personal autonomy and eventual 
institutionalization (Fumagalli et al., 2010).   
 
Falls 
Falls are common among older adults, with an incidence of 33% in those age 65 
years and older and 50% in those age 80 years and older, causing most of the common 
injuries among older trauma patients and a mortality rate of 6% (Pieracci, Eachempati, 
Shou, Hydo, & Barie, 2007). In a retrospective study of 47,717 patients age 65 years and 
older who were hospitalized as a result of a fall that produced traumatic injury,  
intracranial hemorrhages were linked with falls in 2,517 patients (5.1%); the mortality 
rate from these fall-related hemorrhages was 15.5% (n = 394; Pieracci et al., 2007).  
This problem is multifactorial and requires a systematic approach by providers. 
Falls may be triggered by drug interactions, anemia, and dehydration. Physical therapy 
consisting of strength and balance exercises will help in the prevention of falls (Morley, 





older patients taking warfarin who experience falls, usually 1 in 10 of those falls will 
cause a major injury, such as a fracture, and those patients are more likely to develop an 
intracranial hemorrhage (Tay et al., 2009).  
The subject of polypharmacy, or patients taking five or more prescriptions 
simultaneously, occurs in 20% to 40% of older people. This can predispose patients to a 
myriad of side effects that may in turn result in falls. If taking six or more medications 
simultaneously, 81% of patients experience falls (Le Couteur, Hilmer, Glasgow, 
Naganathan, & Cumming, 2004). The risk of falling increases by 71% when older adults 
take psychotropic medications. Benzodiazepines cause an increase in falls at a rate of 
50% to 110%, frequently causing confusion in 11% to 30% of patients and delirium in 
2% to 12% (Le Couteur et al., 2004). These falls are preventable; in fact, the withdrawal 
of psychotropic and other medications reduces falls. As older individuals age, they are 
less likely to be prescribed an OAC due to their age, increased risk of falls, and other 
comorbidities (Riva et al., 2011).  
Older people on a long-term OAC, hospitalized after a fall, are at 50% increased 
risk of intracranial hemorrhage and 57% risk of mortality (Pieracci et al., 2007). These 
numbers are due to the fact that patients on a long-term OAC are older and have more 
comorbidity. Because elderly subjects have been excluded from clinical trials, we do not 
have sufficient information about fall-related injuries while patients are taking an OAC. 
Falls, and injuries resulting from falls, are not included in the guidelines, but in real 
practice falls play a very important role in making a decision about the initiation of OACs 
in older adults with AF. Indeed, current guidelines take age into consideration, but not 





situations in which providers use common risk schemas in addition to considering falls, 
frailty, and dementia (Poli et al., 2011).  
Patients age 85 and older are at greater risk of bleeding due to malignancies, renal 
failure, history of previous bleeding, and falling, which increase bleeding risk fivefold 
(Poli et al., 2011). AF itself maybe a source of falls and syncope due to associated 
bradyarrhythmias, which typically require the use of a pacemaker (Maurer & Bloomfield, 
2002).  
Jacobs, Billett, Freeman, Dinglas, and Jumaquio (2009) found that falls are 
prevalent in older adults, at a rate of 21% compared to the 32% that is reported in the 
literature, and that falls are the most frequently cited reason by providers for 
nonprescription of an OAC. The same study revealed that intracranial hemorrhage risk is 
smaller than ischemic stroke risk, at 2.8% and 13.7%, respectively, suggesting that these 
patients would benefit from the use of an OAC. Patients on an OAC who suffer from falls 
exhibit an overall mortality rate of 45%; it is unclear if this is attributable to the risk 
factors for falls, AF, or warfarin use, or a combination of these factors (Jacobs et al., 
2009). Although warfarin use is clearly beneficial for those at risk for stroke, it remains 
unclear exactly who should be prescribed an OACs in light of the fact that the benefits of 
OACs outweigh the risks of falls (Garwood & Corbett, 2008). 
 
Dementia 
The health problem known as dementia is described as the impairment of memory 
combined with at least one or more cognitive declines (Bunch et al., 2010). Dementia 





dementia are afflicted with Alzheimer’s disease, the most common form of dementia, and 
another 10% to 20% of the dementia population is afflicted by vascular dementia (Bunch 
et al., 2010). AF has been associated with all forms of dementia, increasing mortality 
rates for these individuals as they age (Bunch et al., 2010). Older women make up the 
largest of the groups with cognitive impairment and AF, which is associated with 
dementia (Ott et al., 1997). Because age is the greatest risk factor for Alzheimer’s disease 
as well as AF, the presence of both conditions is not surprising (Moschetti, Cummings, 
Sorvillo, & Kuo, 2012). The idea has been proposed that patients with AF are more likely 
to develop silent cerebral infarctions, causing the development of dementia (Kilander et 
al., 1998; Marengoni, Qiu, Winblad, & Fratiglioni, 2011). Another mechanism that may 
cause an increased prevalence of dementia in AF patients is cardiac output fluctuations, 
contributing to hypoperfusion of the brain (Forti et al., 2007). AF is associated with a 
40% to 50% higher risk of dementia, independent of stroke (Dublin et al., 2011).  
In addition to age, the underutilization of OACs may contribute to dementia, with 
AF possibly contributing to cognitive decline due to a previous cerebrovascular accident 
(CVA) or TIA (Jacobs et al., 2009). Older patients with a stroke are more likely to be 
female and have comorbid conditions and dementia (Dharmarajan, Varma, Akkaladevi, 
Lebelt, & Norkus, 2006; Saposnik et al., 2009). As reported in the ACTIVE W trial 
(Healey et al., 2008), patients treated with warfarin remained within the INR therapeutic 
level less than 65% of the time, which could predispose to microemboli that might 
manifest as cognitive impairment (Flaker et al., 2010). Also discussed was the fact that 
patients with subtherapeutic INR levels of warfarin are more likely to develop dementia, 





bleeding (Flaker et al., 2010).  
Another form of dementia is post-CVA dementia. The presence of AF is driving 
patient risk for dementia to increase, as well as increasing the incidence of post-CVA 
dementia. Given the fact that providers are more likely not to prescribe OACs to older 
adults with dementia, those patients end up with an even higher risk for the occurrence of 
poststroke dementia (Kwok, Loke, Hale, Potter, & Myint, 2011). The role that OACs 
play in patients with dementia is unclear, as it has not been studied, and as a result it is 
difficult to discern which of these maladies occurs first, AF or dementia (Kwok et al., 
2011). Because CVA affects cognition, and the symptoms of this type of injury may also 
be attributed to cognitive weakness associated with age, clinicians may find it difficult to 
distinguish between these two causative factors (DeCarli, 2013). Older patients with 
cognitive impairment were followed for a 10-year period; notably, 40% of them did 
develop dementia (Cacciatore et al., 2012). 
In older populations, falls, frailty, and dementia are significant contributors to 
decision making with regard to OACs for patients with AF. These three conditions are 
among the most common geriatric syndromes. These are usually described as conditions 
that lack clear definition, presenting a constellation of symptoms rather than a single 
disease process (Inouye, Studenski, Tinetti, & Kuchel, 2007). These problems are more 
likely to affect older patients with more severe comorbid conditions, and this presents a 
significant dilemma for clinicians. Although the combination of these factors will 
contribute to the initiation of OACs, falls, frailty, and dementia are not mentioned in the 
guidelines. As the population in the United States ages and clinicians encounter these 





OACs, and the related morbidity and mortality. If our understanding of these problems 
improves sufficiently, we will be better equipped to answer questions that are related to 
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Using a retrospective, descriptive, longitudinal design, we investigated the 
difference in outcomes among patients using oral anticoagulants (OACs), antiplatelet 
agents (ATPLs), and patients who do not take oral anticoagulation or antiplatelet agents 
(No OAC/ATPL) for the prevention of thromboembolism due to atrial fibrillation (AF), 
exploring stroke and hemorrhage outcomes in patients with concomitant geriatric 
syndromes (falls, dementia, frailty). AF is a disorganized rhythm of the atria causing the 
creation of emboli. 
The goal was to determine what impact previously diagnosed falls and/or frailty 
and/or dementia would have in patients who are prescribed oral anticoagulants versus 
antiplatelet agents versus those who are not prescribed either oral anticoagulants or 
antiplatelet agents. Given the recommendations in current guidelines, a randomized 
controlled trial was not feasible for this type of study for ethical reasons, so we chose a 
naturalistic observational approach. This retrospective study utilized baseline 
characteristics and risk factors using multivariate regression modeling while taking into 





were used. The use of a survival analysis assisted in predicting overall hazards of the 
groups. The methods model described below was developed to guide the statistical 
analysis and hypothesized relationships among variables, as well as identification of the 
variables included in the analysis. 
 
Methods Model 
The model was tested sequentially, adding relevant factors at each step. The first 
step was to address the main question: What would happen if patients with AF and 
geriatric syndromes who are older than 65 years of age were to take oral antithrombotic 
therapy (see Figure 3.1)? 
When assessing the relationship between treatment and oral anticoagulants or 
antiplatelet agents for AF, the main events or outcomes to consider are a stroke or a 
hemorrhage. Comprehensive assessments of outcomes allowed for accounting of all 
variables contributing to all-cause mortality rates in these patients.  
The model was tested using data from electronic records, which were stored in an 
enterprise data warehouse (EDW) containing electronic information. Documentation of 
these outcomes and the use of OAC medications compiled for the period of January 1, 
2010 to December 31, 2014, was used. All outcomes were binary, but some were right-
censored. The use of survival analysis, or time-to event analysis, as well as logistic 
regression, helped to examine these data. At the time of each stroke or hemorrhage event, 
a definite result was recorded, but most patients did not experience the event and the data 
became censored at the time of last observation. The Kaplan-Meier method of estimating 





analysis (Figure 3.1), treated as a simple predictive relationship. In the Kaplan-Meier 
approach, each event is represented by an interval which is one observed event time, and 
each interval ends before the beginning of the next, with separate cumulative 
probabilities by OAC or antiplatelet treatments (Singer & Willett, 2003). When 
examining this simple relationship, the main question was answered based on the 
occurrence or nonoccurrence of an event.  
In reality, this relationship is more complex than is expressed in Figure 3.1 
because of the presence of important covariates that also affect the outcomes (see Figure 
3.2). 
The question of what would happen if a patient were to take OACs can be 
answered more accurately by conditioning on these covariates (examining the OAC 
difference within levels of the covariates). Kaplan-Meier analysis can adjust properly for 
categorical covariates, but proper adjustment for continuous covariates requires a Cox 
regression analysis.  
When assessing stroke outcomes, the first relationship requiring assessment is the 
association of the CHA2DS2-VASc risk schema with the stroke. The CHA2DS2-VASc 
was developed to evaluate the risk of a stroke in patients with AF. When assessing 
hemorrhage outcomes, the first relationship requiring assessment is the association of the 
HAS-BLED schema with hemorrhage. HAS-BLED is a tool developed to evaluate the 
risk of bleeding when treated with OAC therapy. Although it is possible to treat these 
covariates as categorical, the more general approach requires the flexibility of Cox 
regression.  





reduction in the instance of cerebrovascular accident (stroke or TIA) and hemorrhage 
outcomes. In practice, however, the importance of both schemas, HAS-BLED and 
CHA2DS2-VASc, is well known and is routinely used prognostically to help determine 
whether to place patients on oral anticoagulants. This makes the relationship considerably 
complex, as shown in Figure 3.3.  
When assessing geriatric syndromes (falls, dementia, and/or frailty), it is evident 
in both the literature and clinical practice that because they are considered when 
assessing the risk factors for determining the initiation of OAC, they do in fact act as 
predictors of this therapy, while they are not included in any stroke- or bleed-related 
schemas. Answering the main question demands taking all variables into consideration, 
as illustrated in the full model represented by the detailed schematic in Figure 3.4. This 
model also represents comparison of two groups of patients with and without the geriatric 
syndromes of dementia, and/or falls and/or frailty.   
 
Setting 
This study was conducted using records generated at the University of Utah 
Hospitals and Clinics, located in Salt Lake City. Specific hospital locations include 
Clinical Neurosciences Center, Health and Wellness Center, Huntsman Cancer Institute, 
John A. Moran Eye Center, the Pain Management Center, Riverton Hospital, Surgical 
Specialty Center, University Neuropsychiatric Institute, and University Orthopedic 
Center. Specific satellite locations include Centerville Health Center, Davis Vision 
Center, Greenwood Health Center, Madsen Health Center, Murray Dermatology Clinics, 





Health Center, Redwood Health Center, South Jordan Health Center, Stansbury Health 
Center, Sugar House Health Center, and Westridge Health Center. 
 
Sample 
Participants were chosen based on the following criteria: patients diagnosed with 
AF at age 65 or older. Participants with incomplete datasets were excluded, as were those  
with a history of stroke or a hemorrhage prior to time zero. 
 
Variables 
Inclusion Criteria Variables 
All variables listed below were requested from the EDW if the dates of the 
diagnosis of atrial fibrillation were made between January 1, 2010 and December 31, 
2014. Consistent with procedures developed by previous investigators to validate the 
target diagnosis, subjects were included in the sample only if they had two or more visits 
related to the AF diagnosis, assuring that they were treated on a long-term basis for this 
disease (Piccini et al., 2012). 
Only patients with atrial fibrillation (ICD-9 code 427.31) were included in this 
sample. All patients in the sample were age 65 years and older. To determine the 
accuracy of the AF diagnosis in the final pool of subjects, 532 individual chart reviews 
were performed. This process was facilitated by using the WartHog program at the EDW. 
This program allows researchers to instantly locate specific phrases in the medical 
records, such as atrial fibrillation, eliminating records unrelated to the term searched and 





searching, it is also extremely accurate. Of a subsample of 532 charts retrieved based on 
the ICD-9 code, we were able to document the diagnosis of AF in all but 11. This 
represents 98% accuracy in locating AF diagnoses, which is higher than the average of 
82.2% found in the literature for accuracy of ICD-9 diagnoses of AF (Thigpen et al., 
2015). 
 
Exclusion Criteria Variables 
Only patients with nonvalvular AF were included in this study; consequently, 
patients with diagnoses of any prior valvular problems were excluded. The purpose for 
this decision was to capture oral anticoagulant use only for AF. Patients with a diagnosis 
of mural thrombus, pulmonary embolism, or deep vein thrombosis were excluded to 
ensure that the warfarin use was directly attributable to patients taking it for AF, and not 
for other problems (see Table 3.1). 
 
Therapy Group Variables 
Medications initiated following the identification of a diagnosis of AF were 
extracted to detect use of anticoagulant or antiplatelet agents commonly used to prevent 
thrombotic complications. Subjects were divided into one of three therapy groups: oral 
anticoagulation (warfarin, apixaban, rivaroxaban, dabigatran); antiplatelet agents (aspirin, 
clopidogrel, prasugrel, ticagrelor); and no oral anticoagulation or antiplatelet agents. If 
subjects had a record of both antiplatelet and oral anticoagulant therapy, they were 
assigned to the oral anticoagulant group. It is difficult to separate these therapies because 





many patients take aspirin.   
 
Geriatric Syndromes 
Causal relationship chains may be explained by using confounding variables to 
help to elucidate certain conditions that produce certain explanations of descriptive causal 
effects (Shadish, 2002). The following geriatric syndromes were included in the study: 
falls, and/or dementia, and/or frailty (see Table 3.2). 
 
Outcome Variables 
CVA/TIA and hemorrhages were the two outcomes captured in this study, as 
shown in Table 3.3. Although TIA does not cause permanent brain damage, it is one of 
the comorbidities measured by the CHA2DS2-VASc scoring system, as it is typically 
considered to be a warning for stroke. It evaluates as an equivalent of a stroke, so both 
stroke and TIA were included as positive indicators of a cerebrovascular event, the 
outcome in this study (Lip, Tse, & Lane, 2012).    
In this study, patients were followed from the start of their medication until they 
either dropped from observation or experienced an event. These types of data are right-
censored (Singer & Willett, 2003).   
 
CHA2DS2-VASc Covariate Variables 
Covariates are variables that we control for in a study to eliminate the effects of 
one variable on another (Trochim, 1999). This study used a calculated CHA2DS2-VASc 





other risk factors for a CVA and maximize the predictive ability of the confounding 
covariates (see Table 3.4).  
 
HAS-BLED Covariate Variables 
Covariates for hemorrhage outcomes are derived from the HAS-BLED schema, 
which includes the most common risk factors for hemorrhages. All diagnoses derived 
from this schema were coded with the appropriate ICD-9 code and verified utilizing 




The electronic EDW at the University of Utah was utilized to create a dataset for 
use in this study. After institutional review board approval, the electronic records of 
eligible patients were used to create the dataset, beginning with January 1, 2010 and 
continuing through December 31, 2014.  
All patients included in the dataset had a diagnosis of AF in their inpatient or 
outpatient records. Falls were included if a patient experienced one or more falls. Frailty 
was included if any of the diagnoses used to describe frailty were present. Dementia 








The EDW was queried to retrieve records of patients with AF from 2010 to 2014 
(N = 4,293). Medication histories for those patients were obtained from the EDW over 
the same period.  
After the AF diagnosis, AF medication was classified as oral anticoagulation 
agent, antiplatelet agent, or no oral anticoagulation or antiplatelet agent. Numeric values 
of “2” for oral anticoagulants, “1” for antiplatelet agents, and “0” for no oral 
anticoagulation or antiplatelet agents were used in the data. Oral anticoagulants were 
present if the patient had any medication record of warfarin, rivaroxaban, apixaban, or 
dabigatran. Antiplatelet agents were present if patients had any medication record of 
aspirin, clopidogrel, prasugrel, or ticagrelor. It is possible that an individual was 
prescribed OAC and antiplatelet therapy concomitantly.  
According to the CHA2DS2-VASc schema, diseases included were stroke, 
hypertension (HTN), aortic plaque (Aorticp), congestive heart failure (CHF), coronary 
artery disease (CAD), diabetes mellitus (DM), and peripheral vascular disease (PVD). 
Scores were computed using the CHA2DS2-VASc scoring system and ICD-9 codes. Each 
of these diseases, and each patient time to disease, was measured as the number of days 
from the date of diagnosis of AF to the first incidence of the disease.  
According to the HAS-BLED schema, diseases included were hypertension 
(HTN), abnormal renal function, abnormal liver function, stroke, bleeding predisposition, 
labile INR, elderly (age 65 and older), and drug or alcohol use. Scores were computed 
using the HAS-BLED scoring system and ICD-9 codes. Each of these diseases, and each 





AF to the first incidence of the disease. Due to the lack of labile INR information in the 
dataset, we anticipated that value to be 0 for all patients, as described in the literature 
(Pisters et al., 2010). 
A geriatric syndrome variable for the presence of dementia and/or falls and/or 
frailty was also created from this information. Disease incidence and time to disease 
allowed estimation of the effect of medication therapy on those who suffered from 




When the dataset was received, exploratory data analyses were performed to 
determine distributions in age, gender, different medications, comorbidities, falls, 
dementia, frailty, strokes, and hemorrhages. Another exploratory procedure determined 
how many people had changes in medications and how long the follow up was available 
in the dataset. These procedures defined the study’s sample. 
Standard statistical techniques were used to find differences among groups in the 
demographic data (Singer & Willett, 2003). The focus of these analyses was on the 
magnitude of the coefficients and determining how great the differences or correlations 
were in pragmatic terms. 
Data for this study involved following patients over time. Over this time interval, 
patients experienced death or an event of interest at a certain time. Patients were followed 
from the start of their medication until they died, dropped from observation, or 





Cox-proportional hazard regression model was used to estimate the risk-outcomes of 
different variables in a right-censored setting (Singer & Willett, 2003). This statistical 
model gave the advantage (nonparametric) of comparisons of risk between groups of 
interest, without having to specify the baseline risk of each group. Hazard ratios from this 
model were produced to estimate risks for variables such as CVAs and hemorrhages. The 
Kaplan-Meier method was used to estimate the discrete time of survival function (Singer 
& Willett, 2003). The Kaplan-Meier curves represented grouping of the variables of OAC 
group, antiplatelet agents group, and non-OAC group.  
The following are examples of the application of a Cox regression equation used 
to establish the basic relationships in the model and covariates represented in Figures 3.1 
and 3.2 (throughout, all explanatory covariates are binary 0/1 with OAC symbolizing 
whether OACs were taken or not; f (demographics) indicates standard regression control 
for categorical and continuous demographic and medical predictors): 
• Y = f (demographics) + OAC 
• Y = f (demographics) + OAC + HAS-BLED + CHA2DS2-VASc 
• Y = f (demographics) + OAC * HAS-BLED 
Two-way ANOVA was performed for AIM 3, with post hoc testing when the 
omnibus F was significant. An alpha level of .05 was set a priori for all analyses.  
 
Protection of Human Subjects 
This was an exempt study that used deidentified patient information. According to 
the University of Utah Institutional Review Board:  
Exempt studies are minimal risk and fit within a set of established exemption 





certain federal regulations and must also follow state laws and University policies 
applicable to research. Studies that qualify for exemption must adhere to 
principles of sound research design and ethics. Participant rights and welfare must 
also be protected in a manner appropriate for research that poses minimal risk. 
Exemption determinations are made by the IRB and may not be made by the 
individual investigator. IRB review of exempt studies ensures that these standards 










Variable ICD-9 Codes 
Closed heart valvotomy, unspecified valve 35 
Closed heart valvotomy, aortic valve 35.01 
Closed heart valvotomy, mitral valve 35.02 
Closed heart valvotomy, pulmonary valve 35.03 
Closed heart valvotomy, tricuspid valve 35.04 
Open heart valvuloplasty of unspecified valve, without 
replacement 
35.1 
Open heart valvuloplasty of aortic valve, without 
replacement 
35.11 
Open heart valvuloplasty of mitral valve, without 
replacement 
35.12 
Open heart valvuloplasty of pulmonary valve, without 
replacement 
35.13 
Open heart valvuloplasty of tricuspid valve, without 
replacement 
35.14 
Replacement of unspecified heart valve 35.2 
Replacement of aortic valve with tissue graft 35.21 
Other replacement of aortic valve 35.22 
Replacement of mitral valve with tissue graft 35.23 
Other replacement of mitral valve 35.24 
Replacement of pulmonary valve with tissue graft 35.25 
Other replacement of pulmonary valve 35.26 
Replacement of tricuspid valve with tissue graft 35.27 
Other replacement of tricuspid valve 35.28 
Mitral stenosis 394 
Mitral stenosis with insufficiency 394.2 
Mitral valve stenosis and aortic valve stenosis 396 
Mitral valve stenosis and aortic valve insufficiency 396.1 
Multiple involvement of mitral and aortic valves 396.8 
Organ or tissue replaced by transplant V42 
Heart valve V42.2 
Organ or tissue replaced by other means V43 
Heart valve V43.3 
Operations of structures adjacent to heart valves 35.3 
Operations on papillary muscle 35.31 
Operations on chordae tendinaea 35.32 
Annuloplasty 35.33 
Infundibulectomy 35.34 
Operations on trabeculae cordis 35.35 
Operations on other structures adjacent to valves of heart 35.39 
Pulmonary embolism 415.12, 449, 513.0, 415.12-septic, 415.11-
iatrogenic, 673.80, 673.82, 673.84-
obstetrical, V12.55-healed/old, 415.19-
other or not elsewhere classified, 416.2-
chronic 
Deep venous thrombosis 453.40-acute, 671.5, 453.41-acute, 453.42-
acute, 453.50-chronic, 453.51-chronic, 
453.52-chronic, V12.51-history of 









Variable ICD-9 Codes 
Dementia Dementia in other conditions (Alzheimer’s, Lewy bodies, Parkinsonism, epilepsy, frontal, 
multiple sclerosis, and so forth) 294.10–294.20, 293 
Uncomplicated, 294.8 
Use the following underlying conditions followed by one of the dementia codes listed 
above: 
  Alzheimer’s 331.0    
  Senile degeneration of brain 331.2   
  Dementia with Lewy bodies/Parkinsonism 331.82 
Dementia unspecified 294.10-294.21 
Presenile 290.10–290.13, 290.39 
Senile uncomplicated 290.0 
Senile dementia w/Delusional features 290.20 
Senile dementia w/Depressive features 290.21 
Senile dementia w/Delirium or confusion 290.3 
Falls Fall on or from sidewalk curb E880.1 
Fall on or from stairs or steps E880.9 
Fall from wheelchair E884.3 
Fall from bed E884.4 
Fall on the same level from slipping, tripping, or stumbling E885.9 
Other and unspecified fall E888.0-E888.9 
History of falling V15.88 
















Ischemic, stroke 434.91 
Embolic, stroke 434.11 
Thrombotic, stroke 434.01 
Impending 435.9 
Postoperative 997.02 
Personal history without deficits V12.54 
Late effects 438.0–438.9 
Personal history of TIA V12.54 
Unspecified transient cerebral ischemia 435.9  
 
Hemorrhage 
Hemorrhage not otherwise specified 459.0 
Postoperative 998.11 
Brain hemorrhage iatrogenic/postoperative 997.02 
Subarachnoid hemorrhage 430 
Intracerebral hemorrhage 431 
Nontraumatic extradural hemorrhage 432.0 
Subdural hemorrhage 432.1 
Unspecified Intracranial hemorrhage 432.9 
Esophageal hemorrhage 530.82 
Gastric ulcer with hemorrhage 531.00, 531.01, 531.20, 531.21, 531.40, 531.41, 
531.60, 531.61 
Duodenal ulcer with hemorrhage 532.00, 532.01, 532.20, 532.21, 532.40, 532.41, 
532.60, 532.61 
Peptic ulcer with hemorrhage 533.00, 533.01, 533.20, 533.21, 533.40, 533.41, 
533.60, 533.61 
Gastrojejunal ulcer with hemorrhage 534.00, 534.01, 534.20, 534.21, 534.40, 
534.41, 534.60, 534.61 
Gastritis and duodenitis with hemorrhage 535.01, 535.11, 535.21, 535.31, 
535.41, 535.51, 535.61, 535.71 
Diverticulosis small intestine with hemorrhage 562.02 
Diverticulitis small intestine with hemorrhage 562.03 
Diverticulosis colon with hemorrhage 562.12 
Diverticulitis colon with hemorrhage 562.13 
Hemorrhage of rectum and anus 569.3 
Hematemesis 578.0 
Melena/blood in stool 578.1 
Hemorrhage of gastrointestinal tract unspecified 578.9 
Hemoptysis unspecified 786.30 
Cough with hemorrhage 786.39 
Traumatic brain hemorrhage 852.00-853.19 









Covariate Variables, CHA2DS2-VASc 
 
 




Ischemic, stroke 434.91 
Embolic, stroke 434.11 
Thrombotic, stroke 434.01 
Impending 435.9 
Postoperative 997.02 
Personal history without deficits V12.54 
Late effects 438.0 – 438.9 
Personal history of transient ischemic attack V12.54 
Unspecified transient cerebral ischemia 435.9  
Diabetes Mellitus 
(DM) 
DM without mention of complication 250.00-250.03 
DM with renal manifestations 250.40-250.43 
DM with ophthalmic manifestations 250.50-250.53 
DM with neurological manifestations 250.60-250.63 
DM with peripheral circulatory disorders 250.70-250.73 
DM with other specified manifestations 250.80-250.83 
DM with unspecified complication 250.90-250.93 
Secondary DM without mention of complication 249.00-249.01 
Secondary DM with renal manifestations 249.40-249.41 
Secondary DM with ophthalmic manifestations 249.50-249.51 
Secondary DM with neurological manifestations 249.60-249.61 
Secondary DM with peripheral circulatory disorders 249.70-249.71 
Secondary DM with  other specified manifestations 249.80-249.81 
Secondary DM with unspecified complication 249.90-249.91 
Congestive Heart 
Failure 
Congestive heart failure, unspecified 428.0 
Systolic heart failure 428.20-428.23 
Diastolic heart failure 428.30-428.33 
Combined systolic and diastolic heart failure 428.40-428.43 
Rheumatic heart failure (congestive) 398.91 
Coronary Artery 
Disease 
Coronary atherosclerosis 414.00-414.07 
Chronic total occlusion of coronary artery 414.2 
Coronary atherosclerosis due to lipid-rich plaque 414.3 











Peripheral vascular disease unspecified 443.9 
PVD in other disease (DM) 443.81 
Atherosclerosis of extremities 440.20-440.4 
Atherosclerosis of other specified arteries 440.8 
Generalized & unspecified atherosclerosis 440.9 
Raynaud’s syndrome 443.0 
Occlusion/stenosis precerebral arteries 433.00-433.91 
Atherosclerosis of renal artery 440.1 
Aneurysm–peripheral arteries 442.0-442.9 
Dissection–peripheral arteries 443.21-443.29 









Covariate Variables, HAS-BLED 
 
 





Ischemic, stroke 434.91 
Embolic, stroke 434.11 
Thrombotic, stroke 434.01 
Impending 435.9 
Postoperative 997.02 
Personal history without deficits V12.54 
Late effects 438.0–438.9 
Personal history of TIA V12.54 
Unspecified transient cerebral ischemia 435.9  
Hypertension Essential hypertension 401.0–401.9 
Hypertensive heart disease 402.00–402.91 
Hypertensive chronic kidney disease 403.00–403.91 
Hypertensive heart and chronic kidney disease 404.00–404.93 
Secondary hypertension 405.01–405.99 
Hypertensive cerebrovascular disease 437.2 
Intracranial hypertension benign 348.2 
Postoperative Hypertension 997.91 
Alcohol Use Alcohol dependence 303.90, 303,91, 303.92, 303.93 
Alcohol abuse 291.0-291.5, 291.8, 291.81, 291.82, 291.89, 291.9, 303.00–303.03, 
305.00, 305.01, 305.02, 305.03, 760.71, 980.0 
Abnormal Renal 
Function 
794.4, acute renal failure 584.5–584.9, unspecified renal failure 586, chronic 
renal failure 585, 585.3–585.6, 585.9, 792.5, V42.0, V45.1, V45.11, V45.12, 
V56.0, V56.1, V56.2, V56.31, V56.32, V56.8 
Abnormal Liver 
Function 
794.8, cirrhosis of the liver without mention of alcohol 571.5, liver abscess and 
sequela of chronic liver disease 572.0-572.4, 572.8, ascites 789.5, 789.59, other 
and unspecified liver disorders 570, 571.6, 571.8, 579.9, 573.0, 573.4, 573.8, 
573.9, 782.4, 789.1, 790.4, 790.5, 794.8, V42.7 
Prior Bleed Hemorrhage not otherwise specified 459.0 
Postoperative 998.11 
Brain hemorrhage iatrogenic/postoperative 997.02 
Subarachnoid hemorrhage 430 
Intracerebral hemorrhage 431 
Nontraumatic extradural hemorrhage 432.0 
Subdural hemorrhage 432.1 
Unspecified Intracranial hemorrhage 432.9 
Esophageal hemorrhage 530.82 
Gastric ulcer with hemorrhage 531.00, 531.01, 531.20, 531.21, 531.40, 531.41, 
531.60, 531.61 
Duodenal ulcer with hemorrhage 532.00, 532.01, 532.20, 532.21, 532.40, 532.41, 
532.60, 532.61 
Peptic ulcer with hemorrhage 533.00, 533.01, 533.20, 533.21, 533.40, 533.41, 
533.60, 533.61 
Gastrojejunal ulcer with hemorrhage 534.00, 534.01, 534.20, 534.21, 534.40, 
534.41, 534.60, 534.61 
Gastritis and duodenitis with hemorrhage 535.01, 535.11, 535.21, 535.31, 





Table 3.5, Continued 
 
 
Variable ICD-9 Codes 
Prior Bleed 
(Continued) 
Diverticulosis small intestine with hemorrhage 562.02 
Diverticulitis small intestine with hemorrhage 562.03 
Diverticulosis colon with hemorrhage 562.12 
Diverticulitis colon with hemorrhage 562.13 
Hemorrhage of rectum and anus 569.3 
Hematemesis 578.0 
Melena/blood in stool 578.1 
Hemorrhage of gastrointestinal tract unspecified 578.9 
Hemoptysis unspecified 786.30 
Cough with hemorrhage 786.39 
Traumatic brain hemorrhage 852.00-853.19 














    Figure 3.1 Basic relationship represented in the model.  








 Figure 3.2 Covariates represented in the model. 











Figure 3.3 Confounding covariates. 






Figure 3.4 Methods model A, B, C. Key: 
A. Aim 1: Difference in risk-adjusted stroke rates contingent on CHA2DS2-VASc in 
patients with geriatric syndromes (falls, dementia, and/or frailty) prescribed OACs, 
antiplatelet agents, and no antithrombotic therapy.  
B. Aim 2: Difference in adjusted hemorrhage rates contingent on HAS-BLED scores in 
patients with geriatric syndromes (falls, dementia, and/or frailty) prescribed OACs, 
antiplatelet agents, and no OAC/antiplatelet agents.  
C. Aim 3: Determine the main and interaction effects of type of thromboembolic therapy 
for older adults with chronic atrial fibrillation and presence of geriatric syndromes (falls, 
dementia, and/or frailty) contingent on CHA2DS2-VASc scores.  
Note. AF = atrial fibrillation; OAC = oral anticoagulant; ATPL = antiplatelet agent; CVA 
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STROKE OUTCOMES IN ATRIAL FIBRILLATION PATIENTS 
WITH GERIATRIC SYNDROMES TREATED FOR THE 
PREVENTION OF THROMBOEMBOLISM 
 
Abstract 
Atrial fibrillation (AF) is the most commonly encountered arrhythmia, which 
presents a major risk for an ischemic stroke and transient ischemic attack (TIA). Oral 
anticoagulation and antiplatelet agents are used to prevent stroke by emboli generated in 
AF. Providers are faced with treating AF in older adults with geriatric syndromes, such as 
dementia, frailty, or falls, that may complicate therapy with anticoagulation drugs used to 
prevent emboli. The goal of this study was to describe differences in incidence of stroke 
over 1- to 3-year follow up depending upon the type of stroke prevention therapy: oral 
anticoagulants (OAC), antiplatelet agents (ATPL), or none of these (No OAC/ATPL). 
Patients age 65 years and older with a diagnosis of AF with concomitant geriatric 
syndromes (dementia, falls, and frailty) were included in this study, using retrospective 
data from an electronic medical record. The primary outcome was the presence of a 
stroke or TIA. Multivariable Cox hazard regression was utilized to determine the 





curves were used for survival analysis. The 758 older adults in the sample who had AF 
and one or more geriatric syndromes in the sample had an average age of 79.2 ± 7.3, and 
357 (47.1%) were males. Even after stroke risk was controlled, patients prescribed oral 
anticoagulants were 75% to 82% less likely to develop stroke than patients on no oral 
anticoagulation/antiplatelet therapy (p < .001) in all 3 years of follow up. Patients 
prescribed antiplatelet agents were 70% to 74% less likely to develop a stroke or TIA 
when compared to patients on no oral anticoagulation/antiplatelet therapy (p < .001). In 
this study, we found that patients age 65 years and older and diagnosed with AF as well 
as geriatric syndromes (dementia and/or falls and/or frailty) benefit from oral 
anticoagulation and antiplatelet therapies in the first, second, and third years of therapy. 
Such therapies are crucial for these patients in preventing strokes. 
 
Introduction 
Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting 2.3 
million individuals in the United States (Olesen, Fauchier, Lane, Taillandier, & Lip, 
2012). AF causes loss of well-organized atrial contracture, resulting in stagnation of the 
blood and thrombus formation (Padanilam & Prystowsky, 2009). AF is a major risk for a 
stroke (cerebrovascular accident [CVA] or transient ischemic attack [TIA]), accounting 
for 15% to 25% of all ischemic stroke. The majority of patients experiencing strokes 
related to AF are age 65 years and older (Fang et al., 2010; Hart, Pearce, & Aguilar, 
2007). One meta-analysis of adjusted-dose warfarin studies indicated stroke reduction at 
64% with this therapy (95% CI, 49% to 74%) in patients of an average age of 71 years  





Depending on individual preferences, comorbidities, and bleeding history, these 
patients may be prescribed antiplatelet therapy consisting of only aspirin or a 
combination of aspirin and clopidogrel. Hart et al. (2007) found that with aspirin and 
clopidogrel, the risk for a stroke is reduced by 40% (95% CI, 18% to 56%). 
Providers rely on numerous guidelines developed in the United States and Europe 
when initiating oral anticoagulation or antiplatelet therapy for the prevention of 
thromboembolism in patients with AF (Ahmad & Lip, 2012; Camm et al., 2010; Fuster et 
al., 2006; Guyatt et al., 2012; Skanes et al., 2012; Wann et al., 2011). 
Geriatric syndromes such as dementia, falls, and frailty represent multifactorial 
problems of overall health decline and are associated with poor outcomes in older 
individuals (Inouye, Studenski, Tinetti, & Kuchel, 2007). These problems are more likely 
to affect older patients with more severe comorbid conditions, and this presents a 
significant dilemma for clinicians when choosing thromboembolic prevention therapy, 
due to concerns about efficacy and safety issues. One reason for differences in the stroke 
prevention regimen followed by older adults is the presence of geriatric syndromes, 
which are highlighted by distinctive features commonly shared only by older adults. 
Although the combination of these factors will contribute to the decision to initiate oral 
anticoagulation, dementia, falls, and frailty are not mentioned within the guidelines. As 
older individuals are more likely to suffer any or all of these problems, providers are less 
likely to treat them with oral anticoagulation (Johnson, Lim, & Workman, 2005; Morley, 
2008).  
When initiating thromboembolic prevention therapy, clinicians use the CHA2DS2-





CHA2DS2-VASc schema assigns one point for each of the following: congestive heart 
failure, hypertension, diabetes mellitus, vascular disease (coronary artery disease, 
peripheral artery disease, or aortic plaque), age 65 to 74 years, and sex (female gender). 
The CHA2DS2-VASc, schema additionally assigns two points each for previous 
stroke/TIA and age ≥ 75 years. An aggregate score from 0 to 9 is derived and is used to 
predict annual stroke and TIA risk values, from 0.2% for a CHA2DS2-VASc score of 0, 
up to 15.2% for a CHA2DS2-VASc score of 9 (Lip, Frison, Halperin, & Lane, 2011). 
When this scoring system is utilized, patients are divided into the following categories: 
(a) low risk, which is associated with a CHA2DS2-VASc score of 0, which may or may 
not require aspirin; (b) intermediate risk, which is associated with a CHA2DS2-VASc 
score of 1, which recommends an antiplatelet agent or oral anticoagulant; or (c) high risk, 
which is associated with a CHA2DS2-VASc score of 2 or higher, which recommends an 
oral anticoagulant (Pamukcu, Lip, & Lane, 2010). 
Dementia manifests as memory problems combined with decline in one or more 
cognitive functions, which may complicate implementation of oral anticoagulation. The 
most common form of dementia is Alzheimer’s dementia, affecting between 60% and 
80% of all individuals diagnosed with dementia, followed by vascular dementia, which 
affects 10% to 20% of older individuals (Bunch et al., 2010). Age is the greatest risk 
factor for both Alzheimer’s disease and AF, so the coexistence of both conditions is not 
surprising (Moschetti, Cummings, Sorvillo, & Kuo, 2012). In addition to age, AF 
contributes to cognitive decline due to the presence of cerebrovascular accidents (CVAs), 
and may affect the ability of a patient to manage anticoagulation therapy (Jacobs, Billett, 





Frailty is a state of increased vulnerability and decline in abilities to react to 
stressors, with multiple systems weakening. These declines manifest as decreases in 
strength; mobility; balance; body mass; overall activity levels; increased risk of falls; and 
changes in serum protein concentrations, which may alter the pharmacokinetics of oral 
anticoagulation or antiplatelet therapy (Fried, Ferrucci, Darer, Williamson, & Anderson, 
2004; McIsaac, Bryson, & van Walraven, 2016). Frail patients are more likely to develop 
complications related to oral anticoagulation therapy. The stroke risk in frail patients age 
75 years and older is 8% (Johnson et al., 2005).  
Falls are more common among older individuals than their younger counterparts, 
with an incidence of 33% annually in people ages 65 to 80, increasing to 50% in people 
80 and older. Falls are the most common cause of injuries among older trauma patients, 
resulting in a mortality rate of 6% (Pieracci, Eachempati, Shou, Hydo, & Barie, 2007). 
This problem is multifactorial and requires a systematic approach by providers. Falls may 
be triggered by drug interactions, frailty, dementia, and dehydration. Typically, 10% of 
older patients taking warfarin who fall will experience a major injury, such as a fracture 
(Tay, Lane, & Lip, 2009). The overall mortality rate for patients on oral anticoagulants 
who fall is 45%. 
In this study we examined the records of subjects age 65 and over with a 
diagnosis of AF who had an indication of geriatric syndromes (dementia and/or frailty 
and/or falls). The goal of this study was to describe differences in incidence of stroke 
over 1- to 3-year follow up, depending on the type of stroke prevention therapy (oral 







Sampling and Setting 
This was a database study of electronic medical records, which were obtained 
from the EDW at the University of Utah. This was a retrospective, descriptive, 
longitudinal study in which each patient was determined to have the diagnosis of AF 
using ICD-9 code 427.31, recorded by the healthcare providers in the patient’s visit notes, 
electrocardiogram, or both during the period from January 1, 2010 to December 31, 2014. 
Subjects included in the study had the diagnosis of AF for varying periods of time. 
According to the literature and the advice of a professional coder, ICD-9 code 427.31 is 
generally used to capture patients with the diagnosis of AF (Piccini et al., 2012).  
The dataset included outpatient and inpatient records. Consistent with procedures 
developed by previous investigators to validate the target diagnosis, subjects were 
included in the sample only if they had two or more visits related to the AF diagnosis, 
assuring that they were treated on a long-term basis for this disease (Piccini et al., 2012). 
Patients with a confirmed diagnosis of AF who were over age 65 were selected in the first 
tier of sampling (see Figure 4.1).   
 
Exclusion Criteria 
In an attempt to ensure that subjects with AF were not taking anticoagulant 
therapy for an indication other than stroke prevention, patients with diagnoses of mural 
thrombus, deep vein thrombosis, pulmonary embolism, and any mechanical heart valves 
were excluded from analysis. After the exclusion criteria were applied, 1,398 of the 





the sampling frame. 
 
Sample Verification 
To determine the accuracy of AF diagnosis in the final pool of subjects, 532 
individual chart reviews were performed. This process was facilitated by using the 
WartHog program at the EDW at the University of Utah. This program allows 
researchers to instantly locate specific phrases in the medical records, such as atrial 
fibrillation, eliminating records unrelated to the term searched and highlighting only the 
search terms used. Not only does WartHog allow for rapid searching, it is also extremely 
accurate. Of a subsample of 532 charts retrieved based on ICD-9 codes, we were able to 
document the diagnosis of AF in all but 11. This represents 98% accuracy in locating AF 
diagnoses, which is higher than the average of 82.2% found in the literature for accuracy 
of ICD-9 diagnoses of AF (Thigpen et al., 2015).    
 
Additional Inclusion Criteria 
Additional inclusion criteria were applied to ensure that all patients in the sample 
had one of, or any combination of, the following geriatric syndromes: dementia, fall(s), 
and frailty. All such diagnoses occurred prior to the first event of a stroke or last 
observation. All codes for diagnoses were derived from the literature and personal 
communication with a professional coder and local and internationally recognized 
researchers in frailty (Garwood & Corbett, 2008; Hubbard et al., 2015; Jacobs et al., 
2009; Jacobs et al., 2014; Morley et al., 2013; Piccini et al., 2012; Rockwood et al., 2005; 





geriatric syndromes and experts consulted are identified in Table 4.1. Subjects were 
included only if one or more geriatric syndromes were identified between the date of 
study entry and the occurrence of a stroke, to ensure that the syndrome was a pre-existing 
condition relative to a stroke. 
 
Procedures 
Medication and disease files were summarized by patient identification number 
using aggregate/structure query language (SQL) commands in SPSS  (Green & Salkind, 
2010) and R (version 3.2.0; Team, 2013). The ICD-9 diagnoses were determined for all 
covariate variables included in the CHA2DS2-VASc schema (see Table 4.1). 
 
Therapy Groups 
Data on medications initiated following the diagnosis of AF were extracted to 
detect the use of anticoagulant or antiplatelet agents commonly used to prevent 
thrombotic complications. Subjects were divided into one of three therapy groups: oral 
anticoagulation group (warfarin, apixaban, rivaroxaban, dabigatran); antiplatelet agents 
group (aspirin, clopidogrel, prasugrel, ticagrelor); and no oral anticoagulation or 
antiplatelet agents. If subjects had a record of both antiplatelet and oral anticoagulant 
therapy, they were assigned to the oral anticoagulant group. Of the 758 subjects, 168 
(22.2%) were prescribed both therapies concomitantly. It is difficult to separate these 
therapies because of comorbidities in these older individuals, particularly coronary artery 







The outcome variables for stroke were derived from the dataset using ICD-9 
codes (see Table 4.1). Although TIA does not cause permanent brain damage, it is one of 
the comorbidities measured by the CHA2DS2-VASc scoring system, as it is typically 
considered to be a warning for stroke,. TIA evaluates as an equivalent of a stroke, so both 
stroke and TIA were included as positive indicators of a cerebrovascular event, the 
outcome in this study (Lip, Tse, & Lane, 2012). 
In this study patients were followed from the start of their medication until they 
dropped from observation or experienced an event. This type of data is right-censored 
(Singer & Willett, 2003). 
 
Statistical Analysis 
Omnibus tests were performed to detect general differences among means and 
proportions using ANOVA and chi-square tests (Kutner, Nachtsheim, Neter, & Li, 2005). 
Post hoc pairwise comparisons among categorical and continuous variables were made 
using proportion and Tukey tests. P values for the post hoc comparisons were adjusted 
using Bonferroni method, declaring significance at α = .05/3. P values for the post hoc 
comparisons involving continuous variables were adjusted using Tukey method, with 
significance at α = .05 (Kutner et al., 2005). Adjustments to post hoc p values were 
made in order to control the probability of encountering one or more Type-I error rates 
(Kutner et al., 2005). All other statistical tests and estimates were carried out at a 
significance level of α = .05.  





medication groups. Three models were utilized to determine if significant differences 
existed in stroke outcomes by medication group. The first Cox model, 1-year follow up, 
observed individuals only over a 1-year period. If an individual’s observation time was 
more than one period, then that person was considered as being observed for 1 full year, 
and as having no stroke event. Similar constructions were done for the 2-year and 3-year 
follow-up models.  
In each Cox model, the censoring variable was 0 if a stroke did not occur within 
the observation period and 1 if it did. Individuals in the Cox models were censored for 
either of two circumstances: a subject’s last event was not a stroke (another type of 
medical event, moved away, or died—lost to follow-up), or a subject reached the end of 
the observation period alive, not having experienced a stroke. A single covariate was 
used for the Cox model, a summed version of the CHA2DS2-VASc schema, which 
comprises the baseline risk factors for stroke. An overall hazard ratio is estimated from a 
dataset in which patients are censored only when they are lost to follow up. 1-, 2-, and 3-
year hazard ratios are estimated from datasets in which patients can be censored if they 
reach 1, 2, or 3 years without experiencing any event, or are lost to follow up before those 
respective times. 
Kaplan-Meier curves were used to help compare risk differences in medication 
groups visually, according to stroke outcomes. A Kaplan-Meier curve is a nonparametric 
estimate of a survival curve. The formula used to construct the curve does not include an 
adjustment for risk factors; to compare survival curves controlling for risks, a Cox model 
was used instead (Singer & Willett, 2003). Visual separation of curves between drug 






Description of Groups 
Overall, the average patient age was 79.2 years ±7.3, and 357 (47.1%) were 
males. The distribution of patients within each medication category was as follows: oral 
anticoagulation, n = 379 (50.0%); ATPL, n = 137 (18.1%); no OAC/ATPL, n = 242 
(31.9%). In Table 4.2, we compare these three treatment groups on demographic and 
treatment variables. The three groups did not differ by age, but there were differences in 
the prevalence of geriatric syndromes between groups.  
The OAC group had the highest prevalence of diagnosed falls, at 72%, with a 
statistically significant difference from the group receiving no antithrombotic 
prophylaxis. The rate of dementia diagnosis differed between the antiplatelet group 
(55.5%) and the oral anticoagulant group (41.7%), but neither differed from the group 
receiving no antithrombotic prophylaxis drugs. The rate of frailty diagnosis (13.2%) in 
the group receiving no antithrombotic drugs was more than twice that in any other group 
(13.2%). The proportion of females differed between two groups (p < .001), with the 
OAC group having the highest number of females (57/3%; Table 4.3). Although the 
mean CHA2DS2-VASc scores indicated high average risk in all groups, scores were lower 
in the no-drug group compared to the two groups receiving antithrombotic agents. The 
higher CHA2DS2-VASc scores of the ATPL and OAC groups represented more 







Group Differences on Outcomes 
The mean time to stroke was less for the no-drug group than for either of the 
therapy groups (see Table 4.4). Time used was  measured in days, using time to event. 
Two groups differed on cumulative incidence of stroke/TIA at 1, 2, and 3 years, with the 
rank order from highest to lowest rate of strokes being no antithrombotic drugs, 
antiplatelet, and oral anticoagulants (p < .001); however, these findings are not controlled 
for risk. The mean time until censored for these subjects was 855.03 ± 611.36 days. 
Kaplan-Meier survival estimates are presented in Figures 4.2 and 4.3, showing the 
survival curves for the time to stroke of the three treatment groups. Initially, during the 
first year (Figure 4.2), when risk of stroke was controlled with CHA2DS2-VASc score, the 
oral anticoagulation and antiplatelet agent groups were similar, with a possible slight 
advantage for antiplatelet agents, but at 6 months oral anticoagulation and antiplatelet 
therapy begin to diverge in favor of oral anticoagulants, a trend which continued through 
Year 3, but it is not certain that the differences were significant. However, the no-oral-
anticoagulation/antiplatelet group had notably lower survival throughout the first year. 
The 3-year outcome demonstrated by Kaplan-Meier curves (Figure 4.3) presented 
possibly greater survival rates (no stroke) for patients prescribed oral anticoagulation than 
for patients prescribed antiplatelet agents, and reduced survival across the 3 years for 
patients who took no anticoagulants/antiplatelet agents.  
 
Risk-Adjusted Hazard Ratios 
Patients prescribed OACs were 82% less likely to develop stroke than patients on 





Patients prescribed antiplatelet agents were 74% less likely to develop stroke when 
compared to patients on no OAC/ATPL therapy in the first year therapy (HR 0.26 [0.13, 
0.51]; p < .001; see Table 4.5).  
Patients prescribed OACs were 79% less likely to develop stroke than patients on 
no OAC/ATPL therapy in the second year of therapy (HR 0.21 [0.13, 0.34]; p < 001). 
Patients prescribed ATPLs were 70% less likely to develop stroke when compared to 
patients on no OAC/ATPL therapy in the second year of therapy (HR 0.30 [0.16, 0.54]; p 
< .001; Table 4.5).  
Patients prescribed OACs were 75% less likely to develop stroke than patients on 
no OAC/ATPL therapy in the third year of therapy (HR 0.25 [0.16, 0.39]; p < .001). 
Patients prescribed ATPL agents were 71% less likely to develop stroke compared to 
patients on no OAC/ATPL therapy in the third year of therapy (HR 0.29 [0.16, 0.52]; p < 
.001).   
 
Discussion 
In this study, we found that patients with AF and geriatric syndromes (dementia 
and/or falls and/or frailty) who take oral anticoagulation and antiplatelet agents have 
lower risk-adjusted rates of stoke/TIA in the first, second, and third years of both  
therapies when compared to patients not prescribed oral anticoagulation or antiplatelet 
therapies, a finding that persists when results are controlled for stroke risk. The study 
included a sample of very old individuals with multiple comorbidities. It allowed 
surveillance of the interplay of risk, treatment, and outcomes of this older group in real 





coincides with multiple risk factors for a stroke in these patients and indicates that 
according to treatment guidelines, the majority of the patients were candidates for OAC 
therapy. 
Our findings of OACs lowering the risk of stroke in the first, second, and third 
years of observation are similar to the findings of studies reported in the literature (Baker, 
Cios, Sander, & Coleman, 2009; Casciano, Dotiwala, Martin, & Kwong, 2013; Fang et 
al., 2010; Gumbinger et al., 2015; Piccini et al., 2012). It is thought provoking that both 
OAC and ATPL agents were similarly preventive of stroke, when prior studies indicated 
that OACs were more effective than ATPL agents (Lip et al., 2012). This might be 
explained by the fact that TIA was included with stroke as a positive cerebrovascular 
event. Interestingly, in spite of the considerable geriatric syndrome burden of the subjects 
in the current study, the results for OACs are the same as in studies conducted with 
younger populations having substantially fewer syndrome burdens (Lip, Nieuwlaat, 
Pisters, Lane, & Crijns, 2010; Lip et al., 2012; Mant et al., 2007). It has been recognized 
that OACs prevent strokes; however, it is challenging to keep these patients on OACs due 
to the increased burden of geriatric syndromes.  
The no-OAC/ATPL therapy group was represented by 242 (31.9%) of the 758 
patients examined in this study. Of the three groups, this group had the lowest CHA2DS2-
VASc scores; however, those scores still indicated for the use of oral anticoagulation. 
This leaves the question of why these subjects were not on oral anticoagulation or 
antiplatelet therapy. Possibly they were taking OACs in the past but stopped before study 
entry, or were never started on this therapy due to dementia, falls, or frailty. This group 





than the OAC group (51.2% vs 41.7%), but had the lowest rate of falls. In the clinical 
setting, it is not uncommon for patients to take oral anticoagulation at first and then 
switch to antiplatelet agents, or to have no antithrombotic therapy due to increased 
severity of dementia, falls, or other adverse events. 
The majority of the OAC group (335, 88.4%) was prescribed warfarin. Warfarin 
presents limitations in use related to narrow therapeutic index, requirement for frequent 
international normalized ratio (INR) monitoring appointments, dietary changes, and 
dosing changes. All of these factors contribute to the challenges associated with the use 
of warfarin for the prevention of thromboembolism among aging populations (Ruff et al., 
2014).  
In the first 15 months of observation during one observational study of 1,049 
older patients, the patients were adherent to taking oral anticoagulants, which is 
associated with lowering the risk of stroke or TIA; however, after 15 months the rate of 
nonadherence to oral anticoagulation therapy was high. Two thirds of patients were not 
taking oral anticoagulation at follow up (Gumbinger et al., 2015). In another 
observational study of 13,289 patients it was found that only 40% of patients who were 
prescribed oral anticoagulation were adherent to this therapy in the 3 years of observation 
(Casciano et al., 2013). Fang et al. (2010), in a different longitudinal study of 4,188 
patients, found that more than one in four patients who were started on warfarin 
discontinued this therapy within the first year. Despite the fact that there is no reason to 
believe this population of older adults with geriatric syndromes has better adherence to 
warfarin therapy than reported in previous studies, the effectiveness of OAC therapy for 





In fact, patients with geriatric syndromes (dementia, falls, frailty) are more likely 
to discontinue oral anticoagulation therapy (Gumbinger et al., 2015). Moreover, patients 
with a diagnosis of dementia and residing in a nursing home are less likely to take 
prescribed OAC therapy. Fear of complications from bleeding, challenges in getting to 
the clinic for warfarin monitoring, and physicians stopping this therapy in patients who 
developed falls are common reasons for stopping this therapy (Gumbinger et al., 2015). 
In the current study, both therapies—oral anticoagulation and antiplatelet agents—were 
effective in prevention of stroke. 
It was reported previously in a meta-analysis of quality of warfarin control that 
patients with AF prescribed warfarin spent less than the recommended time in the INR 
therapeutic range (55%, 95% CI 51%, 58%; Baker et al., 2009). When patients are out of 
therapeutic range, they are more likely to develop bleeding complications and 
thromboembolic complications, leading to discontinuation of the therapy (Baker et al., 
2009; Costa, Ferreira, Valacio, & Vieira Moreira Mda, 2011; Costa, Lamego, Colosimo, 
Valacio, & Moreira Mda, 2012). Another longitudinal study showed that patients who 
spent less than the recommended time in the therapeutic range were more likely to stop 
warfarin therapy (Fang et al., 2010).  
In the ACTIVE W trial (Connolly et al., 2006), it was determined that patients 
taking warfarin spent only 65% of the recommended time in the therapeutic range. 
Taking this one step further was an observational study showing that subtherapeutic INR 
levels contribute to more likely development of microemboli, while supratherapeutic INR 
levels lead to the development of microbleeds (Charidimou et al., 2015; Jacobs et al., 





be diagnosed with dementia, which is most likely to deteriorate if these patients are 
spending less time in the therapeutic range. As individuals 65 and older age, they become 
more prone to hemorrhages and strokes. Moreover, being out of therapeutic range may 
cause the development or progression of dementia in some of these individuals over time. 
In our sample, subjects in the oral anticoagulation group had the highest rate of dementia, 
at 44.7% of all dementia occurrences in the study.  
 
Limitations 
An observational, retrospective, longitudinal study of patients with AF can be 
used only to identify associations, and is unable to establish causality or to determine 
mechanisms. The study relied on medical record information and, as such, the ability of 
providers to make and document the disease states and outcomes. This was an 
observational study, and although baseline characteristics and one multifactorial risk 
indicator were utilized in the multivariable modeling, residual confounding may still be 
present.  
While the academic health system had an integrated EMR for inpatient and 
outpatient services, we acknowledge that we were unable to detect events and diagnoses 
that occurred outside this healthcare system. We also acknowledge that cases of falls and 
frailty were generally underreported, which contributed to the reduced number of subjects 
with these conditions being included in the study. We used diagnosis codes from the 
literature and personal communications to define frailty, and some of these codes may 
have resulted in false positives. While we could confirm that a drug was ordered, there 





Some patients in the study were lost to follow up; no further medical record 
documentation was available, although the subjects may still have been alive and treated 
elsewhere. These patients could potentially have contributed more stroke events had they 
remained in the study, which may have provided more statistical power in comparisons 
among the treatment groups.  
 
Conclusions 
In this study, oral anticoagulation and antiplatelet agents lowered the risk-adjusted 
incidence of stroke in patients with common geriatric syndromes during the first, second, 
and third years of observation. In real-world practice, some patients in this population are 
not prescribed oral anticoagulants due to comorbidities. These individuals may benefit 
from antiplatelet therapy, which is a potential alternative to oral anticoagulation therapy.  
Presently, available guidelines do not reflect such intricate situations as treatment 
of patients with dementia and/or falls and/or frailty; this is something that needs to be 
addressed for both clinicians and patients. Also, no consensus currently exists in relation 
to the treatment of these populations. Further studies should address these issues in order 









ICD-9 Codes Used to Define Stroke Outcomes Variables 
 
 
Disease ICD-9 Codes 
Dementia Dementia in other conditions (Alzheimer’s, Lewy bodies, Parkinsonism, epilepsy, 
frontal, multiple sclerosis, and so forth) 294.10–294.20, 293 
Uncomplicated, 294.8 
Use the following underlying conditions followed by one of the dementia codes 
listed above: 
  Alzheimer’s 331.0    
  Senile degeneration of brain 331.2   
  Dementia with Lewy bodies/Parkinsonism 331.82 
Dementia unspecified 294.10–294.21 
Presenile 290.10–290.13, 290.39 
Senile uncomplicated 290.0 
Senile dementia with delusional features 290.20 
Senile dementia with depressive features 290.21 
Senile dementia with delirium or confusion 290.3 
Falls Fall on or from sidewalk curb E880.1 
Fall on or from stairs or steps E880.9 
Fall from wheelchair E884.3 
Fall from bed E884.4 
Fall on the same level from slipping, tripping, or stumbling E885.9 
Other and unspecified fall E888.0-E888.9 
History of falling-V15.88 
Frailty  Senility without mention of psychosis (frailty) 797 





Ischemic, stroke and TIA 434.91 
Embolic, stroke and TIA 434.11 
Thrombotic, stroke and TIA 434.01 
Impending 435.9  
 Postoperative 997.02 
Personal history without deficits V12.54 
Late effects 438.0–438.9 
Personal history of TIA V12.54 
Unspecified transient cerebral ischemia 435.9 
Hypertension (HTN) Essential hypertension 401.0–401.9 
Hypertensive heart disease 402.00–402.91 
Hypertensive chronic kidney disease 403.00–403.91 
Hypertensive heart and chronic kidney disease 404.00–404.93 
Secondary hypertension 405.01–405.99 
Hypertensive cerebrovascular disease 437.2 
Intracranial hypertension benign 348.2 
Postoperative hypertension 997.91 
Diabetes Mellitus 
(DM) 
DM without mention of complication 250.00–250.03 
DM with renal manifestations 250.40–250.43 
DM with ophthalmic manifestations 250.50-250.53 
DM with neurological manifestations 250.60–250.63 
DM with peripheral circulatory disorders 250.70–250.73 






Table 4.1, Continued 
 
 
Disease ICD-9 Codes 
Diabetes Mellitus 
(DM), Continued 
DM with unspecified complication 250.90–-250.93 
Secondary DM without mention of complication 249.00–249.01 
Secondary DM with renal manifestations 249.40–249.41 
Secondary DM with ophthalmic manifestations 249.50–249.51 
Secondary DM with neurological manifestations 249.60–249.61 
Secondary DM with peripheral circulatory disorders 249.70–249.71 
Secondary DM with other specified manifestations 249.80–249.81 
Secondary DM with unspecified complication 249.90–249.91 
Congestive Heart 
Failure 
Congestive heart failure, unspecified 428.0 
Systolic heart failure 428.20–428.23 
Diastolic heart failure 428.30–428.33 
Combined systolic and diastolic heart failure 428.40–428.43 
Rheumatic heart failure (congestive) 398.91 
Coronary Artery 
Disease 
Coronary atherosclerosis 414.00–414.07 
Chronic total occlusion of coronary artery 414.2 
Coronary atherosclerosis due to lipid-rich plaque 414.3 











Peripheral vascular disease unspecified 443.9 
PVD in other disease (DM) 443.81 
Atherosclerosis of extremities 440.20–440.4 
Atherosclerosis of other specified arteries 440.8 
Generalized and unspecified atherosclerosis 440.9 
Raynaud’s syndrome 443.0 
Occlusion/stenosis precerebral arteries 433.00–433.91 
Atherosclerosis of renal artery 440.1 
Aneurysm–peripheral arteries 442.0–442.9 
Dissection–peripheral arteries 443.21–443.29 














Type of Antithrombotic Therapy 
 




Total number of subjects 242 (31.9%) 137 (18.1%) 379 (50%)  
Age-years (mean ± SD) 79.3 ± 7.9 78.9 ± 8 79.2 ± 6.8 0.9 
Fall (% Yes) 138 (57%) 92 (67.2%) 273 (72%) < .0001a 
Dementia (% Yes) 124 (51.2%) 76 (55.5%) 158 (41.7%) < .0001c 
Frailty (% Yes) 32 (13.2%) 7 (5.1%) 24 (6.3%) < .001a,b 
CHA2DS2-VASC score (mean/± SD) 3.4 ± 1.3 4 ± 1.4 4.1 ± 1.3 < .0001a,b 
Medications      
Warfarin (% Yes) 0 (0%) 0 (0%) 335 (88.4%)  
Apixaban (% Yes) 0 (0%) 0 (0%) 28 (7.4%)  
Rivaroxaban (% Yes) 0 (0%) 0 (0%) 20 (5.3%)  
Dabigatran (% Yes) 0 (0%) 0 (0%) 24 (6.3%)  
Aspirin (% Yes) 0 (0%) 123 (89.8%) 144 (38%)  
Clopidogrel (% Yes) 0 (0%) 40 (29.2%) 23 (6.1%)  
Ticagrelor (% Yes) 0 (0%) 1 (0.7%) 0 (0%)  
Prasugrel (% Yes) 0 (0%) 0 (0%) 1 (0.3%)  
Note. p < .05.  Omnibus F test (continuous variables) or chi-square (categorical variables).  a No drug 





CHA2DS2-VASC Score Composition 
 
Variable 
Type of Antithrombotic Therapy 
p Value* 
No Drug Antiplatelet Oral Anticoagulant 
Hypertension (% Yes) 85 (35.1%) 75 (54.7%) 242 (63.9%) < .0001a,b 
Age 75+ (% Yes) 167 (69%) 92 (67.2%) 280 (73.9%) 0.2 
Age 65-74 (% Yes) 75 (31%) 45 (32.8%) 99 (26.1%) 0.2 
Diabetes Mellitus (% Yes) 77 (31.8%) 42 (30.7%) 125 (33%) 0.9 
Coronary Artery Disease (% Yes) 92 (38%) 80 (58.4%) 175 (46.2%) < .0001
b,c
 
Peripheral Vascular Disease (% Yes) 31 (12.8%) 31 (22.6%) 87 (23%) < .0001a,b 
Aortic Plaque (% Yes) 25 (10.3%) 25 (18.2%) 61 (16.1%) 0.05 
Female (% Yes) 114 (47.1%) 70 (51.1%) 217 (57.3%) < .0001a 
Note. p < .05.   Omnibus F test (continuous variables) or chi-square (categorical variables).  aNo drug 
















Type of Antithrombotic Therapy 
p Value* 
No Drug Antiplatelet Oral Anticoagulant 
Mean time to stroke and TIA 407.1+/-478.2 875.3+/-567.7 1001+/-602.8 < .0001a,b 
1-Year stroke and TIA (% Yes) 48 (19.8%) 11 (8%) 22 (5.8%) < .0001a,b 
2-Year cumulative stroke and 
TIA (% Yes) 
52 (21.5%) 14 (10.2%) 29 (7.7%) < .0001a,b 
3-Year cumulative stroke and 
TIA (% Yes) 
54 (22.3%) 16 (11.7%) 41 (10.8%) < .0001a,b 
Note. p < .05.   Omnibus F test.   aNo drug versus oral anticoagulant.  bNo drug versus antiplatelet.  cOral 









Risk of Stroke With Oral Anticoagulants and Antiplatelet Agents  
Versus  No Oral Anticoagulation/Antiplatelet Agents 
 
 
Hazard Ratios 1-Year 2-Year 3-Year 
Estimate (95% CI) 
   Antiplatelet agents 0.26 (0.13,0.51) 0.30 (0.16,0.54) 0.29 (0.16,0.52) 
Oral anticoagulants 0.18 (0.10,0.31) 0.21 (0.13,0.34) 0.25 (0.16,0.39) 
p values 
   Antiplatelet agents < .001 < .001 < .001 









Figure 4.1 Sample selection for the outcome of stroke. 










Figure 4.2 Unadjusted Kaplan-Meier results for Year 1. 










  Figure 4.3 Unadjusted overall (3-year) Kaplan-Meier results. 
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HEMORRHAGE OUTCOMES IN ATRIAL FIBRILLATION  
PATIENTS WITH GERIATRIC SYNDROMES TREATED  
FOR THE PREVENTION OF THROMBOEMBOLISM 
 
Abstract 
Although the benefits of oral anticoagulants in the prevention of 
thromboembolism in patients with atrial fibrillation are well established, these agents are 
underutilized in the older adult population, in part due to the prevalence of geriatric 
syndromes that potentially increase risks of adverse events, particularly bleeding. This 
study surveyed medical records of AF patients age 65 years and older who were also 
diagnosed with geriatric syndromes (dementia and/or frailty and/or falls), to contrast 
hemorrhage incidence differences during the 3-year follow up while considering the 
following stroke-prevention therapies: oral anticoagulants (OACs), antiplatelet agents 
(ATPLs), or none of these (No OAC/ATPL). Using electronic medical records in a 
retrospective longitudinal design, we identified and included patients age 65 years and 
older with a diagnosis of AF and concomitant geriatric syndromes. Logistic regression 
and Kaplan-Meier survival analysis were utilized to determine differences in the 





hemorrhages. The 617 older AF patients in the sample averaged 79.2 ± 7.1 years, of 
which 259 (42.0%) were males. When compared to subjects not prescribed 
antithrombotic agents over the period of 3 years, both those prescribed antiplatelet drugs 
(OR 3.28, p = 0.04) and those prescribed anticoagulants (OR 3.19; p = 0.03) were more 
likely to develop noncranial bleeding when adjusted for bleeding risk. Older AF patients 
age 65 years and older with concomitant geriatric syndromes who are prescribed 




Currently in the United States, atrial fibrillation (AF) affects 2.3 million older 
individuals; as our population ages, the incidence of AF will also increase (Benjamin et 
al., 1998, Waktare, 2002). AF causes blood stasis due to erratic atrial contractions, which 
contributes to thrombus formation. This presents a risk factor for stroke that can be 
reduced by the use of oral OAC or ATPL agents. The use of OACs reduces the 
possibility of stroke by 68% (Jacobs, Billett, Freeman, Dinglas, & Jumaquio, 2009). The 
use of ATPL agents is correlated with a stroke risk reduction of 40% (Hart, Pearce, & 
Aguilar, 2007). An adverse event commonly associated with OAC and ATPL therapies is 
a hemorrhage. A meta-analysis of major hemorrhages in patients with AF reported that 
patients treated with oral anticoagulation exhibited higher rates of hemorrhages when 
compared to patients treated with antiplatelet therapy (Ogilvie, Welner, Cowell, & Lip, 
2011). Although warfarin trials report major bleeding rates of 1% to 3% per person-year, 





et al., 2013). Also noted in recent literature is that the definition of a major hemorrhage 
has not been consistent among various trials, making it tremendously difficult to compare 
bleeding risks based on these trials (Lane, Kamphuisen, Minini, Büller, & Lip, 2011).  
Clinicians rely on various guidelines established in the United States and Europe 
to determine appropriate therapy when initiating oral anticoagulation or antiplatelet 
therapy for the prevention of stroke in patients with AF (Ahmad & Lip, 2012; Camm et 
al., 2010; Fuster et al., 2006; Guyatt et al., 2012; Skanes et al., 2012; Wann et al., 2011). 
Contingent on the personal inclinations of prescriber and patient, comorbidities, 
and bleeding histories of individual patients, patients with AF may be prescribed 
antiplatelet agents—aspirin only, or a combination of aspirin and clopidogrel—for the 
prevention of stroke.  
Guidelines recommend the use of the HAS-BLED scoring system for predicting 
bleeding risk in patients who require antithrombotic therapy (Lip, Frison, Halperin, & 
Lane, 2011; Lip, Tse, & Lane, 2012). The acronym HAS-BLED represents the risk 
factors of hypertension, abnormal renal or liver function, stroke, bleeding predisposition, 
labile INR, elderly (age 65 and older), and drug or alcohol use. Each HAS-BLED risk 
factor is assigned a 1-point value, for a maximum of 9 points. The annual bleeding risk 
varies from 1.13% for a HAS-BLED score of 0, up to 19.6% for a HAS-BLED score of 
9. When interpreting these results for a bleed risk, 0 and 1 are low risk, 2 is moderate 
risk, and scores of 3 and above are high risk (Lip et al., 2011).  
Geriatric syndromes are defined as a clinical disorder in older individuals that is 
not described by the distinct disease processes (Inouye, Studenski, Tinetti, & Kuchel, 





dementia, falls, and frailty. These geriatric syndromes are significant contributors to 
decision making with respect to the use of oral anticoagulants, which is a substantial 
stumbling block for clinicians faced with this type of scenario. Although the combination 
of the presence of dementia and/or frailty and/or falls can affect the initiation of OACs, 
these conditions are not considered within the guidelines. Because older individuals are 
more likely to be diagnosed with geriatric syndromes, clinicians are less likely to treat 
them with OACs due to the potential for hemorrhage. 
Any medication regimen is more challenging to implement and maintain in 
patients with dementia, which impairs memory. Studies show that 60% to 80% of 
individuals with dementia are afflicted with its most common form— Alzheimer’s—
while vascular dementia accounts for 10% to 20% of dementia diagnoses (Bunch et al., 
2010). Patients with dementia are at greater risk of medication error when using drug 
therapies with narrow therapeutic margins, such as warfarin. In addition, individuals with 
dementia usually require caregiver support to access laboratory monitoring. Early signs 
of bleeding might not be evident to or reported by these patients, leading to additional 
complications related to hemorrhage outcomes (Morley, 2008). 
Frail individuals are biologically unable to withstand stressors, whether physical 
or psychological (Fried et al., 2001). Frailty includes unintentional weight loss, feelings 
of exhaustion, weak grip strength, slow walking speed, and low physical activity 
(Rockwood et al., 2005). This “medical syndrome” leads to multiple system failures and 
increases mortality (Morley et al., 2013). The presence of oral anticoagulation in these 
individuals renders them more likely to develop a bleed (Fried, Ferrucci, Darer, 





Falls may be a part of the process of frailty, or they may exist independently in 
older individuals (Pieracci, Eachempati, Shou, Hydo, & Barie, 2007). Fall prevalence in 
older individuals is 33% for those age 65 to 80 years and 50% for those age 80 years or 
older (Pieracci et al., 2007). Falls are related to various problems such as frailty and 
dementia and may cause head trauma, resulting in intracranial hemorrhage or subdural 
hematoma (Man-Son-Hing, Nichol, Lau, & Laupacis, 1999).  
In the literature, investigators make an unambiguous distinction between 
intracranial hemorrhages and other types of hemorrhages encountered in patients using 
antithrombotic therapies. This distinction is due to the fact that intracranial hemorrhages 
are most likely to be fatal, infrequent, and require thorough examination (Gage et al., 
2005), whereas other types of hemorrhages must also be understood, but are less likely to 
be fatal. Moreover, to obtain valuable information on various types of hemorrhages, 
investigators must create categories for improved interpretation. Intracranial hemorrhages 
are 7 to 10 times more likely to occur in patients prescribed antithrombotic therapy 
(Veltkamp, Rizos, & Horstmann, 2013). The mortality rate of 52% to 67% in patients 
with an intracranial hemorrhage surpasses patients who are not taking any antithrombotic 
therapy (Veltkamp et al., 2013). Older patients who are prone to falls and take oral 
anticoagulation are more likely to develop traumatic intracranial hemorrhages (Dodson et 
al., 2016). 
The current study surveyed medical records of AF patients age 65 years and older 
who were also diagnosed with geriatric syndromes to contrast hemorrhage incidence 
differences during the 3-year follow up, while considering the following stroke 





these (No OAC/ATPL). 
 
Methods 
Sampling and Setting 
This was a database study of electronic medical records which were received from 
the enterprise data warehouse (EDW) at the University of Utah. This was a retrospective, 
descriptive, longitudinal study in which each patient was determined to have the 
diagnosis of AF using ICD-9 code 427.31 recorded by the healthcare providers in the 
patient’s visit notes, electrocardiogram, or both. According to the literature and a 
professional coder who was consulted, this ICD-9 code is generally used to capture 
patients with the diagnosis of AF (Piccini et al., 2012). The dataset included outpatient 
and inpatient records. Consistent with previous investigations, patients who were 
included in the sample had two or more visits related to the AF diagnosis, which ensured 
that they were treated on a long-term basis for this disease (Piccini et al., 2012). Patients 
with a confirmed diagnosis of AF who were age 65 years or older were selected in the 
first tier of sampling (see Figure 5.1). 
 
Exclusion Criteria 
In an attempt to ensure that subjects with AF were not prescribed anticoagulant 
therapy for an indication other than stroke prevention, patients with diagnoses of mural 
thrombus, deep vein thrombosis, pulmonary embolism, and any mechanical heart valves 
were excluded from analysis. After the exclusion criteria were applied, 1,398 of the 





the sampling frame. 
 
Sample Verification 
To determine the accuracy of an AF diagnosis in the final pool of subjects, 532 
individual chart reviews were performed. This process was facilitated by using the 
WartHog program at the EDW at the University. This program allows researchers to 
instantly locate specific phrases in the medical records, such as atrial fibrillation, 
eliminating records unrelated to the term searched and highlighting only the search terms 
used. Not only does WartHog allow for rapid searching, it is also extremely accurate. 
Of a subsample of 532 charts retrieved based on the ICD-9 code, we were able to 
document the diagnosis of AF in all but 11. This represents 98% accuracy in locating AF 
diagnoses, which is higher than the average of 82.2% found in the literature for accuracy 
of ICD-9 diagnoses of AF (Thigpen et al., 2015).  
 
Additional Inclusion Criteria 
Additional inclusion criteria were then applied to ensure that all patients in this 
sample had one of, or any combination of, the following geriatric syndromes: dementia, 
fall(s), or frailty. All geriatric syndrome diagnoses occurred prior to the first event of a 
hemorrhage or the last observation. All codes for diagnoses were derived from the 
literature, personal communications with a professional coder, and local and national 
researchers on the topic of frailty (Garwood & Corbett, 2008; Hubbard et al., 2015; 
Jacobs et al., 2009; Jacobs et al., 2014; Morley et al., 2013; Piccini et al., 2012; 





codes used to define geriatric syndromes and experts consulted are identified in Table 
5.1. Subjects were included only if one or more geriatric syndromes were identified 
between the date of study entry and the occurrence of a hemorrhage, to ensure that the 
syndrome was a preexisting condition relative to a hemorrhage. 
 
Procedures 
Medication and disease files were summarized by patient identification number 
using aggregate/structure query language (SQL) commands in SPSS (version 23.0) 
(Green & Salkind, 2010) and R (version 3.2.0; Team, 2013). The ICD-9 diagnoses were 
also determined for all covariate variables included in the HAS-BLED schema (see Table 
5.1). Owing to the lack of labile INR information in the dataset, we anticipated that value 
to be 0 for all patients, as described in the literature (Pisters et al., 2010).  
 
Therapy Groups 
Medication orders following a diagnosis of AF were extracted to identify the use 
of anticoagulant or antiplatelet agents commonly used to prevent thrombotic 
complications. Subjects were divided into one of three therapy groups: oral 
anticoagulants (OACs; warfarin, apixaban, rivaxaban, dabigatran); antiplatelet agents 
(ATPLs; aspirin, clopidogrel, prasugrel, ticagrelor), or no oral anticoagulation or 
antiplatelet agents (no OAC/ATPL). Of the 617 subjects, 182 (29.5%) were taking both 
antiplatelet and oral anticoagulant therapies concomitantly. It is difficult to separate 
therapies in these older individuals due to the presence of comorbidities, particularly 





these subjects were assigned to the oral anticoagulant group. 
 
Outcome Variables 
The outcome variables of cranial and noncranial hemorrhages were derived from 
the dataset using ICD-9 codes. Cranial hemorrhages included any head-related 
hemorrhages (intracranial hemorrhages, subarachnoid hemorrhages); noncranial 
hemorrhages included any gastrointestinal and other type of hemorrhages (see Table 5.1). 
In this study, patients were followed from the start of their medication until they dropped 
from observation or experienced an event. These types of data are right-censored (Singer 
& Willett, 2003). 
 
Statistical Analysis 
Following omnibus tests of ANOVA for continuous variables and chi-square for 
categorical variables, post hoc pairwise comparisons among categorical and continuous 
variables for significant omnibus tests were conducted using proportion and Tukey tests. 
P values for the post hoc comparisons were adjusted using the Bonferroni method, 
declaring significance at α = .05/3. P values for the post hoc comparisons involving 
continuous variables were adjusted using the Tukey method, with significance at α = .05 
(Kutner, Nachtsheim, Neter, & Li, 2005). Adjustments to post hoc p values were made in 
order to control the probability of encountering one or more Type-I error rates (Kutner et 
al., 2005). All other statistical tests and estimates were carried out at a significance level 
of α = .05.  





fitting model for this dataset. Logistic models were verified in a simple manner using the 
Hosmer-Lemeshow test (Agresti & Kateri, 2011). This helped to check if the predicted 
hemorrhage counts from the models were statistically different from the bleeding counts 
within the data. The application of the Hosmer-Lemeshow test was unable to find 
evidence of predicted counts of hemorrhage differing from the observed counts (p > 
0.05). The HAS-BLED score was used as a covariate in the logistic model to account for 
differences in characteristics among the treatment groups. 
Kaplan-Meier curves were also used to help compare risk differences in 
medication groups visually according to hemorrhages. A Kaplan-Meier curve is a 
nonparametric estimate of a survival curve. The formula used to construct the curve does 
not include an adjustment for risk factors. To compare survival curves controlling for 
risks, a Cox model was used instead (Singer & Willett, 2003). Visual separation of curves 
between drug groups may imply that one drug group had lower survival rates 
(hemorrhage-free time) than another.  
 
Results 
Description of Groups 
Overall, the average patient age was 79.2 ± 7.1 years, and 259 (42.0%) were 
males (see Table 5.2). The distribution of patients within each medication category was 
OACs 65.3% (n = 403), APTL agents 19.8% (n = 122), and no OAC/ATPL 14.9% (n = 
92).  
In Table 5.2, we compare these three treatment groups on demographic and 





differences in the prevalence of geriatric syndromes by group.  
The mean HAS-BLED scores indicated high risk for a hemorrhage in all groups. 
The antiplatelet group represented the highest HAS-BLED scores, demonstrating the 
most risk-related comorbidities (see Table 5.3). 
 
Group Differences on Outcomes 
All hemorrhage outcomes are presented in Table 5.4. The group prescribed no 
antithrombotic therapy had the highest rate of cranial hemorrhages at 1 year (10.9%); 
there were four cases of cranial hemorrhage in this group during the first year and none in 
subsequent years. Both groups receiving antithrombotic therapy had a higher prevalence 
of diagnosed noncranial hemorrhages (13.9%), greater than the no-drug group (4.3%). 
Like the cranial hemorrhages, all of the noncranial hemorrhages in the no-drug group 
were diagnosed in the first year. Nevertheless, the highest rate of cranial and noncranial 
hemorrhages overall was detected in the no-drug group (15.2%), even though these 
findings are not controlled for risk. The number of subjects lost to follow up and 
presumed to have experienced no hemorrhages during the 3 years was 540 (87.5%). 
Kaplan Meier survival estimates for the first year (Figure 5.2) and over all 3 years 
(Figure 5.3) are shown for the three antithrombotic treatment groups of oral 
anticoagulation, antiplatelet therapy, and no oral anticoagulation or antiplatelet therapies, 
controlled for bleeding risk using HAS-BLED scores. These graphs demonstrate a 
crossing of the Kaplan Meyer curves, which may happen when there is the presence of 
confounding variables, due to data collection and recording, or a small number of events 





by Kaplan-Meyer curves (Figure 5.3) represent possibly greater survival rates (avoidance 
of noncranial hemorrhages) among patients prescribed no OAC/ATPL agents than 
patients prescribed OACs.  
 
Logistic Regression Results 
We present logistic regression results for all hemorrhages and noncranial 
hemorrhages, but not for cranial hemorrhages because of the small sample size. For all 
hemorrhages (combined cranial and noncranial), the results were counterintuitive, similar 
to the nonadjusted findings, with those prescribed ATPLs and OACs having a 16% to 
70% less risk of bleeding than those prescribed no antithrombotic therapy (see Table 5.5).  
Subjects who were prescribed antiplatelet agents were 3.28 times more likely to 
develop noncranial hemorrhages when compared to subjects not prescribed OAC/ATPL 
agents over the period of 3 years (OR 3.28 [1.14, 11.8], p = 0.04) when bleeding risk was 
controlled. Subjects who were prescribed oral anticoagulation were 3.19 times more 
likely to develop noncranial hemorrhages when compared to subjects not prescribed 
OAC or ATPL agents over the period of 3 years (OR 3.19 [1.25, 10.7], p = 0.03) when 
bleeding risk was controlled (Table 5.6).   
 
Discussion 
The three treatment groups were similar on age and prevalence of geriatric 
syndromes. However, while all groups were considered high risk for bleeding based on 
the HAS-BLED score, it is notable that the lowest HAS-BLED scores were in the group 





these patients were not on anticoagulants was probably not related to established risk 
factors or the three specific geriatric syndromes (falls, dementia, and frailty). 
The results of this study demonstrate that patients diagnosed with AF and geriatric 
syndromes that use oral anticoagulant and/or antiplatelet therapies are more likely to 
develop noncranial hemorrhages, to include gastrointestinal bleeding. This is consistent 
with analogous findings in the literature. The most common type of bleeding in patients 
taking oral anticoagulation is gastrointestinal, which most commonly affects the upper 
gastrointestinal tract (Hylek et al., 2014). Similarly, hospital admissions of patients taking 
OACs most frequently involves gastrointestinal hemorrhages (Gomes et al., 2012). It is 
also a common finding that patients who develop bleeding events are older, with a higher 
number of comorbidities in addition to AF (Ghate, Biskupiak, Ye, Kwong, & Brixner, 
2011). The rates of gastrointestinal hemorrhage found in various studies may differ due to 
variations in the definition of the gastrointestinal bleeding events. In this study we 
combined gastrointestinal bleeding events with all other noncranial bleeding events.  
In numerous studies gastrointestinal hemorrhages have been defined differently 
due to the specifics of the gastrointestinal bleeding event. For example, studies that 
examined only gastrointestinal bleeds associated with oral anticoagulation have typically 
classified major events as hospitalizations due to the gastrointestinal bleed (Ghate et al., 
2011). In this study we included all inpatient and outpatient gastrointestinal bleeding 
events in the noncranial hemorrhages category. 
As this group ages and experiences more incidences of falls, antithrombotic 
therapy may potentially cause noncranial hemorrhages. A meta-analysis of the presence 





patients have higher rates of hemorrhages when compared to patients treated with 
antiplatelet therapy (Ogilvie et al., 2011). In the current study the risk of noncranial 
hemorrhages was similar among oral anticoagulation and antiplatelet groups. This finding 
could be related to the various comorbidities of this group, and specifically geriatric 
syndromes. As patients with geriatric syndromes age they are more likely to experience a 
progression of their declining health. This in turn may lead to increased sensitivity not 
only to oral anticoagulants but also to antiplatelet agents.  
Intracranial hemorrhage most commonly results in mortality outcomes of 67% in 
patients taking oral anticoagulation (Steiner, Rosand, & Diringer, 2006). In the current 
study, cranial bleeding was represented by such a small number of events that the sample 
size was insufficient for assessment of this outcome. It is possible that all of the 
hemorrhage events in the no-antithrombotic therapy group were accounted for in the first 
year. Perhaps these subjects had been on anticoagulants, possibly in another system, and 
were erroneously assigned to this group, or stopped their oral anticoagulation therapy for 
other reasons. 
In this study, when bleeding risk was not controlled in nonadjusted analyses, the 
group receiving no antithrombotic therapy had more instances of both cranial and 
noncranial bleeding events. This could be related to the fact that the majority of these 
events happened in the first year of observation. For the following two years of 
observation, the recording of data was either lacking or was very infrequent, which may 
be related to the recording practices of the providers, the possibility of events occurring 
outside the study-site system, or lack of patient follow up. These patients could have been 





to perform sufficient follow up. In a recent analysis, researchers discovered that the 
presence of dementia doubled the risk for a traumatic intracranial hemorrhage due to falls 
(Dodson et al., 2016). In our study, almost half of the subjects had a diagnosis of 
dementia, leading to the progression of overall declines in these patients. However, we 
did not have enough cranial hemorrhage events to draw conclusions for this patient 
group. 
Antiplatelet therapy administered concomitantly with warfarin increases the risk 
of major bleeding by 2.3 to 2.5 times (Lane et al., 2011). The post hoc analysis of the 
AMADEUS trial (Lane et al., 2011) showed that age and use of concomitant antiplatelet 
therapy with oral anticoagulation increased bleeding risk among AF patients. The use of 
antiplatelet therapy in addition to oral anticoagulation increases the risk of a major bleed 
by a factor of two. In the current study, 182 subjects out of 403 had been prescribed oral 
anticoagulation and antiplatelet agents concomitantly; however, their risk of noncranial 
hemorrhage was similar to patients who were prescribed antiplatelet therapy alone. This 
could relate to the comorbidities of this group, recording of follow ups, or recording of 
the hemorrhage events in this group. 
Our understanding of the development of dementia in patients with AF has been 
evolving. As these patients develop dementia, they are more likely to develop frailty and 
falls, which leads to increased risk of bleeding.  
In this study of older patients with AF and geriatric syndromes, we confirmed that 
if risk of hemorrhage is controlled using a common risk scale, those prescribed oral 
anticoagulation and antiplatelet therapy are more likely to develop gastrointestinal and 





these therapies may be unsafe for older patients, especially in the presence of falls and/or 
dementia and/or frailty. Providers must reassess these therapies in light of individualized 
benefit–harm ratios and ensure that patients and caregivers receive appropriate education 
for minimization of hemorrhage and early detection of any bleeding.  
 
Limitations 
Because this was a longitudinal, observational, retrospective study of AF patients, 
we were limited to ascertaining associations and were not able to determine causality 
mechanisms. The medical records reviewed in the study reflect the accuracy and 
comprehensiveness of the providers who recorded the disease states and outcomes. 
Residual confounding may exist in this observational study, despite the fact that the 
multivariable modeling included several risk factors and baseline characteristics.  
We acknowledge including only fall and frailty events that were reported, 
knowing that the incidence of falls and frailty are traditionally underreported, 
contributing to the smaller number of subjects in these groups. No consensus currently 
exists for the definition of frailty or definitive ICD-9 codes for it, necessitating the use of 
diagnosis codes extracted from the literature as well as personal communications with 
experts specializing in frailty to acquire a definition.  
There was a potential for loss to follow up of some group participants from death 
or other events unrelated to the study topic. Loss to follow up may underrepresent 
numbers of hemorrhages. The duration of presence of disease varied in length within the 
studied group of older individuals.  





counterintuitive erroneous results of logistic regression, due to various factors, such as 
the small number of cranial hemorrhages, small sample size, dataset collection practices, 
the recording of ICD-9 codes by the providers, and the presence of covariation. This 
limitation must be addressed in future studies, to secure further knowledge about the 
impact of cranial hemorrhages in the geriatric-syndrome population. This can potentially 
be achieved through the use of prospective observational studies, which may be designed 









ICD-9 Codes Used to Define Hemorrhage Outcomes Variables. 
 
 
Disease CD-9 Codes 
Dementia Dementia in other conditions (Alzheimer’s, Lewy bodies, Parkinsonism, epilepsy, 
frontal, multiple sclerosis, and so forth) 294.10–294.20, 293 
Uncomplicated, 294.8 
Use the following underlying conditions followed by one of the dementia codes 
listed above: 
  Alzheimer’s 331.0    
  Senile degeneration of brain 331.2   
  Dementia with Lewy bodies/Parkinsonism 331.82 
Dementia unspecified 294.10-294.21 
Presenile 290.10–290.13, 290.39 
Senile uncomplicated 290.0 
Senile dementia with delusional features 290.20 
Senile dementia with depressive features 290.21 
Senile dementia with delirium or confusion 290.3 
Fall(s) Fall on or from sidewalk curb E880.1 
 Fall on or from stairs or steps E880.9 
Fall from wheelchair E884.3 
Fall from bed E884.4 
Fall on the same level from slipping, tripping, or stumbling E885.9 
Other and unspecified fall E888.0-E888.9 
History of falling V15.88 
Frailty Senility without mention of psychosis (frailty) 797 






Ischemic, stroke 434.91 
Embolic, stroke 434.11 
Thrombotic, stroke 434.01 
Impending 435.9 
Postoperative 997.02 
Personal history without deficits V12.54 
Late effects 438.0–438.9 
Personal history of TIA V12.54 
Unspecified transient cerebral ischemia 435.9  
Hypertension Essential hypertension 401.0–401.9 
Hypertensive heart disease 402.00–402.91 
Hypertensive chronic kidney disease 403.00–403.91 
Hypertensive heart & chronic kidney disease 404.00–404.93 
Secondary hypertension 405.01–405.99 
Hypertensive cerebrovascular disease 437.2 
Intracranial hypertension benign 348.2 
Postoperative hypertension 997.91 
Alcohol Use Alcohol dependence 303.90, 303,91, 303.92, 303.93 
Alcohol abuse 291.0–291.5, 291.8, 291.81, 291.82, 291.89, 291.9, 303.00–303.03, 
305.00, 305.01, 305.02, 305.03, 760.71, 980.0 
Abnormal Renal 
Function 
794.4, acute renal failure 584.5–584.9, unspecified renal failure 586, chronic 









Table 5.1, Continued 
 
 




V56.0, V56.1, V56.2, V56.31, V56.32, V56.8 
Abnormal Liver 
Function 
794.8, cirrhosis of the liver without mention of alcohol 571.5, liver abscess and 
sequela of chronic liver disease 572.0–572.4, 572.8, ascites 789.5, 789.59, other 
and unspecified liver disorders 570, 571.6, 571.8, 579.9, 573.0, 573.4, 573.8, 
573.9, 782.4, 789.1, 790.4, 790.5, 794.8, V42.7 
Prior Bleed Hemorrhage not otherwise specified 459.0 
Postoperative 998.11 
Brain hemorrhage iatrogenic/postoperative 997.02 
Subarachnoid hemorrhage 430 
Intracerebral hemorrhage 431 
Nontraumatic extradural hemorrhage 432.0 
Subdural hemorrhage 432.1 
Unspecified Intracranial hemorrhage 432.9 
Esophageal hemorrhage 530.82 
Gastric ulcer with hemorrhage 531.00, 531.01, 531.20, 531.21, 531.40, 531.41, 
531.60, 531.61 
Duodenal ulcer with hemorrhage 532.00, 532.01, 532.20, 532.21, 532.40, 532.41, 
532.60, 532.61 
Peptic ulcer with hemorrhage 533.00, 533.01, 533.20, 533.21, 533.40, 533.41, 
533.60, 533.61 
Gastrojejunal ulcer with hemorrhage 534.00, 534.01, 534.20, 534.21, 534.40, 
534.41, 534.60, 534.61 
Gastritis and duodenitis with hemorrhage 535.01, 535.11, 535.21, 535.31, 
535.41, 535.51, 535.61, 535.71 
Diverticulosis small intestine with hemorrhage 562.02 
Diverticulitis small intestine with hemorrhage 562.03 
Diverticulosis colon with hemorrhage 562.12 
Diverticulitis colon with hemorrhage 562.13 
Hemorrhage of rectum and anus 569.3 
Hematemesis 578.0 
Melena/blood in stool 578.1 
Hemorrhage of gastrointestinal tract unspecified 578.9 
Hemoptysis unspecified 786.30 
Cough with hemorrhage 786.39 
Traumatic brain hemorrhage 852.00–853.19 


















No Drug Antiplatelet Oral Anticoagulant 
Subject Count 92 (14.9%) 122 (19.8%) 403 (65.3%)  
Age in years (mean ± SD) 79.2 ± 7.9 79 ± 8 79.3 ± 6.7 0.9 
Fall (% Yes) 62 (67.4%) 88 (72.1%) 286 (71%) 0.7 
Dementia (% Yes) 42 (45.7%) 65 (53.3%) 186 (46.2%) 0.08 
Frailty (% Yes) 8 (8.7%) 10 (8.2%) 17 (4.2%) 0.2 
HAS-BLED (mean ± SD) 2.3 ± 1 2.5 ± (1) 2.5 ± (0.9) < .05a 
Medications      
Warfarin (% Yes) 0 (0%) 0 (0%) 363 (90.1%)  
Apixaban (% Yes) 0 (0%) 0 (0%) 31 (7.7%)  
Rivaroxaban (% Yes) 0 (0%) 0 (0%) 26 (6.5%)  
Dabigatran (% Yes) 0 (0%) 0 (0%) 22 (5.5%)  
Aspirin (% Yes) 0 (0%) 113 (92.6%) 156 (38.7%)  
Clopidogrel (% Yes) 0 (0%) 32 (26.2%) 26 (6.5%)  
Ticagrelor (% Yes) 0 (0%) 2 (1.6%) 0 (0%)  
Prasugrel (% Yes) 0 (0%) 0 (0%) 0 (0%)  
Note. p < .05; SD = standard deviation. 
Omnibus F test (continuous variables) or chi-square (categorical variables).        
a No drug versus oral anticoagulant. 
b No drug versus antiplatelet. 


















No Drug Antiplatelet Oral Anticoagulant 
Age 65+ (% Yes) 92 (100%) 122 (100%) 403 (100%) 1.0 
Hypertension (% Yes) 45 (48.9%) 66 (54.1%) 259 (64.3%) <.0001a 
Renal disease (% Yes) 32 (34.8%) 39 (32%) 139 (34.5%) 0.9 
Liver disease (% Yes) 5 (5.4%) 8 (6.6%) 20 (5%) 0.7 
Stroke history (% Yes) 24 (26.1%) 46 (37.7%) 164 (40.7%) <.0001a 
Antiplatelet use (% Yes) 0 (0%) 122 (100%) 0 (0%)  
NSAIDS use (% Yes) 3 (3.3%) 9 (7.4%) 19 (4.7%) 0.4 
Alcohol use (% Yes) 7 (7.6%) 9 (7.4%) 19 (4.7%) 0.3 
Note. p < .05. 
 Omnibus F test (continuous variables) or chi-square (categorical variables).  
a No drug versus oral anticoagulant. 
b No drug versus antiplatelet.  









Type of Antithrombotic Therapy 
p Value 
No Drug Antiplatelet 
Oral 
Anticoagulant 
Cranial Hemorrhages Overall (% Yes) 10 (10.9%) 7 (5.7%) 32 (7.9%) 0.4 
Cranial Hemorrhage 1 year (% Yes) 10 (10.9%) 4 (3.3%) 16 (4%) < .05a 
Cranial Hemorrhage 3 year (% Yes) 10 (10.9%) 5 (4.1%) 25 (6.2%) 0.1 
Noncranial Hemorrhage Overall (% Yes) 4 (4.3%) 17 (13.9%) 56 (13.9%) < .0001a 
Noncranial Hemorrhage 1 year (% Yes) 4 (4.3%) 7 (5.7%) 14 (3.5%) 0.5 
Noncranial Hemorrhage 3 year (% Yes) 4 (4.3%) 9 (7.4%) 32 (7.9%) 0.6 
Total Hemorrhage Overall (Cranial and 
Noncranial) (% Yes) 
14 (15.2%) 14 (11.5%) 56 (13.9%) 0.7 
 
Total Hemorrhage (Cranial and 
Noncranial) 1 year (% Yes) 
14 (15.2%) 7 (5.7%) 22 (5.5%) < .05a 
Total Hemorrhage (Cranial and 
Noncranial) 3 year (% Yes) 
14 (15.2%) 8 (6.6%) 45 (11.2%) 0.1 
Note. p < .05. 
 Chi-square         
a No drug versus oral anticoagulant 
b No drug versus antiplatelet. 











Logistic Model Results for All Hemorrhages (Cranial and Noncranial) 
 
 
Odds Ratio Overall 1-Year 2-Year 3-Year 
Estimate (95% CI)     
ATPL 0.68 (0.30,1.53) 0.32 (0.11,0.82) 0.32 (0.11,0.83) 0.37 (0.14,0.92) 
OAC 0.84 (0.45,1.65) 0.30 (0.15,0.64) 0.46 (0.23,0.93) 0.66 (0.35,1.31) 
p values     
ATPL 0.35 0.02 0.02 0.03 
OAC  0.6 0.001 0.02 0.21 
Note. Reference group = no antithrombotic drug; covariate: HAS-BLED score; ATPL= antiplatelet drugs; 










Odds Ratio Overall 1-Year 2-Year 3-Year 
Estimate (95% CI)     
ATPL 3.28 (1.14,11.8) 1.29 (0.37,5.06) 1.49 (0.45,5.75) 1.63 (0.5,6.21) 
OAC 3.19 (1.25,10.78) 0.75 (0.26,2.71) 1.15 (0.42,4.04) 1.73 (0.66,5.96) 
p values     
ATPL 0.04 0.69 0.52 0.42 
OAC 0.03 0.62 0.79 0.31 
Note. Reference group = no antithrombotic drug; covariate = HAS-BLED score; ATPL = antiplatelet drugs; 


















   Figure 5.2 Unadjusted Kaplan-Meier noncranial hemorrhages. 









 Figure 5.3 Unadjusted overall (3-year) Kaplan-Meier results (noncranial hemorrhages). 
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STROKE OUTCOMES IN ATRIAL FIBRILLATION PATIENTS  
RELATED TO GERIATRIC SYNDROMES AND ORAL  
ANTITHROMBOTIC THERAPIES FOR THE  
PREVENTION OF THROMBOEMBOLISM 
 
Abstract 
In patients having both AF and geriatric syndromes (dementia, frailty, and falls), 
the use of antithrombotic therapy may produce complications. This study observed 
electronic medical records of participants age 65 years and older with AF and geriatric 
syndromes, and another group with AF and no geriatric syndromes, to ascertain 
variations in stroke occurrence over a 3-year follow up, while considering the type of 
stroke prevention therapy used: oral anticoagulants (OACs), antiplatelet agents (ATPLs), 
or none of these (No OAC/ATPL). The primary outcome was the presence of a stroke. 
Multivariable Cox hazard regression determined the treatment correlation with risk-
adjusted stroke incidence. Kaplan-Meier survival curves were used for survival analysis. 
The 1,580 older adults with AF in the sample had an average age of 75.8 ± 7.6 years, and 
of those, 822 (52.1%) were males. After adjustment for risk, older adults with atrial 





likely to have a stroke or TIA than those without geriatric syndrome(s) (HR = 9.11; CI 
2.52, 32.97; p < .0001). For those prescribed oral anticoagulants, the risk of stroke was 
increased by 89% in the presence of geriatric syndromes (HR = 3.4; CI 1.25, 2.87; p = 
.003), while the increased risk for those on no antithrombotic therapy was more than 3-
fold, although differences were not significant (HR = 3.4; CI 0.5, 21.77; p = .196). Older 
AF patients with geriatric syndromes are at higher risk of developing strokes than older 
AF patients without dementia and/or frailty and /or falls, regardless of whether they are 




As the Baby Boom generation ages, the number of older people in the United 
States is increasing, and the cardiac arrhythmia known as atrial fibrillation (AF) is 
projected to increase from the currently affected 2.3 million people to 5.6 million people 
by 2050 (Tsang et al., 2003). AF represents the most significant stroke (cerebrovascular 
accident [CVA] or transient ischemic attack [TIA]) risk factor due to the formation of a 
thrombus resulting from blood immobility in the atria. In clinical practice, oral 
anticoagulation therapy diminishes stroke burden by 64% (Hart, Pearce, & Aguilar, 
2007). Some patients are not able to take oral anticoagulants due to previous bleeding, a 
history of falls, or personal preference; in this case, ATPLs such as aspirin and/or 
clopidogrel may be prescribed instead, reducing the stroke risk as much as 40% (Hart et 
al., 2007).  





thromboembolism in AF are dementia, frailty, and falls. As patients age, these conditions 
typically increase in prevalence, presenting clinicians with questions relating to their 
treatment. These patients present a challenge due to higher incidences of comorbidities 
(Morley, 2008; Morley et al., 2013). 
Caregivers utilize guidelines from Europe and the United States to implement the  
correct thromboembolism-prevention treatment. Providers generally use the CHA2DS2-
VASc scoring system to predict individual stroke risk (Lip, Frison, Halperin, & Lane, 
2011; Lip, Tse, & Lane, 2012). This schema assists providers in reaching conclusions 
about recommending oral anticoagulation to older individuals. The CHA2DS2-VASc 
schema assigns one point for each of the following: congestive heart failure, 
hypertension, diabetes mellitus, vascular disease (coronary artery disease, peripheral 
artery disease, or aortic plaque), age 65 to 74 years, and sex (female gender). The schema 
additionally assigns 2 points each for previous stroke/TIA or age ≥ 75 years. A combined 
score of 0 to 9 results from using this schema, and is used to calculate annual stroke risk 
values from 0.2% for a CHA2DS2-VASc score of 0, up to 15.2% for a CHA2DS2-VASc 
score of 9 (Pamukcu, Lip, & Lane, 2010). 
Dementia affects predominantly older individuals, who are difficult to treat due to 
impaired memory, and its most pervasive form is Alzheimer’s dementia, constituting 
60% to 80% of all dementias; vascular dementia comprises 20% of all dementias (Bunch 
et al., 2010). Patients diagnosed with AF and taking oral anticoagulation are at increased 
risk for the development of dementia (Kwok, Loke, Hale, Potter, & Myint, 2011).  
Frailty expresses as decreases in strength, mobility, balance, body mass, overall 





contributes to serum protein concentration changes, potentially modifying the 
pharmacokinetics of oral anticoagulation or antiplatelet therapy (Fried, Ferrucci, Darer, 
Williamson, & Anderson, 2004; McIsaac, Bryson, & van Walraven, 2016). Frail older 
individuals are very vulnerable, and are at higher risk for stroke from AF than their 
nonfrail counterparts. 
The occurrence of falls is also a problem related to aging, and may also result 
from diseases, medications, or a combination of these factors. Falls are also associated 
with the development of frailty and dementia. They specifically present a problem in 
individuals taking oral anticoagulation because of the potential to develop a hemorrhage. 
In older individuals who experience falls, 1 in 10 will sustain a major injury (Tay, Lane, 
& Lip, 2009). A mortality rate of 45% is attributed to patients on oral anticoagulation 
who suffer from falls (Jacobs, Billett, Freeman, Dinglas, & Jumaquio, 2009). 
This study observed electronic medical records of participants age 65 years and 
older with both AF and geriatric syndromes (dementia, frailty, and falls), and another 
group with AF and no geriatric syndromes, to ascertain variations in stroke occurrence 
over a 3-year follow up, while considering the type of stroke prevention therapy used 
(OACs, ATPLs, or no OAC/ATPL). 
 
Methods 
Sampling and Setting 
This was a database study of electronic medical records, which were obtained 
from the enterprise data warehouse (EDW) at the University of Utah. This was a 





have a diagnosis of AF using ICD-9 code 427.31 recorded by the healthcare providers in 
the patient’s visit notes, electrocardiogram, or both during the period January 1, 2010 to 
December 31, 2014. Subjects included in the study had the diagnosis of AF for varying 
periods of time. According to the literature and the advice of a professional coder, ICD-9 
code 427.31 is generally used to capture patients with the diagnosis of AF (Piccini et al., 
2012). The dataset included outpatient and inpatient records. Consistent with procedures 
developed by previous investigators to validate the target diagnosis, subjects were 
included in the sample only if they had two or more visits related to the AF diagnosis, 
ensuring that they were treated on a long-term basis for this disease (Piccini et al., 2012). 
Patients with a confirmed diagnosis of AF who were older than 65 years were selected in 
the first tier of sampling (see Figure 6.1). 
 
Exclusion Criteria 
In an attempt to ensure that subjects with AF were not taking anticoagulant 
therapy for an indication other than stroke prevention, patients with diagnoses of mural 
thrombus, deep vein thrombosis, pulmonary embolism, and any mechanical heart valves 
were excluded from analysis. The final sample size was 1,580 patients.  
 
Sample Verification 
To determine the accuracy of AF diagnosis in the final pool of subjects, 532 
individual chart reviews were performed. This process was facilitated by using the 
WartHog program at the EDW at the University of Utah. This program allows 





fibrillation, eliminating records unrelated to the term searched and highlighting only the 
search terms used. Not only does WartHog allow for rapid searching, it is also extremely 
accurate. Of the 532 charts retrieved based on the ICD-9 code applied, we were able to 
document the diagnosis of AF in all but 11. This represents 98% accuracy in locating AF 
diagnoses, which is higher than the average of 82.2% that is found in the literature when 
assessing accuracy of ICD-9 diagnoses of AF (Thigpen et al., 2015).   
 
Procedures 
Medication and disease files were summarized by patient identification number, 
using aggregate/structure query language (SQL) commands in SPSS (version 23.0; Green 
& Salkind, 2010) and R (version 3.2; Team, 2013). The ICD-9 diagnoses were also 
determined for all covariate variables included in the CHA2DS2-VASc schema. Those 
variables are listed in Table 6.1. 
 
Geriatric-Syndrome Groups 
The 1,580 subjects were divided into those who did and did not have diagnoses 
indicative of one of three geriatric syndromes: falls, dementia, or frailty. All geriatric 
syndrome diagnoses occurred prior to the first event of a stroke or last observation. All 
codes for diagnoses were derived from the literature and personal communications with a 
professional coder and local and internationally recognized researchers on the topic of 
frailty (Garwood & Corbett, 2008; Hubbard et al., 2015; Jacobs et al., 2009; Jacobs et al., 
2014; Morley et al., 2013; Piccini et al., 2012; Rockwood et al., 2005; Searle, Mitnitski, 





syndromes and experts who were consulted are identified in Table 6.1. Subjects without 




Medication orders following the diagnosis of AF were extracted to identify the 
use of anticoagulant or antiplatelet agents commonly used to prevent thrombotic 
complications. All subjects were divided into 1 of 3 therapy groups: oral anticoagulation 
group (OAC; warfarin, apixaban, rivaroxaban, dabigatran), antiplatelet agents group 
(ATPL; aspirin, clopidogrel, prasugrel, ticagrelor), and no-oral 
anticoagulation/antiplatelet agents (no OAC/ATPL). If subjects had a record of both 
antiplatelet and oral anticoagulant therapy, they were assigned to the oral anticoagulant 
group. Of the 1,580 subjects, 440 (27.8%) were prescribed both therapies concomitantly. 
It is difficult to separate these therapies because of comorbidities in older individuals, 
particularly coronary artery disease, for which many patients take aspirin. 
 
Outcome Variables 
The outcomes variables for stroke were derived from the dataset using the ICD-9 
codes listed in Table 6.1. In this study patients were followed from the beginning of their 
medication therapy until they dropped from observation or experienced an event. These 








Omnibus tests were performed in order to detect general differences among 
means, and proportions using ANOVA and chi-square tests on demographic variables, 
components of the covariate, and outcomes by therapy group and presence of geriatric 
syndromes (Kutner, Nachtsheim, Neter, & Li, 2005). Post hoc pairwise comparisons 
among categorical and continuous variables were completed using proportion and Tukey 
tests. P values for the post hoc comparisons were adjusted using the Bonferroni method, 
declaring significance at α = .05/3. P values for the post hoc comparisons involving 
continuous variables were adjusted using the Tukey method, with significance at α = 
.05 (Kutner et al., 2005). Adjustments to post hoc p values were made in order to control 
the probability of encountering one or more Type-I error rates (Kutner et al., 2005). All 
other statistical tests and estimates were carried out at a significance level of α = .05.  
Multivariable Cox hazard regression was utilized to determine stroke outcomes by 
medication groups. Six multivariable Cox hazard regression models were utilized to 
determine if significant differences existed in stroke outcomes by medication group in the 
groups with and without geriatric syndromes. The first Cox model, 1-year follow up,  
observed individuals only over a 1-year period. If an individual’s observation time was 
more than one period, then that person was considered as being observed for 1 full year, 
and having no stroke event. Similar constructions were done for the 2-year and 3-year 
follow-up models. In each Cox model, the censoring variable was 0 if the stroke did not 
occur within the observation period, and 1 if it did. Individuals in the Cox models were 
censored for either of two circumstances: a subject’s last event was not a stroke (another 





end of the observation period alive, not having experienced a stroke. A single covariate 
was used for the Cox model, a summed version of the CHA2DS2-VASc schema, which 
comprises the baseline risk factors for stroke. An overall hazard ratio was estimated from 
a dataset in which patients were censored only when they were lost to follow-up. One-, 
two-, and three-year hazard ratios are estimated from datasets in which patients can be 
censored if they reach one, two, or three years without experiencing any event, or are lost 
to follow up before those respective times. 
Kaplan-Meier curves were also used to help compare differences in survival 
according to stroke outcomes of those with and without geriatric syndromes. A Kaplan-
Meier curve is a nonparametric estimate of a survival curve. The formula used to 
construct the curve does not include an adjustment for risk factors. To compare survival 
curves controlling for risks, a Cox model was used instead (Singer & Willett, 2003). 
Visual separation of the curves between drug groups may imply that one drug group has 
lower survival than another. 
 
Results 
Description of Groups 
Among the 1,580 subjects in this study, the average patient age was 75.7 ± 7.6 
years; 822 (52.1%) were male; 542 had geriatric syndromes; 364 (63.8%) were 
prescribed an OAC; 115 (21.2%) were prescribed ATPL therapy; 81 (14.9%) were not 
prescribed either OAC or ATPL therapy; and 1,038 had no geriatric syndrome. 
In Table 6.2, we compare groups with and without geriatric syndromes and 





geriatric syndromes were older. Within the group without geriatric syndromes, those 
prescribed anticoagulants were older than those prescribed antiplatelet drugs. Higher 
average CHA2DS2-VASc risk scores were found in the group with geriatric syndromes. 
Those who did not have geriatric syndromes were more likely to be prescribed an OAC, 
both warfarin and the direct anticoagulant drugs, while those with geriatric syndromes 
were more likely to be prescribed clopidogrel. Approximately 44% of both groups were 
prescribed aspirin. On the components of the CHA2DS2-VASc scores, those with 
geriatric syndromes were more likely to be female, to have hypertension, and to have 
peripheral vascular disease. Aortic plaque, diabetes, and coronary artery disease had 
similar prevalence regardless of the presence of geriatric syndromes (see Table 6.3). 
Mean time until censored for subjects with geriatric syndromes was 1003.21 ± 588.84 
days. Mean time until censored for subjects without geriatric syndromes was 1074.03 ± 
551.01 days. 
 
Differences on Outcomes 
The mean time to stroke or TIA was shorter for those with geriatric syndromes. 
Regardless of the presence of geriatric syndromes, the mean time to stroke was the 
shortest, measured in days, for those not prescribed antithrombotic therapy (see Table 
6.4). Those with geriatric syndromes had a higher stroke incidence at all time points; 
however, all strokes/TIAs in those not prescribed antithrombotic therapy occurred in the 
first year, and the cumulative incidence over 3 years was lower in those not prescribed 
antithrombotic therapy, whether or not they had geriatric syndromes. However, these 





Kaplan-Meier survival estimates controlled for risk are shown comparing subjects 
with and without ATPL drugs according to the antithrombotic therapy group: those 
prescribed oral OACs (Figure 6.2), those prescribed ATPLs (Figure 6.3), and those 
prescribed no OAC/ATPL (Figure 6.4). Overall, when risk of stroke was controlled based 
on the application of CHA2DS2-VASc scoring, the two curves diverge, indicating that 
subjects without geriatric syndromes were less likely to develop a stroke when prescribed 
either OAC, ATPL, or no OAC/ATPL.   
 
Risk-Adjusted Hazard Ratios 
When risk was controlled, patients with geriatric syndromes were more likely to 
have a stroke or TIA than those without geriatric syndromes at every time point (Table 
6.5). Overall, the increased risk ranged from 89% for those prescribed oral anticoagulants 
to over 9-fold for those prescribed antiplatelet agents. Older adults with geriatric 
syndromes who were prescribed no antithrombotic therapy had 3.5 times the risk of 
stroke or TIA than those without diagnosed geriatric syndromes.   
 
Discussion 
In this study we compared older adults with atrial fibrillation who had geriatric 
syndromes to those without geriatric syndromes to examine the outcomes of stroke and 
TIA in patients prescribed oral anticoagulants, antiplatelet drugs, and no oral 
anticoagulation or antiplatelet therapies. The results of the study confirm that patients 
with AF and geriatric syndromes are more likely to develop strokes when compared to 
their counterparts without geriatric syndromes. 





observation was anticipated because patients with geriatric syndromes have increased 
numbers of comorbidities, such as cardiovascular disease and diabetes, as well as other 
risk factors for the development of thromboembolism. In clinical practice, these patients 
are the most difficult to treat. Not only do they typically have numerous comorbidities, 
but they may also experience falls. Subsequent to the development of falls, clinicians are 
reluctant to continue oral anticoagulation and will most commonly stop this therapy 
(Zimetbaum et al., 2010). In some instances these patients will be switched to antiplatelet 
therapy, which may also cause bleeding events (Cairns et al., 2008). Although debated in 
the literature, no consensus currently exists regarding the use of antiplatelet therapy, such 
as whether patients should be on aspirin only, the appropriate dosing of aspirin, and 
whether clopidogrel needs to be used in addition to aspirin. Antiplatelet therapy typically 
reduces stroke risk by 40%, whereas warfarin reduces stroke risk by 68% (Hart et al., 
2007). In the ACTIVE-W trial (Hart et al., 2007), oral anticoagulation was superior to the 
combination of aspirin and clopidogrel. Despite the fact that current national and 
international guidelines recommend oral anticoagulation therapy for aging individuals, in 
real practice, patients with geriatric syndromes will be offered this therapy 51% of the 
time (Bo et al., 2016); thus, only half of these patients will have the opportunity to 
discuss this therapy with their family and clinicians.  
Our understandings of the processes related to the development of dementia are 
still emerging. It has been noted previously that patients with AF are at increased risk for 
the development of dementia when compared to patients without AF (Bunch et al., 2010; 
Charidimou et al., 2015). The process of the progression of dementia is multifactorial and 





displaying physical and cognitive deficits, typically leading to prescription 
noncompliance, which will in turn lead to the inability to follow up and check INR levels 
as recommended. AF patients taking warfarin for thromboembolism prevention who do 
not spend the requisite time within the therapeutic range (INR 2–3) are more likely to 
develop dementia. If these patients’ INR levels are subtherapeutic, they are more likely to 
develop microemboli; if INR levels are supratherapeutic, they are more likely to develop 
microbleeds (Bunch et al., 2010, Jacobs et al., 2014). These micro rather than macro 
insults to the brain lead to the development or more rapid progression of dementia. The 
decline of these patients, both cognitively and physically, leads to frailty and falls. 
Providers are faced with these common scenarios in geriatric settings. Direct OACs 
(apixaban, rivaroxaban, and dabigatran) are new on the market and present an attractive 
alternative to warfarin in that they do not require blood-level monitoring or dietary 
adjustments, pose fewer side effects, and cause fewer drug interactions. Perhaps these 
medications will offer a better option for oral anticoagulation therapy, when compared to 
warfarin, as use outcomes of these drugs are evaluated over time. 
The major challenge in managing these frail patients is that we do not have a 
standard definition of frailty, which contributes to the potential for patients to not receive 
appropriate diagnoses and/or therapy. Moreover, these patients may reside in the 
community as opposed to being institutionalized or hospitalized (Fried et al., 2001). 
Most often, geriatric syndromes are interrelated and will evolve simultaneously. 
For example, an older individual with developing dementia will most likely suffer from 
falls due to balance problems, and over time will become frail due to decreased appetite, 





stress. If this type of individual resides at home, family assistance will become absolutely 
necessary; the other alternative would be placement in an assisted care facility. 
Many older individuals are quite resistant to relocation from their cherished home, 
but most often they will not be able to function at full capacity, performing the necessary 
daily tasks of cleaning, cooking, buying groceries, and so forth. These concerns can be 
doubly impactful if an older husband and wife reside in the same home, with both of 
them requiring outside assistance. This is a scenario frequently encountered by healthcare 
providers, and because the potential for a fall in this type of situation is quite high, 
providers are somewhat reluctant to prescribe oral anticoagulation due to the potential for 
a fall and a resultant bleed (Pugh, Pugh, & Mead, 2011).  
In this study we determined that patients with geriatric syndromes were more 
likely to develop stroke/TIA than patients with no geriatric syndromes. These same 
patients with geriatric syndromes also had greater numbers of comorbidities and were 
older when compared to those with no geriatric syndromes. These findings are consistent 
within the literature and suggest that the potential reasons for the underutilization of oral 
anticoagulation are at least partially due to the greater number of comorbidities and older 
age of these patients (Jacobs, Cutler, Day, & Bunch, 2014). Patients without geriatric 
syndromes have fewer comorbidities and are more likely to be anticoagulated; however, 
in this study we had patients without geriatric syndromes not being anticoagulated and 
not taking antithrombotic therapy or antiplatelet agents. This leads to the possible 
conclusion that patients both with and without geriatric syndromes have some similar 
disease processes such as diabetes, coronary artery disease, or peripheral vascular 





coronary artery and peripheral vascular diseases are typically prescribed aspirin and 
clopidogrel for these conditions. Frequently, patients do not wish to add a third 
antithrombotic agent in the form of an oral anticoagulant due to the fear of bleeding. 
Future research should examine this complex problem of oral antithrombotic use 
in patients with dementia and/or frailty and /or falls. Early identification of these 
conditions may help to determine further treatment strategies. Looking at various times 
when oral anticoagulation could be unsafe would allow for the development of improved 
therapies. Examining frailty and whether to offer palliative versus active treatments is 
extremely important. Another significant question is when to switch from oral 
anticoagulation to antiplatelet therapy, if appropriate, and what type of antiplatelet 
therapy to employ—aspirin only or aspirin plus clopidogrel. This study indicated that the 
greatest increase in incidence of stroke and TIA among older adults with geriatric 
syndromes was in the group prescribed antiplatelet therapy, so extreme caution may be 
warranted. Direct oral anticoagulants present a newer and potentially safer treatment 
modality to that of warfarin. Because these agents are relatively new, their efficacy and 
safety in geriatric patients need to be established through future studies.  
 
Limitations 
This observational study included baseline characteristics and used one 
multifactorial risk indicator in the multivariable modeling, but may still contain residual 
confounding. Observational, retrospective, and longitudinal in design, the study cannot 
define causality but can recognize associations. The accuracy and comprehensiveness of 





integrated EMR did not allow us to include diagnoses, drugs prescribed, or events that 
took place external to the academic healthcare system at which the study was conducted. 
While falls and frailty are known to be underreported as a general rule, we included only 
falls and frailty cases recorded in patient charts. This fact contributed to the lesser 
number of subjects in the groups with these diagnoses. As no consensus exists on the 
description of frailty, experts in that field were consulted; in addition, we extracted 
diagnosis codes from within the literature to secure a usable definition of frailty for this 
study. Some patients in the study were lost to follow up (no further EMR documentation 
was available, although the subject may still have been alive and treated elsewhere). 
These patients could potentially have contributed more stroke events had they remained 
in the study, which may have provided more statistical power in comparisons among the 
treatment groups. The duration of AF varied within this group. While we could confirm a 
drug was ordered, there was no way to determine whether patients adhered to the 
medication. 
Although data in this study included more than 1,500 patient records, the 
incidence of stroke events in some of the antithrombotic therapy subgroups was still 








ICD-9 Codes Used to Define Stroke Outcomes Variables 
 
 
Disease ICD-9 Codes 
Dementia Dementia in other conditions (Alzheimer’s, Lewy bodies, Parkinsonism, epilepsy, 
frontal, multiple sclerosis, and so forth) 294.10–294.20, 293 
Uncomplicated, 294.8 
Use the following underlying conditions followed by one of the dementia codes 
listed above: 
  Alzheimer’s 331.0    
  Senile degeneration of brain 331.2   
  Dementia with Lewy bodies/Parkinsonism 331.82 
Dementia unspecified 294.10–294.21 
Presenile 290.10–290.13, 290.39 
Senile uncomplicated 290.0 
Senile dementia with delusional features 290.20 
Senile dementia with depressive features 290.21 
Senile dementia with delirium or confusion 290.3 
Falls Fall on or from sidewalk curb E880.1 
Fall on or from stairs or steps E880.9 
Fall from wheelchair E884.3 
Fall from bed E884.4 
Fall on the same level from slipping, tripping, or stumbling E885.9 
Other and unspecified fall E888.0-E888.9 
History of falling V15.88 
Frailty Senility without mention of psychosis (frailty) 797 






Ischemic, stroke 434.91 
Embolic, stroke 434.11 
Thrombotic, stroke 434.01 
Impending 435.9 
Postoperative 997.02 
Personal history without deficits V12.54 
Late effects 438.0–438.9 
Personal history of TIA V12.54 
Unspecified transient cerebral ischemia 435.9  
Hypertension Essential hypertension 401.0–401.9 
Hypertensive heart disease 402.00–402.91 
Hypertensive chronic kidney disease 403.00–403.91 
Hypertensive heart and chronic kidney disease 404.00–404.93 
Secondary hypertension 405.01–405.99 
Hypertensive cerebrovascular disease 437.2 
Intracranial hypertension benign 348.2 
Postoperative hypertension 997.91 
Diabetes Mellitus DM with other specified manifestations 250.80–-250.83 
DM with unspecified complication 250.90–250.93 
Secondary DM without mention of complication 249.00–249.01 
Secondary DM with renal manifestations 249.40–249.41 





Table 6.1, Continued 
 
 
Disease ICD-9 Codes 
Diabetes Mellitus, 
Continued 
Secondary DM with neurological manifestations 249.60–249.61 
Secondary DM with peripheral circulatory disorders 249.70–249.71 
Secondary DM with other specified manifestations 249.80–249.81 
Secondary DM with unspecified complication 249.90–249.91 
Congestive Heart 
Failure (CHF) 
Congestive heart failure, unspecified 428.0 
Systolic heart failure 428.20–428.23 
Diastolic heart failure 428.30–428.33 
Combined systolic and diastolic heart failure 428.40–428.43 
Rheumatic heart failure (congestive) 398.91 
Coronary Artery 
Disease (CAD) 
Coronary atherosclerosis 414.00–414.07 
Chronic total occlusion of coronary artery 414.2 
Coronary atherosclerosis due to lipid-rich plaque 414.3 
Coronary atherosclerosis due to calcified coronary lesion 414.4 
Peripheral Vascular 
Disease (PVD) 
Peripheral vascular disease unspecified 443.9 
PVD in other disease (DM) 443.81 
Atherosclerosis of extremities 440.20-440.4 
Atherosclerosis of other specified arteries 440.8 
Generalized and unspecified atherosclerosis 440.9 
Raynaud’s syndrome 443.0 
Occlusion/stenosis precerebral arteries 433.00–433.91 
Atherosclerosis of renal artery 440.1 
Aneurysm–peripheral arteries 442.0–442.9 
Dissection–peripheral arteries 443.21–443.29 












Sample Characteristics at Study Entry for Patients With and Without Geriatric  




















































c < .0001 
 
Fall (% Yes) 
53 
(65.4%) 




     
 
Dementia (% Yes) 
34 
(42.0%) 





     
 
Frailty (% Yes) 
11 
(13.6%) 




     
 
CHADS-VASC, 
Mean + (SD) 
3.5 ± 
(1.2) 









a,c < .0001 
 
Medications   
Warfarin (% Yes) 0 (0%) 0 (0%) 309 (89.3%) 
309 
(57.0%)  









0 (0%) 0 (0%) 60 (17.3%) 
60 
(11.1%) 



















0 (0%) 35 (30.4%) 23 (6.6%) 
58 
(10.7%)  







0 (0%) 0 (0%) 0 (0%) 
1 
(0.18%)  
0 (0%) 2 (0.9%) 0 (0%) 2 (0.2%) 
 
1 
Note. p < .05.  
*
Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran).  Omnibus F test (continuous variables) or chi-square (categorical variables).  
a
No drug versus oral 
anticoagulant.  
b
 No drug versus antiplatelet.  
c








CHA2DS2-VASC Score Composition for Patients With and Without  




Geriatric Syndrome No Geriatric Syndrome  
p Value 





























Age 75+ (% Yes) 











b,c < .0001 
Age 65–74 (% Yes) 













b,c < .0001 
Diabetes Mellitus 
(% Yes) 













Disease (% Yes) 



























28 (12.5%) 76 (11.7%) 
119 
(11.5%) 
0.6 < .0001 
Aortic Plaque (% 
Yes) 
7 (8.6%) 22 (19.1%) 58 (16.8%) 
87 
(16.1%) 
0.1 9 (5.4%) 27 (12.1%) 71 (11%) 
107 
(10.3%) 
0.05 < .01 
Female Gender (% 
Yes) 






96 (42.9%) 277 (42.7%) 
454 
(43.7%) 
0.3 < .0001 
Note.  p < .05.  Omnibus F test (continuous variables) or chi-square (categorical variables).  
a
No drug versus oral anticoagulant.  
b
No drug versus antiplatelet.  
c
Oral anticoagulant 











Outcomes of Stroke Patients With and Without Geriatric Syndromes On  





















Total p Value* 
Mean days to 
stroke or TIA 


























Overall stroke or 






















































































0.08 < .0001 
Note.  p < .05.  Omnibus F test (continuous variables) or chi-square (categorical variables).  
a
No drug versus oral anticoagulant.  
b
No drug versus antiplatelet.  
c
Oral anticoagulant 







Risk of Stroke Among Older Adults With Geriatric Syndromes  
by Type of Antithrombotic Therapy 
 
 







Overall 1.89 0.21 0.0028, CI (1.25, 2.87) 
1 Year 1.59 0.4 0.2448, CI (0.73, 3.5) 
3 Year 1.57 0.26 0.0823, CI (0.94, 2.62) 
Antiplatelet therapy  
Overall 9.11 0.66 8.00E-04, CI (2.52, 32.97) 
1 Year 15.07 1.09 0.0128, CI (1.78, 127.6) 
3 Year 7.54 0.68 0.0029, CI (1.99, 28.49) 
No oral anticoagulant/antiplatelet therapy  
Overall 3.4 0.95 0.1959, CI (0.53, 21.77) 
1 Year 6.59 1.19 0.1115, CI (0.65, 67.28) 
3 Year 3.4 0.95 0.1959, CI (0.53, 21.77) 

















Figure 6.2 Unadjusted overall (3-year) Kaplan-Meier of oral anticoagulant (OAC) with 










Figure 6.3 Unadjusted overall (3-year) Kaplan-Meier of no oral anticoagulant (OAC) or 







Figure 6.4 Unadjusted overall (3-year) Kaplan-Meier of antiplatelet agents (ATPL) with 
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CONCLUSIONS, FUTURE NURSING RESEARCH,  
AND IMPLICATIONS FOR NURSING SCIENCE 
 
The number of older people in the United States increases as the Baby Boom 
generation ages. America’s population distribution is changing due to the 10,000 Baby 
Boomers turning 65 each day during the next decade (Cohn & Taylor, 2010; Harden & 
Watman, 2015). Our healthcare system is evolving as older people live longer with 
numerous comorbidities, providing healthcare that is becoming more individualized and 
personalized. These factors require more resources and that more research be dedicated to 
finding more efficient ways of delivering care to older individuals. It is evident that 
improvement of our healthcare system is essential. 
The nursing profession is at the forefront of increasing knowledge about 
personalized care. Nursing professionals are faced with challenges linked to providing 
care to the aging population. Preparation for this care is vital due to the increased demand 
for gerontological nurses. The National Hartford Center of Gerontological Nursing 
Excellence exists to prepare more and better educated nursing professionals in 
gerontological nursing (Harden & Watman, 2015). This initiative started in 2000 and 





of gerontological nurses requires that more nursing professionals be trained. Future 
nurses must be proficient in gerontological topics, research, collaboration, and overall 
public health (Sheetz, 2012).  
One of the initiatives of the National Institute of Nursing Research (NINR) was to 
develop innovative questions that will lead the way to an innovative future in nursing 
research (Grady, 2015). One of the NINR’s innovative question topics is related to the 
integration of new technologies to provide physiological feedback, such as detection of 
AF, and how it can be integrated to provide better healthcare outcomes (Grady, 2015). 
The presence of new technologies and innovative ways of managing patients with home 
monitoring, personal emails, innumerable smart devices, and frequent nursing 
interventions will direct our healthcare system in the future. Nursing science is also 
undergoing scientific advances related to patient care. Nurses provide care based on 
previous research that allows them to incorporate this knowledge into practice. Nurses 
provide care to older individuals at every level of nursing practice, whether in a doctor’s 
office, hospital, home care, or hospice, advanced practice nurses provide care to older 
individuals in an even wider variety of settings. 
Many older individuals who require care will have AF, which brings along with it 
another potential comorbidity in the form of increased stroke risk, making OACs central 
to the care of those patients. Nursing research informs nurses as providers of care with 
regard to AF. 
Our understanding of complex conditions such as frailty and dementia is 
evolving, and currently nurses provide care to an increased number of older individuals 





focus on these conditions when educating gerontological nurses. Gerontological research 
frequently focuses on these difficult and multifaceted conditions because it is 
encountered more frequently as nurses provide care to older individuals. The definition of 
frailty is still debated, but it is agreed that this multipart condition encompasses 
psychological and physiological components that are not completely understood (Fried, 
Ferrucci, Darer, Williamson, & Anderson, 2004; Fried et al., 2001). 
Geriatric syndromes are conditions that share similarities but are not accepted as 
diagnostic criteria for a particular disease process, as they are typically not well defined 
(Inouye, Studenski, Tinetti, & Kuchel, 2007). Healthcare providers encounter geriatric 
syndromes in various settings when working with older individuals. Most frequently, 
medical professionals focus on the main complaint and how to treat that. The nursing 
profession is the link that brings together various disciplines for assessing and treating 
these geriatric syndromes. The nursing profession focuses on the individual as a whole 
and assesses all facets of the patient’s life. The most important task of the nursing 
professional in this setting is to determine how best to assist these older individuals in 
each particular situation.  
Declines associated with dementia are gradual, slowly progressing into cognitive 
and physical deficits. The physical deficits will ultimately result in frailty and falls, 
whereas the cognitive deficits will result in the inability to withstand psychological stress. 
Nursing professionals must consider each patient’s social and economic situation in order 
to determine their comprehensive care requirements. Another vital help that nursing 
professionals provide these patients is bringing patient and family together to discuss the 





the patient’s circumstance. Patient education is extremely important in all areas, 
particularly when it comes to oral anticoagulation for thromboembolism prevention in the 
older frail individual.  
The presence of geriatric syndromes in these individuals presents additional 
aspects of care which need to be considered and discussed with family and other 
providers. Issues related to oral anticoagulation, stroke risk in AF patients, and 
hemorrhage risk should be discussed with the patient and family, especially if a patient is 
presenting with dementia after a fall. Normally, family members will rely on providers, 
but these decisions are extremely important and must be made by informed family 
members and healthcare providers. Geriatric syndromes affect families of older 
individuals in many ways; for example, change of residence, placement in a nursing care 
facility, caregiver assistance, which medication will be continued, and how to get to 
scheduled appointments. As nursing professionals assist in a multidisciplinary approach 
to these and other problems, patients and their families will enjoy a better chance of 
making informed decisions about their healthcare. 
This retrospective observational study addressed the incidences of strokes and 
hemorrhages in AF patients age 65 and older who had been diagnosed with dementia, 
frailty, and/or falls. Focusing on three therapeutic approaches to thromboembolism 
prevention, the study revealed that patients who are prescribed OAC and antiplatelet 
therapy benefit from these therapies. This potentially happens because the subgroup 
population is older, with increased comorbidities and high mortality rates. Additionally, 
these patients are more likely to develop complications from prescribed OACs and need 





these complications to allow for changes in patient treatment plans and to be vigilant 
about possible complications of these therapies. Whether nursing professionals are 
working in the clinic or hospital environment, they will encounter older patients 
prescribed OACs. It is common knowledge among nurses that those patients prescribed 
OACs are at increased risk of bleeding. Moreover, patients who are prone to falls and 
have been diagnosed with dementia and/or frailty are more likely to develop hemorrhages 
and potential complications due to the number of existing comorbidities.  
Through this study, we have shown that not only are patients with the above 
diagnoses prone to the development of bleeds when prescribed OACs, but also when 
prescribed antiplatelet therapy. In fact, antiplatelet therapy in this subgroup of patients 
may be as harmful in terms of bleeds as OACs. This is an interesting finding, demanding 
that caregivers of these patients ensure that appropriate monitoring is ongoing. The 
presumption that antiplatelet therapy is less harmful than OACs was not confirmed in this 
study, which warns providers to be extremely careful working with this patient subgroup. 
In the comparison of the incidence of strokes in the subgroup of AF patients with 
dementia, falls, and frailty to AF patients without dementia, falls, and frailty, we found 
that strokes are more frequent among patients with these three geriatric syndromes. This 
allows caregivers to be more alert to any stroke symptoms in this subgroup. Antiplatelet 
therapy is also used in this population, which had similar patterns as those taking OACs. 
 
Distributions of CHA2DS2-VASc/HAS-BLED Scores by Group 
In Chapter 4 we examined the incidence of strokes in AF patients with geriatric 





OAC/ATPL. CHA2DS2-VASc scores in the oral anticoagulation group were represented 
by a nice bell-shaped distribution, with the highest number of subjects having a score of 
4. This group represents high stroke risk and was appropriately anticoagulated. 
CHA2DS2-VASc scores in the antiplatelet agents group were also represented by a bell-
shaped distribution, with the highest number of subjects having a score of 4. This group 
represents high stroke risk, which according to guidelines should be anticoagulated. 
CHA2DS2-VASc scores in the no-antithrombotic group were represented by a bell-
shaped distribution as well, with the highest number of subjects having a score of 3. This 
group represents high stroke risk, which according to guidelines also needs to be 
anticoagulated. It is thought-provoking that all of the subjects in this study were at high 
risk for a stroke; however, not all of them were anticoagulated. On the other hand, the 
presence of geriatric syndromes causes providers and patients either to stop completely, 
or not even begin oral anticoagulation therapy due to the perceived risks associated with 
geriatric syndromes (Hylek et al., 2006).  
In Chapter 5 we observed occurrences of hemorrhages in AF patients with 
geriatric syndromes, contingent on the type of stroke-prevention therapy. HAS-BLED 
scores in the oral anticoagulation group were represented by a bell-shaped distribution, 
with the highest number of subjects having a score of 3, which represents the highest 
bleeding risk. HAS-BLED scores in the antiplatelet agent group indicated the highest 
number of subjects having a score of 2. HAS-BLED scores in the no-antithrombotic 
therapy group indicated the highest number of subjects also having a score of 2. 
Interestingly, the OAC group had the highest HAS-BLED score: 3. Typically patients 





guidelines recommend that these patients be anticoagulated to prevent a stroke/TIA 
(Camm et al., 2010). 
In Chapter 6 we compared two groups of patients with and without geriatric 
syndromes while taking into consideration three types of stroke-prevention therapy: 
OAC, ATPL, and no OAC/ATPL. For the geriatric syndromes groups, CHA2DS2-VASc 
scores in the OAC group were represented by a bell-shaped distribution, with the highest 
number of subjects having a score of 4; the CHA2DS2-VASc scores in the ATPL therapy 
group were represented by a bell-shaped distribution, with the highest number of subjects 
having a score of 4; the CHA2DS2-VASc scores in the no-OAC/ATPL group were 
represented by a bell-shaped distribution, with the highest number of subjects having a 
score of 4. For the no-geriatric-syndrome groups, the CHA2DS2-VASc scores in the 
OAC group were represented by a bell-shaped distribution, with the highest number of 
subjects having a score of 4; the CHA2DS2-VASc scores in the ATPL therapy group 
were represented by a bell-shaped distribution, with the highest number of subjects 
having a score of 3; the CHA2DS2-VASc scores in the no-OAC/ATPL group were 
represented by a bell-shaped distribution, with the highest number of subjects having a 
score of 3.  
If we compare the geriatric-syndromes group to the no-geriatric-syndromes 
groups, we can conclude that patients in the geriatric syndromes groups were represented 
by the higher numbers of comorbidities, with higher CHA2DS2-VASc scores. Oral 
anticoagulation groups in geriatric-syndromes and no-geriatric-syndromes groups had the 
highest CHA2DS2-VASc scores and were appropriately anticoagulated. Antiplatelet 





geriatric-syndromes group having the lowest CHA2DS2-VASc scores; however, 
according to guidelines, these subjects should be anticoagulated. The no antithrombotic 
therapies groups with geriatric syndromes had higher CHA2DS2-VASc scores when 
compared to no geriatric syndromes. Nevertheless, both groups should have been 
anticoagulated according to guidelines.  
This study revealed that patients with geriatric syndromes exhibit higher 
CHA2DS2-VASc scores when compared to those with no geriatric syndromes, and that 
they exhibit higher HAS-BLED scores in the OAC group. Yet, not all of these patients in 
the study were anticoagulated, even when indicated according to guidelines. Subjects 
who were taking antiplatelet therapy and were also indicated for anticoagulant therapy 
according to guidelines may have declined the addition of oral anticoagulant therapy due 
to the fear of bleeding complications, or may possibly have experienced bleeding 
complications in the past. Subjects not taking any antithrombotic therapy, but according 
to guidelines were indicated as candidates for anticoagulant therapy, may have declined 
these therapies due to experiencing previous falls and hemorrhages. 
 
Future Research 
Presently, existing guidelines do not include recommendations that would include 
older individuals with dementia, frailty, and falls. This is something that needs to be 
considered, especially in the future, when our healthcare system will need to 
accommodate larger numbers of older individuals with these conditions. This study lays 
the groundwork for future research that will provide information that should be included 





patients with these conditions.  
Future research is required to address numerous questions related to this issue; the 
inclusion of randomized controlled trials or pragmatic clinical trials that address and 
correct one glaring inadequacy of this type of trial, which does not typically include the 
very old individuals with multiple comorbidities and multiple medications; and 
prospective and retrospective studies to examine the following questions: 
• Should we consider both age and comorbidities in deciding on the 
treatment for AF in older patients with dementia, falls, and frailty? 
• What is the optimal OAC treatment for this subgroup—warfarin, or the 
newer direct oral anticoagulants (DOACs)? 
• What is the dose of DOACs? 
• What are the outcomes of strokes/TIAs, hemorrhages, and mortality for 
these older individuals on these therapies? 
• What is the optimal antiplatelet therapy for this subgroup of older 
individuals—aspirin, and which dose, aspirin and clopidogrel, and which 
dose?  
• What are the preferences of patients and caregivers in relation to these 
therapies, and how can they obtain help from clinicians? 
These and other questions, if answered, will paint a picture of optimal treatment 
for older individuals with these conditions. Nursing science strives to optimize patient 
care and treatment of older individuals with AF and dementia, frailty, and falls; it is one 
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